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Abstract 
 
 The majority of pharmaceutical dosage forms are marketed as solids, and 
the active pharmaceutical ingredient (API) can exist in various physical forms.  
These physical forms can be either crystalline or amorphous, and will have 
different physical properties.  The physical form of the API is selected to provide 
the appropriate solubility, stability, and bioavailability for the formulation.  
However, processing steps involved in the production of the formulation can 
induce changes in the physical form of the API and thus impact the performance 
of the formulation.  Therefore, it is critical to characterize the physical form of the 
API in the formulation, and to monitor it for any changes in the physical form 
during storage. 
 Multiple solid-state characterization techniques are typically employed in 
order to identify and quantitate physical forms of APIs.  However, most of these 
techniques suffer from significant issues related to the interference of excipient 
signals with API signals when analyzing formulations.  Additionally, in order to 
perform quantitative measurements pure standards are needed and calibration 
curves must be generated for most of these characterization techniques. 
 This dissertation demonstrates the superior ability of solid-state nuclear 
magnetic resonance (SSNMR) spectroscopy to both detect and quantitate 
physical forms of APIs within formulations, relative to other solid-state 
characterization techniques.  Specifically, SSNMR has been used to understand 
the dehydration of levofloxacin hemihydrate, including the discovery of a 
previously unreported anhydrous polymorph.  Three formulations for 
pulmonary delivery have been characterized by both differential scanning 
iv 
calorimetry (DSC) and SSNMR.  DSC could not clearly identify the physical form 
of the APIs in the formulations, but SSNMR was able to unambiguously 
determine the physical forms of the APIs in all cases. 
 The work presented in the dissertation also demonstrates that SSNMR can 
be used to quantitate the relative amounts of physical forms of APIs within 
formulations without pure standards or calibration curves.  Finally, the relative 
ability of SSNMR and other solid-state characterization techniques were 
compared and clearly illustrate that SSNMR is considerably more powerful in 
the relative quantitation of API physical form in both pure materials and 
formulations. 
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Chapter 1 
 
Introduction to Pharmaceutical Solids 
 
2 
1.1 Objectives 
 
 The primary objective of this dissertation is to determine the capability of 
solid-state characterization techniques to detect and quantitate physical forms of 
drugs within pharmaceutical formulations.  The first section of this dissertation 
will focus on the ability of various techniques to identify physical forms of a 
drug and to detect the physical forms within formulations.  Later sections will 
focus on the development of methods using solid-state nuclear magnetic 
resonance (SSNMR) spectroscopy to quantitate physical forms of drugs within 
formulations and compare the performance of those methods with other solid-
state characterization techniques that are commonly used for physical form 
quantitation. 
 The following sections will provide a general introduction to 
pharmaceutical solids.  The first section will cover crystalline and amorphous 
materials.  In addition, a variety of solid form classifications will be introduced, 
including polymorphs, salts, solvates, and cocrystals.  Attention will also be 
given to the selection of a physical form for use in a solid pharmaceutical 
formulation.  And finally, the potential impacts of manufacturing processes on 
the physical form of the drug within the formulation will also be presented. 
 
1.2 Introduction 
 
 More than 80% of all pharmaceutical dosage forms are solids.1,2  They can 
utilize various routes of drug administration including: injection, inhalation, 
topical application, and oral ingestion.  They are more difficult to develop and 
3 
manufacture than liquid formulations.  Nonetheless, patients generally prefer 
solid pharmaceuticals, which are typically more stable than liquid formulations, 
resulting in longer shelf lives. 
 A single dose of a drug will typically be in the range of a few milligrams 
to hundreds of milligrams depending upon the potency of the drug.  For most 
drugs, if the needed dose was simply compressed into a tablet, it would be too 
small for the majority of patients to handle without difficulty.  Therefore a drug, 
often referred to as the active pharmaceutical ingredient (API), is typically mixed 
with various excipients to produce a formulation.  Some excipients help to make 
handling of the API easier by improving the flow properties of the powders so 
that they do not clog the manufacturing equipment.  Other excipients aid in the 
dissolution of the tablets once they are ingested by a patient or make the tablets 
physically stronger so that they do not crumble before reaching the patient.  
Individual excipients are classified based on the roles that they play within a 
formulation, such as binders, disintegrants, lubricants, wetting agents, coatings, 
and flavoring agents, but oftentimes an excipient plays more than one role. 
 Unfortunately, an API cannot simply be mixed with a set of excipients, 
compressed into a tablet and then given to a patient without further 
characterization.  There are a variety of physical states in which the API can exist, 
and different physical forms of a material will have distinct properties that can 
affect things like dissolution rate and chemical stability.  Therefore it is important 
to identify the physical forms of an API and carefully choose the one with the 
most appropriate physical properties for use in the formulation.  The following 
sections will introduce the concept of physical forms as they relate to 
pharmaceuticals and discuss the selection of a physical form for use in a solid 
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formulation. 
 
1.3 Physical Forms of Pharmaceuticals 
 
 Generally speaking, a pharmaceutical solid will exist in either a crystalline 
or an amorphous state.  A crystalline solid is characterized by highly ordered 
packing of the molecules within the material.  Conversely, amorphous solids are 
defined as lacking any long-range molecular order.  The choice of using a 
crystalline or amorphous solid can dramatically affect the development of a solid 
formulation.  The following sections will describe both crystalline and 
amorphous solids along with their advantages and disadvantages for use in 
pharmaceutical solids. 
 
1.3.1 Crystalline Solids 
 A solid material where the molecules are packed in a repetitive order over 
long distances in three dimensions is said to be crystalline.  In a crystal, the 
smallest repeating unit is called the unit cell.  It contains one or more molecules 
that have a specific conformation and arrangement in the unit cell.  The unit cell 
then repeats in three dimensions to produce a crystal lattice that is held together 
by the presence of various non-covalent bonding interactions, including intra- 
and intermolecular hydrogen bonding and van der Waals forces.3  In many cases 
a material may have different crystal structures made by adopting different 
conformations or packing arrangements of the molecules, resulting from 
changing the bonding interactions.  The different crystal structures are termed 
polymorphs, and the phenomenon of polymorphism is very common within 
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pharmaceuticals.4 
 Polymorphs will have different thermodynamic and physical properties 
due to the differences in their non-covalent bonding interactions.  While multiple 
polymorphs can exist at a given temperature and pressure, they will each have a 
different free energy.  The one with the lowest free energy is the most 
thermodynamically stable form at that temperature and pressure, and all the 
other polymorphs are said to be metastable compared to the most stable form.  
Given a sufficient amount of time at the given temperature and pressure, all of 
the metastable forms would eventually convert to the most stable form.  
However, it may take anywhere from seconds to years for the conversion to 
occur, and the kinetics of interconversion will be different for each form. 
 The relative thermodynamic stability of polymorphic forms may change at 
different temperatures.5,6  When one polymorph has a lower free energy than 
another polymorph at all temperatures below the melting point of the forms, 
then the pair of forms are said to be monotropically related.  A pair of 
polymorphs are enantiotropically related if at some temperature, called the 
transition temperature, there is a change in which form has the lower free 
energy.  Figure 1 illustrates a polymorphic system that consists of three forms 
(Forms A, B, and C).  In this example Form A and Form B are enantiotropically 
related to each other while Forms A and B are each monotropically related to 
Form C.  Form A is the thermodynamically stable form while B and C are 
metastable at all temperatures below the transition temperature.  Above the 
transition temperature Form B is the thermodynamically stable form while A and 
C are metastable. 
 While polymorphic systems are defined by their thermodynamic
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Figure 1.1  Theoretical phase diagram of a polymorphic system that consists of three 
forms (A, B, and C).  Form A and B are enantiotropically related with their transition 
temperature indicated on the phase diagram.  Both Form A and B are monotropically 
related to Form C. 
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relationships, it is really their physical properties that are of greatest interest 
when developing a pharmaceutical formulation.  Chief among these properties is 
solubility, because an API that does not dissolve cannot be absorbed by the 
patient and have the desired physiological effects.  The thermodynamically 
stable form will have the lowest solubility (the equilibrium solubility of the API) 
and often be the most chemically stable of the polymorphs.  Therefore the stable 
form is often the first choice when picking the polymorph that will be used in a 
formulation.7 
 One potential complication when choosing the most stable polymorph is 
when that form is enantiotropically related to another polymorph.  The API will 
typically experience a variety of conditions, including a range of temperatures, 
from the time that it is made until it is included into the formulation and 
ultimately used by the patient.  Some of these conditions may be controlled, such 
as drying steps used in the manufacturing process, while others may be outside 
the control of the manufacturer, such as a patient leaving their bottle of tablets in 
their car on a hot summer day.  While every possible situation cannot be 
anticipated, it is still important to consider these factors when picking the 
polymorph that will be formulated.  As an example, consider the system shown 
in Figure 1 and assume that the transition temperature of the forms is 50 °C.  
Form A could be a good choice because it is the most stable form at temperatures 
the product would experience under normal storage.8  However, assume that 
drying steps will probably be needed during manufacturing, and will be done at 
80 – 100 °C.  In a typical enantiotropic system, the actual polymorph conversion 
from Form A to B could occur at a temperature significantly higher than the 
point at which the relative free energies invert, and if cooled back down there 
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may not be any observed conversion of Form B back to A.9-12  Therefore, 
significantly more information would be needed about the kinetics of 
transformation between Form A and B at a variety of temperatures before 
making a final decision on which form to include in the formulation, but in many 
cases Form B would be chosen to avoid unintended conversions during 
manufacture and because it would likely remain unchanged over the shelf life of 
the product.9 
 It is becoming increasingly common that the most stable form is not 
sufficiently soluble to achieve the necessary bioavailability from the formulation.  
If the polymorphs are ranked in order of increasing free energy the order will 
also represent the rank ordering of the forms from the least to most soluble in 
terms of apparent solubility.  Therefore, a metastable form will have an apparent 
solubility that is higher than the equilibrium solubility of the API, and may 
provide the necessary increase in solubility to produce a viable formulation.  
However, formulation of metastable polymorphs must be approached with great 
caution because conversion to the stable polymorph within a formulation can 
have devastating effects.13,14  Unfortunately, if significant increases in solubility 
are required, the least stable polymorph may be needed but it will also be the 
most prone to convert to the stable form.  In situations where no metastable 
polymorph can provide sufficient solubility and physical stability other physical 
forms must be explored.  The amorphous state can be particularly useful in these 
situations and will be discussed in the following section. 
 
1.3.2 Amorphous Solids 
 When the molecules of a solid lack any long-range order the material is 
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said to be amorphous.  Amorphous materials have also been described as frozen 
liquids and are thought to contain a distribution of conformations and molecular 
orientations.  A key characteristic of amorphous systems is the lack of a melting 
point and the presence of a glass transition temperature (Tg).  The Tg designates a 
change in the heat capacity of the material.  At temperatures below the Tg the 
material is in what is referred to as the glassy state, in which the molecules are 
relatively static with few modes of motion.  In the rubbery state, above Tg, the 
material is able to flow and the molecules have much greater mobility.3 
 A major issue with amorphous materials is that molecules have higher 
mobility and thus are metastable and significantly more susceptible to chemical 
degradation than crystalline forms of the same material.  However, they often 
have apparent solubilities that are dramatically higher than their stable 
crystalline counterparts.15,16  It has been observed that if amorphous materials are 
stored at a temperature that is significantly below their Tg that they typically do 
not crystallize or undergo significant chemical degradation.  Thus a rule of 
thumb has developed which states that if an amorphous material is stored at 
least 50 °C below its Tg the material will be stable.17  Therefore, a material stored 
at room temperature (approximately 25 – 30 °C) should be stable if its Tg is 
greater than about 75 – 80 °C. 
 The most stable crystalline form is typically the first choice when choosing 
the solid form that will be used in a formulation, but as noted previously, in 
some cases solubility is a limitation.  A metastable crystalline form may be 
chosen to provide moderate increases in the solubility of the API.  However, 
metastable polymorphs cannot always achieve the needed bioavailability or may 
be physically unstable.  An amorphous solid can be used to resolve these 
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situations, provided that it does not have physical and chemical stability issues.  
When the Tg is too low to prevent changes at room temperature, one option is to 
store the material at lower temperatures.  While this choice is sometimes used, it 
makes handling of the final product more difficult and expensive due to the need 
for special handling. 
 An alternative to special storage conditions is the preparation of an 
amorphous dispersion.  When the API is molecularly dispersed into another 
material, typically a polymer, the resulting amorphous material will in theory 
have a Tg that is the weighted average of the Tg’s of the individual components in 
their pure form.18,19  If the polymer that is used to produce the amorphous 
dispersion has a higher Tg than the API, it may be possible to prepare an 
amorphous material that would offer the enhanced solubility that is needed and 
the resulting increase in the Tg may by sufficient to allow the product to be stored 
under ambient conditions.  Apart from amorphous dispersions, only physical 
forms that involve different packing arrangements of the same chemical 
compound have been considered.  The next section will explore crystalline forms 
where other molecules, in addition to the API, are incorporated into the crystal 
structure. 
 
1.3.3 Solvates, Salts, and Cocrystals 
 The previous section on crystalline solids focused on polymorphism, 
which is defined as different forms having the same chemical composition but 
differ in their crystal structures.  In some cases it is also possible for a compound 
to pack into a crystalline lattice that incorporates other molecules into the crystal 
structure.  They are not polymorphs, since these additional crystal structures 
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have a different chemical composition than the original compound, but they are 
related physical forms.  These physical forms are classified as solvates, salts, or 
cocrystals, depending upon the ionization state of the molecules and the physical 
properties of the components when in their pure forms. 
 Solvates, salts, and cocrystals will contain at least two chemical entities 
that are usually present in stoichiometric amounts, but also may be non-
stoichiometric.20-22  The material is classified as a solvate if one of the chemical 
entities is a liquid in its pure form at room temperature.  The remaining materials 
can be categorized as a salt if a proton has been transferred between the 
components, or a cocrystal if no proton transfer has occurred between the 
components.  These physical forms can offer alternatives to the formulation of 
polymorphs or amorphous forms when the physical properties (i.e., solubility, 
stability, etc.) of the known polymorphs or amorphous form are not sufficient for 
formulation. 
 Considerable time, effort, and resources are spent to identify and 
characterize all of the potential physical forms of API’s.  Once the desired 
physical form is identified, the final step in the synthetic route to make the API is 
typically designed to produce the desired form.  The API is then mixed with the 
other formulation components to produce the final product that is to be used by 
the patient.  Ideally, the physical form of the API is unaltered during processing.  
Unfortunately, this is not always the case.  The following sections will describe 
some of the processing steps that are commonly involved in the manufacture of a 
pharmaceutical formulation and the effects that they can have on the physical 
form of the API. 
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1.4 Processing Induced Physical Form Changes 
 
 The practice of converting a powder of pure API into a tablet involves the 
use of numerous processing steps, or unit operations, that can expose the API to 
various thermal and physical stresses.  These stresses can induce partial or full 
conversions of the API into an undesirable physical form.  In the event of an 
unidentified physical form change the API may undergo accelerated chemical 
degradation or fail to fully dissolve and deliver a full dose to the patient.  The 
subsequent sections will give an overview of some of the more common unit 
operations that are used in the production of pharmaceutical formulations and 
some of the physical form changes that they can induce.  
 
1.4.1 Crystallization 
 The final step in the synthesis of an API is typically crystallization to yield 
the desired physical form for the formulation.  The crystallization is typically 
carried out under specific conditions (solvent, temperature, etc.) in order to 
control the physical form that is obtained.  In some cases seed crystals of the 
desired form are added to the mixture to help drive the crystallization to the 
desired form.23  However, in some cases the desired form is still not obtained or 
the product may be a mixture of forms.  This may be caused by a variety of 
factors, including the presence of impurities in the crystallization medium and 
the presence or lack of scratches in the vessel in which the crystallization is 
performed.7,24,25  Unlike most unit operations, issues during crystallization can 
often be fixed so that the desired physical form is still obtained.  This is typically 
done by repeating the crystallization several times to remove an impurity, 
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changing to another vessel, or somehow modifying the procedure to overcome 
the cause of the initial issue. 
 
1.4.2 Wet Granulation 
 An important property in the manufacture of pharmaceutical solids is the 
flowability of the powders that are used.  If a powder does not flow well it will 
tend to clog the manufacturing equipment and result in tablets that are not of a 
uniform size and do not contain a uniform dose of the API.  One method of 
improving the flowability of a powder is through a process called wet 
granulation.  This process involves mixing the powder with a small amount of a 
liquid (typically water) in order to agglomerate the particles followed by drying 
and sieving.  These larger agglomerates will have better flow properties and 
yield tablets that are more uniform in size and dose. 
 The presence of liquid during the wet granulation can cause a variety of 
changes in the physical form of the API.  For formulations of a metastable 
polymorph, the liquid may provide a medium in which the API can dissolve and 
crystallize in the stable form.  A formulation containing an anhydrous form of 
the API may crystallize as a solvate by incorporating some of the liquid into its 
crystal structure.  Other physical forms, such as salts, may undergo 
disproportionation and crystallize in their individual components.26-28  However, 
the liquid that is added is only intended to facilitate the formation of 
agglomerates and needs to be removed before proceeding to additional unit 
operations. 
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1.4.3 Drying 
 Several unit operations involve the use of solvents but if not removed they 
can cause issues with both the chemical and physical stability of the API.  
Therefore, at least one drying step will often be used during the manufacture of a 
pharmaceutical solid, and will simply involve heating the material to a particular 
temperature for a certain amount of time. 
 While drying is one of the simplest unit operations it can have multiple 
effects on the physical form of the API in a formulation.  The addition of heat and 
solvent molecules (liquid or vapor) can induce many of the polymorph 
conversion and disproprtionation issues that were discussed previously.  
However, without careful control and monitoring it can also result in either 
under or over drying of the materials.  If the drying process is not carried out 
long enough there may still be too much residual solvent in the material.  But in 
some cases a certain amount of residual solvent is desirable, especially when the 
API is in a solvated form, and if too much solvent is removed then the API may 
no longer be physically stable and may convert to another physical form, lower 
order solvate or desolvated form.  In some cases the removal of the solvent 
molecules from a solvate can lead to collapse of the crystal structure and result in 
an amorphous material. 
 
1.4.4 Compression 
 Compression is used in two different unit operations, dry granulation and 
tableting, during the manufacture of pharmaceutical solids.  Dry granulation is 
an alternative to wet granulation but rather than using a liquid to facilitate 
aggregation, the powder is compressed and then lightly broken apart.  In 
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tableting a tablet press uses enormous compression forces to compact the 
formulation into a hard tablet.  Some API physical forms are sensitive to pressure 
and can undergo conversions during compression.29-31 
 
1.5 Summary and Overview of Subsequent Chapters 
 
 In the previous sections the concepts of physical forms as they relate to 
pharmaceutical solids have been introduced.  It was shown that the drug 
formulation does not simply involve the selection of a physical form that is to be 
used in a formulation.  Rather it is necessary to monitor the entire manufacturing 
process and the final product for changes in the physical form of the API.  The 
remainder of this dissertation will describe the methods that are used to identify 
and quantify the physical forms of API’s.  These methods will then be used to 
analyze multiple pharmaceutical systems.  The following sections provide brief 
descriptions of each of the subsequent chapters of this dissertation. 
 
Chapter 2: Understanding the Dehydration of Levofloxacin Hemihydrate 
 Levofloxacin is a fluoroquinolone antibiotic and is known to have several 
physical forms.  Previous reports have claimed that dehydration of levofloxacin 
hemihydrate leads to collapse of the crystal lattice and produces a mixture of 
physical forms.32  However, additional studies will be presented which show that 
dehydration of the hemihydrate leads to a pure anhydrous form.  Additionally, a 
previously unknown form of anhydrous levofloxacin was discovered and 
interesting observations concerning the mobility of functional groups within 
these physical forms will be discussed. 
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Chapter 3: Detection of Physical Forms in Formulations 
 It has been shown previously that the physical form of an API can be 
changed during the manufacture of a formulation.  Formulations are mixtures of 
several materials and it can be difficult to accurately determine the physical form 
of the API in the end product.  In addition, advanced drug delivery technologies 
(i.e., nanotechnology) can complicate the analysis.  Three cases involving 
nanoparticles of API will be presented: one where the desired API physical form 
was achieved, one where an undesired API physical form was produced, and 
another case where a previously unknown form or forms were produced. 
Additionally, the superior ability of SSNMR spectroscopy, as compared to 
differential scanning calorimetry, in detecting the physical form of all three APIs 
within the formulations is demonstrated. 
 
Chapter 4: Quantitation of Physical Forms in Formulations by SSNMR Spectroscopy 
 Previous studies have demonstrated the ability of SSNMR spectroscopy to 
quantitate the relative amounts of physical forms.  These methods will be 
extended to the analysis of API within formulations.  In this chapter the analysis 
of API that has been diluted in an excipient in order to mimic a formulation is 
shown.  In addition, improvements in the efficiency of quantitative SSNMR 
spectroscopy experiments are presented.  The precision of these quantitative 
methods is also discussed. 
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Chapter 5: Comparison of Physical Form Quantitation by Solid-State Characterization 
Techniques 
 The quantitative SSNMR method developed in Chapter 4 is utilized to 
analyze physical form mixtures of both pure API and API in a mock formulation.  
The same mixtures are also analyzed by other solid-state characterization 
techniques that are commonly used for physical form characterization and 
quantitation.  The results from each of the techniques are compared and the 
relative abilities of each of the techniques to detect and quantitate the physical 
forms are discussed.  Additionally, issues related to the homogeneity of samples 
prepared by mixing powders are discussed. 
 
Chapter 6: Conclusions and Future Work 
 A brief discussion of the general results and implications of this thesis will 
be provided.  In addition, suggestions for future work will be presented. 
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Understanding the Dehydration of Levofloxacin Hemihydrate 
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2.1 Introduction 
 
 The specific aim of this chapter is to understand the dehydration behavior 
of levofloxacin hemihydrate.  Previous studies concluded that dehydration of the 
hemihydrate form of levofloxacin lead to collapse of the crystal lattice and 
produces a mixture of physical forms, including amorphous levofloxacin.1  Thus 
in a manufacturing process, drying of levofloxacin hemihydrate could generate 
amorphous material which is chemically or physically unstable.  Therefore, 
further investigations into the dehydration behavior of levofloxacin hemihydrate 
were undertaken to better understand the materials that are generated. 
 Significant efforts are typically invested in attempts to identify all of the 
possible physical forms in which a drug can exist.2-4  In the case of levofloxacin, a 
broad spectrum fluoroquinolone antibiotic which is the S-enantiomer of 
ofloxacin and is twice as potent as the racemate,5 initial studies showed that it 
could exist in three anhydrous forms (!, ", and #), a hemihydrate form, and a 
monohydrate form.1  An additional six forms (A, B, C, F, G, and H) were 
discovered later and are primarily solvates.6   
 The crystal structures and dehydration behavior of the hemihydrate and 
monohydrate forms of levofloxacin were reported by Kitaoka et al.1  They 
produced the # and ! anhydrate forms, respectively, upon dehydration.  When 
the hemihydrate was heated in a differential scanning calorimeter (DSC), the 
melting of all three anhydrous forms was observed.  The authors concluded that 
the dehydration of the hemihydrate resulted in a collapse of the crystal lattice 
and, in some cases, produced a mixture of the anhydrous forms.  This conclusion 
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was based primarily on DSC experiments in which either the nitrogen gas flow 
rate or sample heating rate was changed, but little supporting data was provided 
from orthogonal techniques to reinforce those claims.  They also claimed that 
several of the experiments produced some amount of amorphous material, but 
they never directly observed any amorphous material. 
 The primary methods of characterization of levofloxacin so far have been 
DSC and powder X-ray diffraction (PXRD).  PXRD is effective at studying 
differences in crystal structure, which has made it the most common technique 
for the determination of polymorphic forms.  However, preferred orientation can 
cause dissimilarities in the PXRD patterns of samples that have the same crystal 
structure due to differences in the shape of the particles in the samples.7  DSC 
also has limitations because the material can convert between forms during the 
experiment.  Thus, the characterization of pharmaceutical solids often utilizes a 
variety of techniques in addition to DSC and PXRD.8-12 
 Levofloxacin was initially investigated as a possible model compound for 
physical form detection and quantitation studies.  However, the initial 
characterizations and attempts to produce the anhydrous forms led to 
observations that suggested the possible existence of a previously unknown 
physical form, the $ anhydrate, which was observed when the # anhydrate was 
cooled below 54 °C.  Additionally, data suggests that the crystal structure of the 
hemihydrate is closely related to the crystal structures of the $ and # anhydrous 
forms.  These three forms appear to interconvert reversibly based upon their 
storage conditions (temperature and relative humidity).  The initial observations 
and the subsequent characterization of the materials are reported below. 
26 
2.2 Experimental 
 
2.2.1 Materials 
 Levofloxacin was purchased from Sigma-Aldrich (Fluka 28266 Lot 
1238030, St. Louis, MO) and used without further processing, except where 
noted.  Single crystals of levofloxacin hemihydrate were grown from mixtures of 
acetonitrile and water with water activities of 0.1 to 0.5 (0.0035 to 0.0280 mL 
H2O/mL acetonitrile).  Excess levofloxacin was added to each solution at room 
temperature.  The solutions were then heated to approximately 80 °C to dissolve 
all of the material and then allowed to slowly cool back to room temperature 
overnight. 
 XRF Thin Mylar® support film was purchased from SPI Supplies (West 
Chester, PA).  The film was microfine polyester (Mylar®) with a thickness of 
0.00010” or 2.5 µm. 
 
2.2.2 Thermogravimetric Analysis (TGA) 
 Levofloxacin was analyzed by TGA (Q50 TGA from TA Instruments, New 
Castle, DE) to ascertain residual solvent content and determine the degradation 
temperature.  Approximately 2.75 mg of material was placed in a platinum pan 
and heated from room temperature to 500 °C at a rate of 10 °C/min under a dry 
nitrogen atmosphere (total N2 flow rate = 100 mL/min).  The temperature was 
calibrated by the Currie point method with alumel (TC = 154.16 °C) and nickel (TC 
= 358.28 °C). 
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2.2.3 Differential Scanning Calorimetry (DSC) 
 A Q100 DSC from TA Instruments (New Castle, DE), with a refrigerated 
cooling system, was utilized to characterize levofloxacin samples.  
Approximately 2.6 mg of levofloxacin was placed in an aluminum pan without a 
lid and was heated from 0 to 250 °C at a rate of 10 °C/min.  A hermetically sealed 
aluminum pan containing 1.14 mg of levofloxacin hemihydrate was heated from 
0 to 150 °C at a rate of 20 °C/min, then cooled to 0 °C, and finally heated to 250 
°C at 20 °C/min. 
 The thermal behavior of each of the anhydrous forms of levofloxacin was 
investigated using DSC by analyzing 2.7 to 3.7 mg of levofloxacin hemihydrate 
placed in aluminum pans without lids.  The # anhydrous form of levofloxacin 
was studied by heating from -50 to 90 °C at a rate of 10 °C/min, held 
isothermally for 30 min, then cooled to -50 °C at 10 °C/min, reheated to 90 °C at a 
rate of 10 °C/min, cooled back to -50 °C at 10 °C/min, and finally heated to 250 
°C at 30 °C/min.  The " and ! anhydrous forms of levofloxacin were studied by 
heating from 40 to 226 or 231 °C (for the " and ! forms respectively) at a rate of 
30 °C/min, held at the appropriate temperature for 2 min, cooled to 0 °C, and 
then heated to 250 °C at 30 °C/min. 
 All samples were analyzed in a dry nitrogen atmosphere (N2 flow rate = 
50 mL/min).  The temperature was calibrated by observation of the melting 
point of decane (TM = -26.7 °C), indium (TM = 156.60 °C), and tin (TM = 231.9 °C).  
The melting of indium (%HF = 28.11 J/g) was also used to measure the cell 
constant. 
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2.2.4 Raman Spectroscopy 
 Raman spectra of levofloxacin were collected on a HoloLab series 5000 
Raman Microscope from Kaiser Optical Systems, Inc. (Ann Arbor, MI).  Single 
crystals of levofloxacin hemihydrate were placed on gold-coated microscope 
slides for analysis with the 20x objective.  Data was collected with the 
HoloGRAMS software (version 4.1) using a 10 sec exposure time repeated 6 
times with cosmic ray filtering.  The spectra were collected from 75 to 1876.8 cm-1 
with a data spacing of 0.3 cm-1.  Data was transferred to GRAMS/32 software 
(version 6.00) and then saved.  Variable temperature studies were performed 
with a Mettler Toledo FP82HT HotStage and a FP90 Central Processor 
(Columbus, OH).  Levofloxacin hemihydrate crystals were heated on the hot 
stage to remove the water of hydration.  While at elevated temperature, the 
crystals were covered with a microscope cover slip and high vacuum grease was 
placed around the edges to prevent adsorption of water when the crystals were 
cooled.  The temperature of the hot stage was checked by observing the melting 
point of 3-methylglutaric acid (mp ~86 °C). 
 
2.2.5 Powder X-Ray Diffraction (PXRD) 
 PXRD patterns were collected on a Bruker AXS GADDS/D8 Discover 
diffractometer system (Madison, WI) with a CuK! radiation source.  The sample 
was oscillated during the 60 sec period of data collection, which covered a 2& 
range from 6 to 38.2° with a resolution of 0.05°.  The sample was held on a 
variable temperature XYZ stage and the sample temperature was controlled with 
the GADDS software.  Hemihydrate material was heated to 90 °C to remove the 
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water of hydration and prior to cooling to ambient temperature the material was 
covered with two layers of Mylar® film, attached with high vacuum grease, to 
prevent rehydration of the material.  The dehydrated levofloxacin was heated 
from 25 to 95 °C and subsequently cooled to 30 °C with diffraction patterns 
collected approximately every 5 °C, during both the heating and cooling steps, 
following a 10 min equilibration period at each temperature. 
 
2.2.6 Solid-State NMR (SSNMR) Spectroscopy 
 Levofloxacin 13C data was collected with a Chemagnetics CMX-300 
spectrometer (Fort Collins, CO) operating at a 1H resonance frequency of 300 
MHz.  Samples were packed into 7.5 mm ZrO2 rotors and held in the rotor with 
Kel-F® end caps, with the top cap containing a small hole to allow water vapor 
to escape.  The packed rotor was spun at the magic angle (MAS)13 at a rate of 4 
kHz with dry compressed air (dew point -40 °C).  Free induction decays (FIDs) 
were collected on a Chemagnetics HX probe using a ramped amplitude cross-
polarization (CP)14 sequence with total suppression of spinning sidebands 
(TOSS)15,16 and approximately 66 kHz of proton decoupling using the SPINAL-
6417 method.  Between 800 and 3,600 transients were collected for each FID with a 
pulse delay of either 1, 3, or 5 sec and a contact time of either 2.5 or 1 msec for 
hemihydrate and the dehydrate respectively.  The FIDs contain 2,048 points with 
a dwell time of 33.3 µsec.  Spectra were externally referenced to tetramethylsilane 
(TMS) using the methyl peak of 3-methylglutaric acid (MGA) at 18.84 ppm.18  The 
temperature of the exhaust gas was used to determine the sample temperature 
based upon calibration with lead nitrate.19  Peaks in the spectra were assigned 
based upon 13C chemical shift predictions from the ChemBioDraw Ultra software 
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package (version 11.0 from CabridgeSoft) and dipolar dephasing experiments 
using a 60 µsec delay between CP and decoupling.20 
 The 13C MAS direct polarization spectra were collected on the same CMX-
300 spectrometer.  In these experiments the 13C nuclei were polarized with a 5.1 
µsec pulse followed by continuous wave (CW) proton decoupling.  Each FID was 
the sum of between 32 and 168 transients that were collected with a pulse delay 
of 120 sec and consisted of 1024 points with a dwell time of 33.3 µsec.  The 
spectra were the result of applying 20 Hz of exponential apodization prior to 
Fourier transformation and they were externally referenced in the same manner 
as the 13C CPMAS spectra. 
 Additional SSNMR spectra of levofloxacin were collected on a Bruker 
Avance DSX 500 MHz (1H frequency) NMR spectrometer (Billerica, MA).  
Samples were packed into 4 mm ZrO2 rotors and held in the rotor with either a 
Kel-F® or o-ring sealed Torlon® drive cap, for levofloxacin hemihydrate and 
dehydrated levofloxacin hemihydrate respectively.  The dehydrated material 
was prepared by storage of a rotor, packed with levofloxacin hemihydrate, over 
P2O5 at 70 °C for 16 hrs prior to insertion of the o-ring sealed drive cap.  The 
packed rotors were oriented at the magic angle13 and spun at a rate of 15 kHz 
with compressed nitrogen gas.  FIDs were collected on a Bruker-Biospin BL HFX 
probe using either a direct polarization sequence, for 1H and 19F, or a ramped 
amplitude CP14 sequence, for 13C.  The 19F and 13C data was also collected using 
approximately 85 kHz of proton decoupling via the two-pulse phase modulated 
(TPPM)21 method.  The 1H spectra are the result of 1 to 2 transients collected with 
an effective pulse delay of 40 sec and the FIDs consist of 3,598 points with a 
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dwell of 11.1 µsec.  19F spectra are the result of 64 transients collected with a pulse 
delay of 13 and 60 sec for hemihydrate and dehydrated materials respectively, 
and the FIDs contain 1,024 data points with a dwell of 10.9 µsec.  The 13C spectra 
are the result of between 2,048 and 4,096 transients collected with a pulse delay 
of either 1.5 or 2 sec and a contact time of 2 msec, while the FIDs contain 1,024 
data points with a dwell of 33.3 µsec.  Spectra were externally referenced to TMS 
using either H2O at 4.7 ppm for 1H, trifluoroacetic acid in water at -76.54 ppm for 
19F, or the upfield peak of adamantane at 29.5 ppm for 13C.  The temperature of 
the exhaust gas was used to reflect the sample temperature but was not 
calibrated due to safety concerns related to the use of lead compounds within the 
facility. 
 
2.2.7 Single Crystal X-Ray Diffraction 
 The levofloxacin hemihydrate crystal structure was determined at 296 K 
(23 °C) on a Bruker APEX diffractometer using CuK! radiation (1.54178 Å).  The 
crystal structure was solved by direct methods with SHELX Version 5.1 (Bruker 
AXS) and subsequently refined by the full-matrix least squares method.  The 
locations of the hydrogen atoms of the carboxylic acid groups were found with 
the Fourier difference map and were refined with restrained distances.  A final 
difference Fourier revealed no missing or misplaced electron density.  Data was 
visualized using the Mercury 2.2 software package from the Cambridge 
Crystallographic Data Centre (CCDC). 
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2.3 Results & Discussion 
 
2.3.1 Thermal Analysis (DSC/TGA) 
 The material that was obtained from Sigma-Aldrich was characterized by 
TGA and showed a mass loss of 2.59% when heated to 70 °C (Figure 2.1).  This 
mass loss agrees well with the theoretical water content of levofloxacin 
hemihydrate (2.43%) and previous observations.1  The observed mass loss is 
slightly higher than the theoretical value and may reflect the presence of some 
additional water adsorbed to the surface of the particles.  Thus the levofloxacin 
material will from this point forward be referred to as levofloxacin hemihydrate.  
No further significant mass loss was observed until the material reached 240 °C, 
at which point the material appears to undergo degradation.  DSC of the 
levofloxacin hemihydrate (Figure 2.1) shows an endothermic transition over a 
broad temperature range (20 to 70 °C) that corresponds to the 2.59% mass loss 
that was observed by TGA.  Three endotherms are also observed, which 
correspond to melting of the three anhydrous forms of levofloxacin,1 # ( 225.4 °C), 
" ( 229.6 °C), and ! ( 232.7 °C).  Additionally, an exothermic event was observed 
between the melting of the # and " forms, likely due to crystallization of ! or " 
forms from the melted # form.  It is not clear from the data shown in Figure 2.1 if 
dehydration resulted in a mixture of physical forms, as Kitaoka et al.1 
hypothesized, or a pure # form that produced the other forms after it melted. 
 If dehydration of levofloxacin hemihydrate results in collapse of the 
crystal lattice, it would be expected that the material would not readily take up 
water to reform the hemihydrate.  In order to test this hypothesis, the
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Figure 2.1  DSC (––––) and TGA (- - -) thermographs for levofloxacin hemihydrate.  Loss 
of the water of hydration occurs over a temperature range from 30 to 70 °C.  The mass 
loss (2.59%) is consistent with the theoretical water content of 2.43% for levofloxacin 
hemihydrate.  Melting of all three anhydrous forms of levofloxacin is also observed in 
the DSC thermograph, # (225.4 °C), " (229.6 °C), and ! (232.7 °C). 
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levofloxacin material was heated in a hermetically sealed pan and subsequently 
cooled to observe the behavior of the dehydrated material.  The resulting DSC 
thermograph is shown in Figure 2.2.  The increased pressures in the sealed pan 
resulted in dehydration at a higher temperature (approximately 110 °C).  A 
broad exotherm was observed at 100 °C when the material was cooled.  This 
appears to indicate that the water vapor adsorbed to the material at 
approximately the same temperature as the dehydration event.  The similarity of 
the dehydration endotherm and adsorption exotherm appears to indicate that the 
crystal lattice did not collapse.  When the material was reheated the same 
endotherm was observed at 110 °C, indicating that the hemihydrate was 
produced during the cooling step.  Further heating of the material resulting in a 
relatively sharp endotherm that was consistent with melting of the # form. 
 If amorphous levofloxacin was produced by the dehydration of the 
hemihydrate it might readily crystallize as the hemihydrate in the presence of the 
water vapor, which could explain the exotherm that was observed in Figure 2.2.  
Therefore, a similar experiment (Figure 2.3) was performed except the water 
vapor was allowed to escape to reduce the likelihood of crystallization due to the 
presence of the water, which was seen in the sealed pan.  Levofloxacin 
hemihydrate was heated to 90 °C in an open pan and held isothermally for 30 
min.  The subsequent heating and cooling steps did not show any events that 
would be consistent with the presence of any amorphous material.  However, the 
dehydrated material does show various endo- and exothermic events when 
heated and cooled, respectively. 
 A previously unreported exothermic event was observed at 54 °C when 
the dehydrated levofloxacin hemihydrate was cooled (Figure 2.3).  The event
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Figure 2.2  DSC thermograph of levofloxacin hemihydrate sealed in a hermetic 
aluminum pan.  The initial heating (blue) shows an endotherm centered at 110 °C, 
which likely corresponds to dehydration.  When the sample is cooled (red) an exotherm 
occurs at a similar temperature.  The second heating (green) of the sample shows an 
endotherm at a slightly higher temperature than the first heating period and the sample 
eventually melts as the # anhydrate of levofloxacin. 
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Figure 2.3  DSC thermograph of levofloxacin hemihydrate analyzed in an aluminum 
pan without a lid.  The insert expands the data from the temperature cycles between -50 
and 90 °C.  The initial heating (red) shows dehydration at approximately 55 °C.  When 
the sample was cooled (fuchsia) an exotherm is observed at 55 °C.  The second heating 
(black) of the sample presents two endotherms at 20 and 55 °C, respectively.  A second 
cooling period (magenta) shows an exotherm, comparable to the first cooling period.  
The final heating (green) shows two endotherms that appear similar to the endotherms 
that were observed during the second heating period.  Melting of the three, anhydrate 
forms of levofloxacin (#, ", and !) is also observed in the final heating period. 
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occurred at the same temperature as the dehydration but has a significantly 
smaller heat of transition.  Heating of the material resulted in two endothermic 
events at 20 and 54 °C.  The endotherm at 54 °C was similar to the heat of 
transition and the temperature of the exotherm that was observed during 
cooling.  This suggests that the process may be reversible but it does not seem to 
be consistent with the previously observed dehydration/hydration behavior.  
The second cooling of the dehydrated material displayed behavior that was 
virtually identical to the first cooling.  Subsequent heating of the material at an 
elevated heating rate showed the same two endotherms, suggesting that both of 
the events are reversible.  The event at 54 °C did not change in temperature when 
the heating rate was changed, suggesting that the event is thermodynamic, rather 
than kinetic.  Conversely the 20 °C event appears to be kinetic because it shifted 
to approximately 26 °C when the heating rate was increased.  However, while 
the event does seem to be reversible, a corresponding exotherm is not observed 
when the sample is cooled. 
 It is not clear what physical changes in the dehydrated levofloxacin 
produce the transitions that are observed in Figure 2.3.  When the dehydrated 
levofloxacin was finally heated to 250 °C, melting of all three anhydrous forms 
was observed (Figure 2.3).  In an effort to understand if the low temperature 
transitions were related to the # anhydrate, another anhydrous form, or a 
combination of the forms, the data in Figures 2.4 and 2.5 were collected.  During 
these experiments the levofloxacin hemihydrate was heated to either 226 or 231 
°C to ensure melting of only # or both # and " forms, respectively.  The resulting 
materials were cooled and reheated to see if the same low temperature
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Figure 2.4  DSC thermograph of levofloxacin hemihydrate analyzed in an aluminum 
pan without a lid.  The initial heating (blue) to 226 °C shows an endotherm centered at 
75 °C, which is consistent with dehydration.  When the sample is cooled (red) no 
exotherm or other event is observed.  The second heating (green) of the sample shows 
only two endotherms corresponding to melting of the " and ! anhydrous forms of 
levofloxacin. 
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Figure 2.5  DSC thermograph of levofloxacin hemihydrate analyzed in an aluminum 
pan without a lid.  The initial heating (blue) to 231 °C shows an endotherm centered at 
75 °C, which is consistent with dehydration, and melting of the # anhydrous form of 
levofloxacin.  When the sample is cooled (red) a broad exotherm is observed at 
approximately 225 °C.  The second heating (green) of the sample shows only one 
endotherm corresponding to melting of the ! anhydrous form of levofloxacin. 
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transitions would be observed.  Figure 2.4 contains the data from the experiment 
where the material was initially heated to 226 °C to melt only the # form.  When 
the sample was cooled and reheated the only observed events were melting of 
the " and ! forms.  Similar results were observed when the material was initially 
heated to 231 °C (Figure 2.5), except only melting of the ! form was observed 
during the second heating step.  An exothermic event may also have occurred at 
the beginning of the cooling step (Figure 2.5), and likely represents 
crystallization of the ! form from melted levofloxacin.  This data indicates that 
the low temperature transitions are either isolated to the # form or at least require 
the presence of the # form. 
 
2.3.2 Raman Spectroscopy 
 The Raman spectrum of levofloxacin hemihydrate is shown in Figure 2.6.  
Unfortunately there is no previously reported Raman data that can be used to 
confirm that the material is consistent with the previously reported hemihydrate 
materials.  The spectrum was collected on a microscope in order to use a hot 
stage to examine the effects of dehydration and temperature upon levofloxacin 
hemihydrate.  When the levofloxacin hemihydrate was dehydrated there were 
significant changes in the Raman spectrum (Figure 2.6).  Unfortunately, there is 
also no reference Raman data for the anhydrous forms of levofloxacin.  
Therefore, it is not possible to identify the physical form or forms that were 
present in the dehydrated material. 
 The dehydrated levofloxacin hemihydrate was sealed under a glass cover 
slip with grease, which prevented levofloxacin hemihydrate from forming when
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Figure 2.6  Raman spectrum of a single crystal of levofloxacin hemihydrate that was 
grown from an acetonitrile solution with a water activity of 0.2.  The crystal was heated 
to 85 °C to remove the water of hydration.  The spectrum of the resulting anhydrous 
material is shown for comparison. 
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the material was cooled to 30 °C.  The dehydrated material was then heated and 
Raman spectra were collected at various temperatures (Figure 2.7).  There were 
no obvious changes in the Raman spectra that were collected from 30 to 100 °C; 
however, some very subtle changes were observed below 700 cm-1.  The changes 
are indicated by arrows in Figure 2.7 and were most apparent at approximately 
206, 268, 318 to 364, 494, 557, 588, 598, and 631 cm-1.  In addition, these changes 
occurred around 48 °C and were reversible when the material was cooled (data 
not shown).  At the conclusion of the experiment the cover slip was removed and 
the Raman spectrum of the resulting material matched the spectrum of the initial 
levofloxacin hemihydrate. 
 These variable temperature Raman investigations were consistent with the 
previous DSC observations.  Following dehydration of levofloxacin hemihydrate 
the resulting material has the ability to readily reform levofloxacin hemihydrate 
when cooled in the presence of water vapor.  In addition, when the dehydrated 
levofloxacin hemihydrate is protected from water vapor it undergoes a reversible 
transformation at approximately 50 to 55 °C.  Unfortunately, the hot stage did 
not have the ability to cool the sample so it was not possible to use Raman to 
investigate the endothermic event that was observed at around 20 °C by DSC for 
the dehydrated material. 
 
2.3.3 PXRD 
 A reference PXRD pattern of levofloxacin hemihydrate was published by 
Kitaoka et al.1 and could be compared with the pattern in Figure 2.8.  
Unfortunately the relatively low quality of the reference data prevents an 
unambiguous match of the patterns.  However, the two patterns are similar and
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Figure 2.7 Raman spectra of the dehydrated levofloxacin hemihydrate single crystal 
(Figure 2.6) collected at the indicated temperatures.  The crystal was dehydrated at 85 °C 
and then was protected from water vapor with a cover slip and high vacuum grease.  
The anhydrous material was then cooled to 30 °C and then progressively heated to 100 
°C with spectra collected at various points during the heating.  The red arrows designate 
locations of spectra changes that occur during heating.  The spectrum of the original 
hemihydrate material is shown for comparison; note that this spectrum was collected 
without the cover slip in place.  Other portions of the spectra were omitted because they 
did not change during the experiment. 
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Figure 2.8 PXRD pattern of levofloxacin hemihydrate.  The material was heated to 90 °C 
to remove the water of hydration, and the PXRD pattern of the resulting anhydrous 
material is shown at 90 °C.  The material was protected from water vapor with a double 
layer of Mylar® film prior to cooling to 25 °C.  The PXRD pattern of the cooled, 
dehydrated material is also shown.  * = Peaks that are characteristic of levofloxacin 
hemihydrate. 
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the pattern in Figure 2.8 is not consistent with the diffraction patterns of any of 
the other levofloxacin materials that the authors reported.1 
 Dehydration of levofloxacin hemihydrate at 90 °C produced significant 
changes in the PXRD pattern (Figure 2.8), reflecting significant changes in the 
crystal structure upon dehydration.  The diffraction pattern of the dehydrated 
material at 90 °C is similar to the data that was reported by Kitaoka et al.1 when 
levofloxacin hemihydrate was heated to 108 °C.  However, as with the Raman 
spectra it is not possible to identify the physical form or forms that may be 
present due to a lack of reference data for the anhydrous forms.  The dehydrated 
levofloxacin hemihydrate was protected from atmospheric water vapor with 
Mylar® film and the material was cooled to 25 °C.  The resulting diffraction 
pattern is shown in Figure 2.8 and displays subtle differences from the 
dehydrated material at 90 °C.  In addition, three small diffraction peaks were 
observed in the cooled material, which indicate that a small amount of 
hemihydrate was present in the material. 
 PXRD patterns were collected at a variety of temperatures in order to 
identify the temperature at which these subtle changes in the diffraction pattern 
occur (Figure 2.9).  The diffraction pattern changed when the dehydrated 
material was heated from 47 to 52 °C.  Specifically, changes were observed at 
13.5, 18, 21.4, 22.9 to 24, 25.8 to 28, and 31.4 °2&.  These changes were reversible 
when the material was cooled, and the temperature of the conversion was the 
same as when the material was heated.  The observations are consistent with the 
DSC and Raman studies where an unidentified transition occurs in the 
dehydrated levofloxacin at 50 to 55 °C and appears to be reversible.  
Additionally, the PXRD results indicate that the transition is related to a change
46 
 
 
 
 
 
 
 
Figure 2.9  PXRD patterns of hemihydrate hemihydrate following dehydration at 90 °C 
and protection from water vapor with a double layer of Mylar® film.  Diffraction 
patterns were collected approximately every 5 °C as the material was heated from 25 to 
95 °C and subsequently cooled to 30 °C.  * = Peaks that are characteristic of levofloxacin 
hemihydrate. 
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in the crystal structure, albeit a subtle change.  Unfortunately, the equipment did 
not have the ability to cool the sample and thus PXRD could not be used to 
investigate the lower temperature transition that was observed in the DSC 
experiments. 
 The peaks associated with levofloxacin hemihydrate increased in intensity 
(Figure 2.9) until the sample was heated over 52 °C, at which point the peaks 
disappeared.  When the dehydrated material was cooled back to 35 °C the peaks 
were observed and increased in intensity when the sample was cooled further.  
The Mylar® film is not impervious to water and thus water vapor is able to 
slowly diffuse though the film and generate levofloxacin hemihydrate when the 
temperature is sufficiently low.  However, this process is very slow which 
minimized the levels of hemihydrate that formed during the variable 
temperature experiments.  After the dehydrated material was cooled back to 30 
°C the Mylar® film was removed and the PXRD pattern (not shown) revealed 
that the material rapidly converted back to levofloxacin hemihydrate after 
exposure to atmospheric water vapor.  This observation is also consistent with 
the earlier studies, which showed that the dehydrated levofloxacin hemihydrate 
readily takes up water vapor to produce the hemihydrate when it is below the 
dehydration temperature. 
 
2.3.4 SSNMR (1H 300 MHz) 
 The 13C cross-polarization magic angle spinning (CPMAS) spectrum of 
levofloxacin hemihydrate is shown in Figure 2.10.  The assignments of the peaks 
in the spectrum reveal that, for the most part, each carbon atom gives rise to one 
peak in the spectrum.  The piperazine ring contains four carbons but only
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Figure 2.10  13C CPMAS spectra (1H 300 MHz) of levofloxacin hemihydrate and 
dehydrated levofloxacin hemihydrate.  The peak assignments are from dipolar 
dephasing experiments and ChemBioDraw software predictions of 13C chemical shifts in 
solution. 
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displays two peaks because in the levofloxacin hemihydrate the chemically 
equivalent pairs (C-3’,5’ and C-2’,6’) likely do not have sufficiently different 
environments to yield distinct peaks.  Three carbons (C-1, C-7, and C-7’) are split 
into two peaks each, which can be explained by the previously reported crystal 
structure of levofloxacin hemihydrate.1  The crystal structure consists of two 
molecules in the asymmetric unit cell (Z’ = 2) indicating that there are two 
different molecular conformations that exist within the crystal structure.  
Therefore, some carbons give rise to two peaks, one for each of the conformations 
that exist in the crystal structure. 
 When levofloxacin hemihydrate was dehydrated there were significant 
changes in the 13C spectrum; however, due to a number of complicating factors 
the assignment of the peaks was performed at -20 °C.  Figure 2.10 shows the peak 
assignments for the dehydrated material.  Many of the carbon atoms produce a 
single peak after dehydration, and the piperazine ring carbons still yield only 
two peaks.  However, C-5 (assignments from dipolar dephasing experiment) and 
C-10 show peak splitting that is consistent with a Z’ = 2, and C-7’ is no longer 
split into two peaks.  In addition, splitting is observed in the peaks around 123 
ppm (three peaks representing two carbon atoms) but it is not clear which carbon 
atom is associated with the splitting.  The shape of the downfield peak (124.7 
ppm) suggests that it is coupled to nitrogen and thus would be C-14, and the 
other two peaks (121.3 and 123.0 ppm) appear more symmetrical in shape and 
seem to be consistent with C-9.  These observations suggest that only one 
crystalline form of levofloxacin was present following dehydration.  If multiple 
crystalline forms were present it would be expected that more peaks would be 
observed.  In addition, there is no evidence of any amorphous levofloxacin being 
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present after dehydration of the hemihydrate. 
 As the dehydrated levofloxacin hemihydrate was heated to 20 °C (Figure 
2.11) the peaks of the piperazine ring carbons gradually decreased in intensity 
and broadened.  One potential explanation is a reduction in CP efficiency 
resulting in reduced magnetization transfer to the piperazine carbons.  If changes 
in CP efficiency are the cause of the peak disappearance then direct polarization 
experiments should not show the same behavior because CP is not used to 
polarize the 13C nuclei.  In fact, direct polarization experiments (Figure 2.12) do 
show the same disappearance of the piperazine peaks, which suggests that the 
actual cause is a loss of 1H decoupling.  This effect is isolated to the piperazine 
ring and suggests that the ring is undergoing motions and that those motions are 
beginning to occur on the timescale of the decoupling (66 kHz) or MAS rate (4 
kHz) at around 0 to 20 °C. 
 When the dehydrated material was heated further (Figure 2.11) all of the 
peaks that were split appear to merge into a single peak.  Thus above 50 °C each 
carbon atom yields only one peak, except for the piperazine ring carbons which 
are still too broad to be observed.  The splitting in the 13C CPMAS spectra of the 
dehydrated levofloxacin hemihydrate at temperatures below 50 °C suggested 
that the crystal structure contained two molecules in the asymmetric unit cell (Z’ 
= 2).  The loss of that splitting above 50 °C indicates that the crystal structure has 
changed and now only contains one molecule per asymmetric unit cell (Z’ = 1).  
The levofloxacin hemihydrate (Figure 2.13) did not display any changes over the 
entire temperature range (-20 to 60 °C), with the exception of the highest 
temperature where peaks associated with the dehydrated material were 
observed. 
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Figure 2.11  13C CPMAS spectra (1H 300 MHz) of dehydrated levofloxacin hemihydrate 
at various temperatures.  Between -20 and 20 °C significant changes are observed in the 
peaks for the piperazine ring carbons.  At 50 °C there is a change in the splitting 
behavior of the peaks of carbons 1, 5, 10, and either 9 or 14. 
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Figure 2.12  13C MAS spectra (1H 300 MHz) of dehydrated levofloxacin hemihydrate at 
various temperatures.  The spectra display the same trends as the CPMAS spectra in 
Figure 2.13, indicating that none of the changes are due to a change in the ability to 
perform cross polarization between 1H and 13C.  * = spinning sidebands 
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Figure 2.13  13C CPMAS spectra (1H 300 MHz) of levofloxacin hemihydrate at various 
temperatures.  There are no significant differences in the spectra apart from the 
appearance of small peaks in the spectrum at 60 °C due to some dehydration of the 
material.  * = Peaks that are associated with dehydrated levofloxacin hemihydrate. 
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2.3.5 SSNMR (1H 500 MHz) 
 In order to confirm the SSNMR observations and see how they would 
change with field strength, both the hemihydrate and the anhydrous materials 
were also studied with a spectrometer operating at a 1H frequency of 500 MHz.  
The 1H spectrum of levofloxacin hemihydrate (Figure 2.14) does not display any 
clearly resolved peaks, which is typical for pharmaceutical solids.  But when the 
material was dehydrated the resolution of the peaks improved, suggesting that 
there is increased mobility of the material.  Based on the previous data (1H 300 
MHz) the increased mobility is likely associated with the piperazine ring.  This is 
supported by the 13C spectra (Figure 2.15), which are consistent with the previous 
experiments (Figure 2.11). 
 Safety concerns prevented calibration of the sample temperature.  Thus 
the reported temperatures reflect the temperature of the gas that was escaping 
the spin module, which contained the sample.  Based upon previous work it is 
known that spinning of a sample, in the probe that was used, results in sample 
heating of approximately 35 °C when no temperature control is used.  Therefore, 
the reported temperatures in Figures 2.14, 2.15, and 2.16 could be as much as 35 
°C below the actual sample temperature, although the use of temperature control 
likely reduces the differences between the measured temperature and actual 
sample temperature. 
 The 13C spectra (Figure 2.15) are consistent with the previously observed 
changes in dehydrated levofloxacin hemihydrate when the temperature is 
changed.  The disappearance of the piperazine ring peaks appears to occur at 
about the same temperature but is actually occurring at a higher sample 
temperature (see discussion above about sample heating).  This transition was
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Figure 2.14  1H MAS spectra (1H 500 MHz) of levofloxacin hemihydrate and dehydrated 
material at various temperatures.  Temperatures are only approximate as spinning at 15 
kHz results in sample heating of approximately 35 °C when the temperature of the 
sample is not controlled.  * = spinning sidebands 
56 
 
 
 
 
 
 
 
 
 
Figure 2.15  13C CPMAS spectra (1H 500 MHz) of levofloxacin hemihydrate and 
dehydrated material at various temperatures.  The spectra are consistent with the 
spectra collected at lower field strength (1H 300 MHz), particularly the disappearance of 
the piperazine ring carbon peaks and loss of peak splitting in the dehydrated material.  
Temperatures are only approximate as spinning at 15 kHz results in sample heating of 
approximately 35 °C when the temperature of the sample is not controlled.  * = spinning 
sidebands 
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previously explained as a change in mobility of the ring resulting in a loss of 
decoupling efficiency.  The data in Figure 2.15 was collected with a higher 
decoupling field than the previous data (85 vs. 66 kHz) and thus it is not 
surprising that the peak disappearance would occur at a higher temperature.  
The motions would have to occur faster (shorter timescale) to match the higher 
decoupling frequency and as the temperature of the material increases so will the 
rate of the motions. 
 The loss of the peak splitting in the 13C spectrum appeared to occur at a 
lower temperature (30 °C in Figure 2.15) than the previous experiments (50 °C).  
The unaccounted sample heating likely results in an actual sample temperature 
that is approximately 15 to 25 °C higher than the observed temperature, thus the 
loss of splitting probably occurs closer to a sample temperature of 45 to 55 °C, 
which is consistent with the previous study.  This is also true of the 19F spectra 
that are shown in Figure 2.16. 
 Levofloxacin contains only one fluorine atom; however the 19F spectrum of 
the hemihydrate (Figure 2.16) displays two peaks due to the Z’ = 2.  When the 
hemihydrate is dehydrated and cooled to -20 °C it also displays two peaks, 
indicating that the crystal structure still has a Z’ = 2.  But the changes in the peak 
positions and the separation of the two peaks suggest that the crystal structures 
are different.  Interestingly, when the dehydrated material is heated the two 
peaks decrease in intensity and a new peak appears between them.  The presence 
of three distinct peaks indicates that these are separate molecular conformations 
or states.  If the transition was associated with exchange between two 
conformations or states then the peaks should coalesce into a single peak. 
 All of the previous DSC, Raman, and PXRD suggested that when
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Figure 2.16  19F MAS spectra (1H 500 MHz) of levofloxacin hemihydrate and dehydrated 
material at various temperatures.  The 19F spectra display the same change in peak 
splitting for the dehydrated material as the 13C spectra (Figure 2.15).  Temperatures are 
only approximate as spinning at 15 kHz results in sample heating of approximately 35 
°C when the temperature of the sample is not controlled. 
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levofloxacin hemihydrate is dehydrated there is a change in the physical form of 
the material.  In addition, if the material was protected from water vapor to 
prevent rehydration there appears to be a change in the crystal structure at 
around 50 to 55 °C.  SSNMR at two field strengths supports this hypothesis and 
suggests that the dehydration of the hemihydrate leads to a relatively pure 
crystalline form which has a Z’ of 1 at temperatures above 50 to 55 °C and a Z’ of 
2 below that temperature range.  This indicates that the dehydrated material 
undergoes a polymorphic transition between two anhydrous forms at 
approximately 54 °C, according to DSC. 
 The physical form above 54 °C must be the # form based on the melting 
point of the material; however, it is not clear if the form below 54 °C is one on the 
other known anhydrous forms.  According to the heat of transition rule, physical 
form changes observed as an endothermic transition (such as the one observed at 
54 °C by DSC) indicate that the polymorphs are enantiotropically related.22,23  The 
heat of fusion rule states that in an enantiotropic system the melting point of the 
form that is more stable at lower temperatures will be lower than the form that is 
more stable at high temperatures. 22,23  This dictates that both the ! and " forms 
cannot be the polymorph below 54 °C because they have melting points that are 
higher than the # form.  Hence the low temperature form must be a new 
anhydrous form, the $ form. 
Additionally, DSC of the levofloxacin displayed a reversible event that appeared 
to be kinetic in nature at approximately 20 °C (Figure 2.3).  The previous 
techniques could not study the phenomenon due to an inability to cool the 
samples during the analysis.  However, SSNMR was able to investigate lower 
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temperatures and did observe changes in mobility of the piperazine ring of 
levofloxacin over similar temperature ranges.  This suggests that the DSC may 
have been detecting changes in the mobility of the ring in the dehydrated 
material. 
 
2.3.6 Hemihydrate Crystal Structure 
 The crystal structure of levofloxacin hemihydrate was previously 
determined by Kitaoka et al.1; however, it is not available from the Cambridge 
Structure Database.  Therefore single crystals of levofloxacin hemihydrate were 
grown and then subjected to single crystal X-ray diffraction.  The resulting 
crystallographic data is provided in Table 2.1 and is in good agreement with the 
previously reported values.1 
 The molecular packing of the levofloxacin hemihydrate unit cell is show in 
Figure 2.17.  Interestingly, the water molecules appear to be hydrogen bonded to 
the methylated nitrogens of the piperazine rings.  In addition, the asymmetric 
unit cell contains two molecules (Z’ = 2), indicating that levofloxacin exists in two 
different conformations within the crystal structure.  When the levofloxacin 
molecules are colored according to their conformations (Figure 2.17, lower 
image) it is obvious that both molecules of levofloxacin that are hydrogen bound 
to a particular water molecule are in the same conformation.  Furthermore, these 
two conformations pack such that they produce planes that run parallel to the b-
axis and only one conformation is found within a plane. 
 The existence of these planes in the crystal structure suggests that the 
water molecules may align in a channel through the crystal.  The alignment of 
solvent molecules as a channel in the crystal structure is an important property
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Table 2.1  Crystal structure data and refinement parameters. 
 
 Hemihydrate 
Emerical Fomula C18H20FN3O4 ! 0.5 H2O 
Formula Weight (g/mol) 379.39 
Crystal System Monoclinic 
Space Group C2 
Unit Cell Dimensions  
A (Å) 28.758 
b (Å) 6.799 
c (Å) 18.765 
" (°) 113.85 
Volume (Å3) 3355.7 
Z 8 
Density (g/cm3) 1.431 
Absorption Coefficient (mm-1) 0.921 
F(000) 1520 
Reflections Collected 9932 
Independent Reflections 4745 
Parameters 500 
Goodness-of-fit on F2 1.099 
Final R indices [I>2' (I)] R1 = 0.0474    (R2 = 0.1121 
Largest Diffraction Peak and Hole (e/Å3) 0.590 and -0.757 
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Figure 2.17  Crystal structure of levofloxacin hemihydrate viewed along the b-axis.  The 
image in the top portion of the figure shows the packing of the molecules in the unit cell 
with the molecules colored according to the element of each atom.  The bottom image is 
identical to the top image except that the levofloxacin molecules have been colored 
according to their conformation, Conformation A (red) and Conformation B (green), and 
water molecules are shown in black. 
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because it can allow the crystal structure to take up or release solvent molecules 
without destroying the crystal lattice.24  The previous experiments (DSC, Raman, 
PXRD, and SSNMR) all demonstrated that levofloxacin hemihydrate could be 
dehydrated and would readily rehydrate in the presence of water vapor if the 
temperature was below approximately 55 °C.  This lends support to the idea that 
levofloxacin hemihydrate could be a channel hydrate. 
 The crystal structure of the hemihydrate is shown in Figure 2.18 with the 
atoms of the molecules represented in a space-filling model to represent the 
actual space that is taken up by each molecule.  When the water molecules are 
removed from the crystal structure (Figure 2.18, lower image) it is possible to see 
a void or “channel” though the crystal structure where the water molecules had 
been.  However, the Mercury CSD software package was used to perform a void 
space calculation on the crystal structure after the water molecules were 
removed.  This showed that while the water molecules are aligned in the crystal 
structure their locations are not connected by open spaces that are large enough 
to allow the passage of water molecules.  Therefore, levofloxacin hemihydrate 
does not meet the traditional definition of a channel hydrate. 
 While the hemihydrate does not fit the traditional definition of a channel 
hydrate it does seem to behave like one.  It was observed previously that the 
water molecules are associated with the piperazine rings by hydrogen bonding.  
Therefore, the rings line the water “channels”.  In addition, it was observed by 
SSNMR that the rings undergo dynamic motions once the water molecules are 
removed.  Thus it may be possible for a water molecule at the surface of the 
crystal to be removed and subsequently allow its neighboring piperazine ring to 
move.  The movement of the ring may open a space large enough for the
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Figure 2.18  Crystal structure of levofloxacin viewed along the b-axis with a space-filling 
model.  The packing has been replicated in each of the crystallographic dimensions to 
aid visualization.  The image in the top portion of the figure shows the levofloxacin 
hemihydrate crystal structure.  The bottom image is identical to the top image except 
that the water molecules were removed from the crystal structure. 
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neighboring water molecule to escape.  This behavior may then propagate down 
the “channel” and allow all of the water to be removed without causing the 
crystal lattice to collapse.  Conversely, under the appropriate conditions water 
molecules may be able to populate the channel and progressively fill the channel 
to reform the hydrate.  The formation of empty channels that are lined by the 
piperazine rings would also explain the ability of the rings to undergo dynamic 
motions in the dehydrated material.  In the hemihydrate the rings are held in 
place due to the presence of the water molecules, but once the water is gone the 
rings would have more space in which to undergo small motions. 
 The differences in the # and $ forms of levofloxacin appeared to be 
associated with a change from a crystal structure with a Z’ of 2 at low 
temperatures to a crystal structure with a Z’ of 1 at higher temperature.  The two 
conformations of levofloxacin from the crystal structure of the hemihydrate are 
overlaid in Figure 2.19.  Apart from the piperazine ring, levofloxacin is a fairly 
rigid molecule and thus carbons in the more rigid portion of the molecule were 
chosen for alignment to identify the differences in the conformations.  There are 
subtle differences in the methyl group (C-1), but it is not clear if those are due to 
uncertainties in the crystal structure.  More dramatic differences are observed in 
the piperazine ring, which is rotated approximately 90° about the C-6 N-1’ bond.  
Assuming that the crystal lattice of the hemihydrate is maintained upon 
dehydration it would appear that the most likely conformational change that 
would result in the Z’ change would be rotation about the C-6 N-1’ bond so that 
the two molecules are virtually identical.  This is also supported by the previous 
discussion regarding the presence of channels in the crystal structure.  The 
piperazine rings appear to have space to move and it may be sufficient for
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Figure 2.19 Overlay of the two conformations of levofloxacin in the levofloxacin 
hemihydrate crystal structure: Conformation A (red) and Conformation B (green).  The 
top and bottom images are different rotations of the overlay.  Hydrogen atoms have 
been removed and functional groups have been labeled to aid visualization. 
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rotation about that bond.  Therefore, it is thought that the crystal structure of the 
$ and # forms are very similar and primarily differ in the orientations of the 
piperazine rings to the remainder of the levofloxacin molecule. 
 
2.4 Summary 
 
 Kitaoka et al.1 previously studied the hemihydrate form of levofloxacin 
and hypothesized that dehydration of the material lead to collapse of the crystal 
lattice and resulted in formation of a mixture of anhydrous forms and in some 
cases produced amorphous levofloxacin.  They believed that the dehydration 
conditions determined which forms were generated and their relative 
proportions.  However, they offered limited data to support their claims. 
 SSNMR suggests that when levofloxacin hemihydrate is dehydrated a 
relatively pure crystalline form, specifically the # form, is produced.  
Additionally, when the dehydrated material is cooled below 54 °C, the 
levofloxacin converts to the $ form, which has not been reported previously.  The 
results also suggest that the crystal structures of the hemihydrate, #, and $ forms 
are all closely related, primarily with changes in the conformation and 
orientation of the piperazine ring relative to the rest of the molecule. 
 The crystal structure of levofloxacin hemihydrate does not fit the 
traditional definition of a channel hydrate.  However, the # and $ anhydrous 
forms readily hydrate to produce the hemihydrate in the presence of water 
vapor.  Additionally, the water molecules of the hemihydrate are aligned 
through the crystal structure.  Therefore, it proposed that levofloxacin 
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hemihydrate is a pseudo channel hydrate that behaves like a channel hydrate, 
but does not fit the traditional definition. 
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Chapter 3 
 
Detection of Physical Forms in Formulations 
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3.1 Introduction 
 
 The specific aim of this chapter is to characterize the physical form of the 
API within formulations.  Specifically, three formulations will examined to 
determine if the processing of the materials resulted in changes in the physical 
forms of the APIs.  The formulations will be evaluated by both DSC and SSNMR 
to evaluate the ability of each technique to determine the physical form of the 
API in the final formulation. 
 Particle engineering, particularly the preparation of nanoparticles, is one 
of the most popular technologies that is currently being developed and used to 
improve the delivery of poorly water soluble drugs.  When the particle size of a 
material is reduced, the relative surface area of that material is increased.  This 
increase in surface area leads to increases in dissolution rate, apparent solubility, 
and ultimately can dramatically impact the bioavailability of the drug.1,2  In 
addition, the drug can be dispersed in a slowly dissolving matrix to allow 
prolonged release of the drug.3-7 
 These formulations are carefully designed and developed to provide 
specific drug release profiles in order to achieve the desired outcomes.  However, 
the physical form of the API will also impact the release profile of the 
formulation.8  Therefore it is critical not only to measure physical properties such 
as particle size, but also to know the physical form of the API and if that form is 
physically stable.  A nanoparticle formulation may give improved dissolution 
properties immediately after production; however, those gains could be due to 
the formation of a metastable form of the API.  Over time the API may convert to 
a more stable form, resulting in changes in the dissolution or release profile and 
75 
ultimately diminishing the initial improvements that were observed with the 
formulation.   Despite these potential ramifications, some studies make no 
attempt to characterize the API physical form that is present within the 
formulation.9,10 
 Most characterization studies of the API physical form in nano- and 
microparticle formulations are limited to DSC,11 PXRD,12,13 or a combination of 
both techniques.8,14-16  In the introduction of the previous chapter some of the 
limitations of both DSC and PXRD in the detection of physical forms of 
pharmaceuticals are discussed; however, the presence of excipients can 
complicate the analysis of these materials.  One of the biggest issues in analyzing 
formulations by both DSC and PXRD is the potential for overlap of API and 
excipient signals.  Additionally, the drug loading may not be sufficient for 
detection by the instrumentation that is being utilized.  Furthermore, melting of a 
crystalline API may not be observed by DSC if the API forms a eutectic with a 
formulation component.17  It has also been observed that when the particle size of 
a material is reduced there will be a decrease in the observed melting point of the 
material.18  Therefore, interpretation of DSC thermographs of these types of 
formulations are fraught with complications and typically require several 
assumptions about the behavior of the materials that are being analyzed. 
 SSNMR has been used to identify physical forms of APIs within 
formulations,19,20 but not for the analysis of pharmaceutical nanoparticle 
formulations.  This chapter will present three examples of nanoparticle 
formulations that were analyzed by both DSC and SSNMR to compare the ability 
of both techniques to identify the API physical form within the formulations.  
The formulations were developed in the laboratory of Dr. Cory Berkland while 
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the subsequent characterization of the materials was performed in collaboration 
with the Munson laboratory.21-23 
 The remainder of this chapter has a non-traditional organization and is 
divided into subchapters that cover each of the APIs that were analyzed 
(budesonide, nifedipine, and ciprofloxacin).  Each of these subchapters contains a 
brief introduction to the work, experimental methods, results with discussion, 
and a brief summary.  Additionally, an overall summary of the general 
conclusions will be presented at the end of this chapter. 
 
3.2 Budesonide 
 
3.2.1 Background 
 Budesonide (Figure 3.1) is a corticosteroid that is used for the prophylactic 
treatment of asthma.  Dry powder and metered dose inhalation formulations 
have previously been developed for pulmonary delivery.  However, it was 
hypothesized that nanosuspension technology could be utilized to develop a 
formulation that, once inhaled, would provide rapid dissolution of budesonide 
despite its poor water solubility (approximately 21.5 µg/mL).  Nanoparticles of 
budesonide were generated and subsequently aggregated to produce particles 
with good aerodynamic characteristics and improved dissolution.  Unfortunately 
DSC analysis of the materials offered no clear insight into the physical state of 
the budesonide in the formulation.  SSNMR was able to clearly show that most of 
the budesonide was in an amorphous state and even suggests that a small 
amount of crystalline budesonide may be present within the formulation.22 
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Figure 3.1.  Chemical structures of budesonide (top), nifedipine (middle), and 
ciprofloxacin (bottom), shown with assigned atom numbering. 
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3.2.2 Experimental 
 
3.2.2.1 Materials 
 Budesonide, sodium chloride, L-!-phosphatidylcholine (lecithin), cetyl 
alcohol, L-leucine, polyvinylpyrrolidone, and sorbitan trioleate (Span 85) were 
obtained from Sigma Chemicals Co. (St. Louis, MO).  Pluronic F-127 (MW = 
12,220) was purchased from BASF, The Chemical Company (Shakopee, MN).  
Polyvinyl alcohol (MW = 22,000, 88% hydrolyzed) was purchased from Acros 
Organics (Fair Lawn, NJ).  Ethanol, acetone, acetonitrile, potassium dihydrogen 
phosphate, and disodium hydrogen phosphate were purchased from Fisher 
Scientific (Fair Lawn, NJ).  Deionized water was obtained from a Millipore 
EASYpure® RODI (Barnstead International, Model # D13321, Dubuque, IA).  All 
materials were used without further purification, and solvents were of HPLC 
grade. 
 
3.2.2.2 Nanoparticle and Agglomerate Preparation 
 Solutions of budesonide in acetone at concentrations of 0.1% (w/v) 
budesonide and 0.02% (w/v) lecithin were produced.  In order to form 
nanoparticles, water was utilized as an anti-solvent and was added to the 
budesonide/lecithin solution at a rate of 1 mL/min with simultaneous sonication 
(Fisher Scientific, Sonic Dismembrator, amplitude 46%) in an ice bath. 
 To agglomerate the nanoparticles, a 1% (w/v) L-leucine solution in water 
was slowly added to the nanoparticle suspension until a 1:1 budesonide:leucine 
ratio was achieved.  The addition of the L-leucine was performed with 
homoginization at 25,000 rpm for 30 sec.  Evaporation of the acetone was done 
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overnight at room temperature, at which point the nanoparticle agglomerate 
suspension was frozen at -80 °C and subsequently lyophilized for ~36 hr 
(Labconco, FreeZone 1, Kansas City, MO). 
 In order to produce amorphous budesonide, approximately 1 g of 
budesonide was placed in an oven that was preheated to 250 °C.  After the 
material melted it was immersed in liquid nitrogen.  This “melt-quenched” 
material was subsequently used as an amorphous budesonide reference material 
for subsequent analyses. 
 
3.2.2.3 DSC 
 A Q100 DSC from TA Instruments (see Section 2.2.3 of Chapter 2, New 
Castle, DE) was utilized to assess the physical form present in each of the 
materials: budesonide, lecithin, nanoparticles, and agglomerates.  Approximately 
5 mg of each nanoparticle/agglomerate sample was placed in a crimped 
aluminum pan for analysis; 1, 10, and 20 mg of material were used for stock 
budesonide, melt-quenched budesonide, and lecithin, respectively.  Lecithin was 
analyzed by heating from -70 to 260 °C at a rate of 5 °C/min.  Stock budesonide 
was heated from -40 to 260 °C at 10 °C/min, held isothermally for 5 min, then 
cooled back to -40 °C and reheated to 260 °C at 10 °C/min to check the feasibility 
of producing amorphous material from a melt-quench method.  The 
nanoparticles and agglomerates were heated from 40 to 260 °C at a rate of 5 
°C/min, except for the modulated DSC (MDSC) experiment which was 
performed on the nanoparticle sample by heating from -20 to 230 °C at 5 °C/min 
with a modulation of ± 0.8 °C every 60 sec. (heat only conditions). 
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3.2.2.4 TGA 
 Stock budesonide and leucine were analyzed by TGA (see Section 2.2.2 of 
Chapter 2, New Castle, DE) to ascertain residual solvent content and determine 
the degradation temperatures.  Approximately 2 mg of budesonide and 10 mg of 
leucine were each placed in platinum pans and heated from room temperature to 
over 300 °C at a rate of 10 °C/min. 
 
3.2.2.5 SSNMR Spectroscopy 
 SSNMR data was collected on a Chemagnetics CMX-300 spectrometer (see 
Section 2.2.6 of Chapter 2, Fort Collins, CO).  Samples were packed into 7 mm 
zirconia rotors and held in place with Teflon® end caps (Revolution NMR, Fort 
Collins, CO).  Packed rotors were spun with MAS24 at a rate of 4 kHz in a 7 mm 
spin module (Revolution NMR, Fort Collins, CO). 
 All 13C FIDs were collected with a ramped amplitude CP25 sequence with 
~81 kHz of proton decoupling using the SPINAL-6426 method.  Between 2,000 
and 48,000 transients were collected for each FID with a pulse delay of 1 – 1.5 sec, 
a contact time of 0.5 – 2 msec, and a 1H 90° pulse width of 3 – 4.5 µsec.  The FIDs 
contain 512 – 2,048 points with a dwell time of 33.3 µsec.  Spectra were externally 
referenced to TMS using the methyl peak of MGA at 18.84 ppm.27 
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3.2.3 Results & Discussion 
 
3.2.3.1 Particle Characterization 
 The budesonide nanoparticles had an average particle size of 161 ± 16 nm, 
while the nanoparticle agglomerates had geometric and aerodynamic diameters 
of approximately 3 and 1.4 µm, respectively.  The agglomerates gave favorable 
aerosolization characteristics with high emitted and respirable fractions of 75 and 
96%, respectively.  The fraction of budesonide that was dissolved after 8 hrs was 
highest for the nanoparticles (62%) and lowest for the stock budesonide, with the 
agglomerates showing intermediate dissolution (42%).  The differences in 
dissolution behavior were initially attributed to the differences in particle size, 
but further investigation was necessary to eliminate physical form differences as 
a contributing factor. 
 
3.2.3.2 Thermal Analysis (DSC/TGA) 
 The DSC thermograph of stock budesonide (Figure 3.2) contains an 
endotherm at 254 °C, which is assumed to be the melting point of the material.  
This is supported by TGA of budesonide which showed no significant mass loss 
below 300 °C (Figure 3.3).  The molten budesonide was rapidly cooled to -40 °C 
in the DSC and then reheated.  A glass transition was then observed at 96 °C 
(Figure 3.2), indicating that amorphous budesonide could be formed by rapid 
cooling of melted budesonide. 
 L-leucine shows complete mass loss above approximately 190 °C (Figure 
3.3), which agrees with its previously reported sublimation temperature.28  TGA
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Figure 3.2.  DSC of stock budesonide heated to 260 °C (blue), cooled to -40 °C, and then 
reheated to 260 °C (red).  The insert shows the glass transition that was observed during 
the second heating.  The Tg measurement is shown with the onset, offset, and inflection 
point (I) temperatures. 
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Figure 3.3.  TGA of stock budesonide and leucine heated to > 300 °C.  The mass loss for 
leucine agrees with the temperature of sublimation (approximately 175 to 190 °C) for L-
leucine, based on vapor pressure measurements reported by Svec and Clyde.28  The 
observed sublimation of L-leucine is likely observed at higher temperatures in the TGA 
because the system is being heated and not at equilibrium. 
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was not performed on lecithin; however, the series of sharp endotherms in its 
DSC thermograph suggest that it undergoes degradation above 160 °C (Figure 
3.4).  The broad endotherm in the lecithin DSC thermograph at 25 °C is likely due 
to melting of the material because the material has a soft, waxy appearance when 
it is handled at ambient conditions. 
 Amorphous budesonide was prepared by melting stock budesonide at 250 
°C in an oven, and then the molten material was immediately immersed in liquid 
nitrogen.  The DSC of the resulting melt quenched material did not show any 
endotherm at 254 °C that would correspond to the melting that was observed for 
stock budesonide (Figure 3.4).  Instead, the material shows a broad endotherm at 
80 °C and then a small, sharp endotherm at 220 °C followed by what appears to 
be degradation.  Amorphous materials typically contain adsorbed water and so 
the 80 °C endotherm likely represents dehydration of adsorbed water.  
Unfortunately, water acts as a plasticizer and will decrease the Tg of amorphous 
materials.  This endotherm occurs at temperatures just below the Tg that was 
observed when the stock material was temperature cycled in the DSC (Figure 
3.2), thus any glass transition that may be occurring in the melt quenched sample 
is probably masked by the dehydration endotherm.  There have been no reports 
of additional crystalline forms of budesonide (polymorphs or solvates) and the 
relatively small size of the endotherm at 220 °C suggests that the sample did not 
melt or contained only very small amounts of crystalline material.  So there is no 
clear evidence that the melt quenched sample displayed a glass transition; 
however, it did seem to contain adsorbed water and did not melt which suggests 
that it is actually amorphous. 
 Analysis of the nanoparticles by DSC showed two broad endotherms at 60
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Figure 3.4.  DSC overlay of stock budesonide, melt quenched budesonide, budesonide 
nanoparticles, agglomerates of budesonide nanoparticles, and lecithin.  For the stock 
budesonide the first heating (Figure 3.2) is shown to display the observed melting of 
budesonide.  The large endotherm at approximately 187 °C in the thermography of the 
agglomerates is consistent with sublimation of L-leucine (Figure 3.3). 
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and 230 °C (Figure 3.4).  The first endotherm is likely due to loss of adsorbed 
water; however the origin of the higher temperature transition is not as clear.  
The event is much broader and lower in temperature than the observed melting 
point of the stock budesonide.  The size of the nanoparticles cannot explain the 
dramatic difference in the temperatures of the melting point and the new 
endotherm (> 20 °C difference) because particles that are ~160 nm should only 
display a melting point depression of approximately 8 °C.18  Additionally, neither 
of the endotherms correspond to transitions that were observed for lecithin.  
Thus, the origins of the endotherm at 230 °C is unclear but likely due to either the 
presence of a previously unknown crystalline form of budesonide or formation 
of a eutectic with lecithin and budesonide. 
 Furthermore Figure 3.4 shows the DSC of the agglomerates, which also 
displays two broad endotherms.  One of the endotherms is at approximately 60 
°C and is similar to the endotherm that was observed with melt quenched 
budesonide and nanoparticles, and was attributed to dehydration.  However the 
second endotherm is very large and has an onset of 177 °C, which is consistent 
with sublimation of L-leucine (Figure 3.3).28  Therefore, the agglomerate 
thermograph does not seem to display any transitions that can be clearly 
attributed to budesonide in order to determine its physical state within the 
sample. 
 The melt quenched budesonide, nanoparticles, and agglomerates did not 
show any clear melting endotherms for crystalline budesonide and they lacked 
any obvious glass transition events.  Therefore, the thermographs in Figure 3.4 
were expanded to show the region in which the Tg of the temperature cycled 
stock budesonide was observed.  This expansion of the data is shown in Figure 
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3.5 with the exception that the second heating of the stock budesonide is shown 
to visualize the observed glass transition. 
 Figure 3.5 clearly shows the Tg, at 96 °C, of the stock budesonide when it 
was reheated.  The lecithin shows several small endotherms in this same 
temperature range, which are of unknown origin.  The melt quenched 
budesonide, nanoparticles, and agglomerates all show the broad endotherm at 60 
– 80 °C that was previously described and attributed to dehydration.  It was 
previously pointed out that the melt quenched material is most likely amorphous 
but no glass transition is observed due to overlap with the dehydration 
endotherm. 
 Similar behavior is observed with both the nanoparticles and 
agglomerates (Figure 3.5).  However, there do appear to be transitions that 
follow the endotherms from both of these samples.  These signals might be due 
to glass transitions but their close proximity to the endotherms makes 
interpretation of the results difficult.  Additionally, if these events are glass 
transitions they are higher in temperature than the previously observed Tg of 
pure budesonide. 
 Modulated DSC (MDSC) of the nanoparticles is shown in Figure 3.6 and 
was used to help identify this transition.   A glass transition should appear in the 
reversing signal of an MDSC experiment, but the results do not show any 
transitions in the reversing heat flow that are consistent with a glass transition.  
Therefore, the data is not consistent with the presence of any amorphous 
budesonide.  However, closer inspection of Figure 3.5 appears to show that the 
transition following the endotherm may actually be an exotherm that is poorly 
resolved from the endotherm.  An exotherm could result from a polymorphic
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Figure 3.5.  Expansion of DSC thermographs shown in Figure 3.4, but for the stock 
budesonide the second heating (Figure 3.2) is shown to display the observed Tg for 
budesonide.  The Tg measurements are shown with onset, offset, and inflection point (I) 
temperatures. 
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Figure 3.6.  MDSC of budesonide nanoparticles.  The Tg measurement is shown with the 
onset, offset, and inflection point (I) temperatures.  The “Nonrev” and “Rev” heat flow 
signals are the non-reversing and reversing heat flow signals, respectively, that are 
obtained from the modulation of the heating rate while the heat flow signal is analogous 
to the heat flow from the previous conventional DSC experiments (Figures 3.2, 3.4, and 
3.5). 
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form conversion or crystallization of amorphous material.  Unfortunately the 
DSC offers no clear evidence as to the physical state of the budesonide within the 
melt quenched budesonide, nanoparticles, or agglomerates. 
 
3.2.3.3 SSNMR Spectroscopy 
 The 13C CPMAS spectrum of stock budesonide (Figure 3.7) contains 
relatively narrow peaks indicating that the material is in a crystalline form, while 
the spectrum of melt-quenched material has relatively broad peaks and is 
consistent with amorphous material.  Examination of the spectra for both the 
nanoparticles and agglomerates clearly shows that the budesonide is amorphous 
in both samples.  However, a small but relatively narrow peak is seen at 185 ppm 
in the spectra of both the nanoparticles and the agglomerates, and there is 
another small peak at 23 ppm in the spectrum of the agglomerates.  These peaks 
are consistent with peaks from the stock budesonide and suggest that the 
samples contain small amounts of crystalline budesonide. 
 The other narrow peaks in the spectrum of the agglomerates are due to 
the presence of L-leucine (Figure 3.8).  Again, the narrow width of the L-leucine 
peaks in the spectrum signifies that it is in a crystalline form while the 
budesonide is amorphous.  This indicates that both compounds exist in distinct 
phases within the sample.  Additionally, no peaks associated with lecithin are 
observed in the spectra of the nanoparticles or the agglomerates.  This is likely 
due to the relatively low concentrations of lecithin that were used, since the 
lecithin concentrations were approximately an order of magnitude lower than 
the budesonide concentrations, on a molar basis. 
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Figure 3.7.  13C CPMAS spectra of budesonide samples.  The bottom two spectra are of 
the stock budesonide and budesonide melted at 250 °C and then immersed in liquid 
nitrogen.  Note that an 8-fold vertical expansion has been performed on the top 
spectrum to aid visualization of the budesonide peaks.  * = Peaks in the nanoparticle and 
agglomerate spectra that align with peaks that were observed for stock budesonide. 
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Figure 3.8.  13C CPMAS spectra of L-leucine, lecithin, and budesonide samples (melt 
quenched, nanoparticles, and agglomerates).  The melt quenched spectrum is the result 
of budesonide that was melted at 250 °C and then immersed in liquid nitrogen. 
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3.2.4 Summary 
 While DSC was unable to clearly identify the physical form of budesonide 
that was present in either the nanoparticles or agglomerates, SSNMR was able to 
unambiguously show that the budesonide was mostly amorphous in both 
materials.  Finally, it is clear that there was a change in the physical form of the 
budesonide when it was processed to form the nanoparticles and agglomerates, 
but it is not obvious what impact the changes had on the observed dissolution of 
the materials. 
 
3.3 Nifedipine 
 
3.3.1 Background 
 Nifedipine (Figure 3.1) is a calcium channel blocker with a variety of 
therapeutic indications including hypertension and chronic angina.  Its use is 
typically limited due to side effects that are associated with the high oral dosages 
that are usually needed for treatment.  The primary site of action is in the heart 
and lungs, thus it is hypothesized that pulmonary delivery may permit the use of 
smaller targeted doses that would limit the side effects that are often experienced 
with oral delivery (i.e., diarrhea, hepatotoxicity, mental confusion, and gastritis).  
Additionally, nanoparticles of nifedipine may improve dissolution and release 
since its water solubility is relatively low (approximately 10 µg/mL).  Therefore, 
a formulation strategy similar to the one used for budesonide was utilized to 
produce agglomerates of nifedipine nanoparticles.  The materials showed trends 
in the dissolution behavior that were similar to the budesonide, and once again 
DSC did not offer conclusive evidence as to the physical form of the nifedipine 
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within the materials.  However, SSNMR was able to show that all of the 
materials contained the same crystalline form of nifedipine.23 
 
3.3.2 Experimental 
 
3.3.2.1 Materials 
 Nifedipine, stearic acid, and sodium chloride were obtained from Sigma 
Chemicals Co. USA (St. Louis, MO).  Ethanol (95% denatured), acetone, and 
phosphate buffered salts, and Spectra/Por cellulose dialysis membranes (MW 
cut-off = 6 – 8 kDa) were purchased from Fisher Scientific (Fair Lawn, NJ).  
Deionized water was obtained from a Millipore EasyPure unit or EASYpure1 
RODI (Barnstead International, Model # D13321, Dubuque, IA).  All materials 
were used without further purification, and solvents were of HPLC grade. 
 
3.3.2.2 Nanoparticle and Agglomerate Preparation 
 Whenever possible, steps were taken to protect nifedipine solutions and 
samples from excessive exposure to light, since it is known to undergo 
photodegradation (~10% in 24 hr).29  Approximately 10 mg of nifedipine and 1 
mg of stearic acid was dissolved in 1 mL of ethanol and stirred overnight to 
ensure complete dissolution.  Under probe sonication (Fisher Sonic 
Dismembrator, model 500, amplitude 60%), ~29 mL of cold deionized water was 
rapidly added to the ethanol solution and sonication was continued for 20 sec to 
produce nifedipine nanoparticles.  The suspension was frozen at -20 °C and 
subsequently either lyophilized (FreeZone 1, Labconco, Kansas City, MO) or 
stored at 4 °C. 
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 Nifedipine nanoparticle agglomerates were prepared by adding sodium 
chloride, sufficient to achieve a concentration of 0.1 M, to the refrigerated 
nanoparticle suspension followed by homogenization at 20,000 rpm.  The 
material was allowed to sit at room temperature for either ~4 hr or 24 hr 
(followed by decantation of the liquid to remove most of the salt) before being 
frozen at -20 °C and subsequently lyophilized (FreeZone 1, Labconco, Kansas 
City, MO). 
 
3.3.2.3 DSC 
 The DSC described in Section 3.2.2.3 of this chapter, was utilized to assess 
the physical form present in each of the materials: stearic acid, stock nifedipine, 
nanoparticles, and agglomerates.  Approximately 1 to 4 mg of either 
nanoparticles or agglomerates were heated from 50 to 200 °C at a heating rate of 
10 °C/min.  While ~9 mg of stock nifedipine was heated form 120 to 200 °C and 
~11 mg of stearic acid was heated from 40 to 190 °C, both at a heating rate of 10 
°C/min. 
 
3.3.2.4 TGA 
 Stock nifedipine and stearic acid were analyzed by TGA (see Section 
3.2.2.4 of this chapter) to ascertain residual solvent content and determine the 
degradation temperatures.  Approximately 7 mg of each sample was placed in a 
platinum pan and heated from room temperature to over 400 °C at a rate of 20 
°C/min. 
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3.3.2.5 SSNMR Spectroscopy 
 SSNMR data was collected on the CMX-300 spectrometer with the same 
rotors and MAS spinning conditions reported in Section 3.2.2.5.  FIDs were 
collected with a ramped amplitude CP25 TOSS30,31 sequence with ~81 kHz of 
proton decoupling using the SPINAL-6426 method.  Between 1,600 and 3,600 
transients were collected for each FID with a pulse delay of 20 – 45 sec, a contact 
time of 2 – 7 msec, and a 1H 90° pulse width of 3.1 µsec.  The FIDs contain 2,048 – 
3,072 points with a dwell time of 33.3 µsec.  Spectra were externally referenced to 
TMS using the methyl peak of MGA at 18.84 ppm.27 
 
3.3.3 Results & Discussion 
 
3.3.3.1 Particle Characterization 
 The nanoparticles had an average particle size of 470 ± 40 nm, while the 
agglomerates had geometric and aerodynamic particle diameters of 
approximately 10 and 2 µm, respectively.  The agglomerates displayed high 
emitted and respirable fractions of 91 and 94%, respectively.  Also the materials 
followed the same dissolution trends as the budesonide22 materials for both 
extent and rate of dissolution (nanoparticles > agglomerates > stock).  It was 
even possible to correlate the particle size to the dissolution rate of the materials, 
which suggested that the particle size and thus surface area was the controlling 
factor in the rate of dissolution for the materials.  However, the physical state of 
the nifedipine in the materials still needed to be eliminated as a contributing 
factor. 
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3.3.3.2 Thermal Analysis (DSC/TGA) 
 Nifedipine is known to have three anhydrous polymorphs (Form I, II, and 
III) and has the ability to form amorphous materials.32  Form I has a reported 
melting point of 173 °C and amorphous nifedipine has a Tg of 45 °C.32  The DSC 
of the stock nifedipine (Figure 3.9) is consistent with Form I, and the endothermic 
event that is observed for stearic acid is consistent with its reported melting point 
(69 – 70 °C).33  Neither nifedipine nor stearic acid showed any significant loss of 
mass below approximately 190 °C (Figure 3.10). 
 When nanoparticles were prepared in the absence of stearic acid the only 
observed transitions were a broad endotherm at 150 °C followed by a broad 
exotherm at 160 °C (Figure 3.9).  This cannot be due to formation of a eutectic as 
the sample only contains nifedipine.  Also, the event is significantly lower (> 20 
°C difference) in temperature than melting of Form I, and melting point 
depression due to reduced particles size should only result in a change of ~0.5 °C 
(500 nm particles).  Thus it would appear that the nifedipine might be in a 
different physical form, possibly a crystalline state, in the nanoparticles.  
However the endotherm is not consistent with melting of either Form II (163 °C) 
or Form III (135 °C).34  The nanoparticles that were prepared with stearic acid 
show a very similar thermograph, but also show melting of stearic acid at 65 °C. 
 The agglomerates thermograph (Figure 3.9) also shows the melting 
endotherm for stearic acid.  However, only a broad endothermic transition is 
observed at higher temperatures (170 °C) but it is still not consistent with melting 
point depression or one of the known crystalline forms.18,34  It should also be 
noted that none of the materials were analyzed at low enough temperatures to
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Figure 3.9.  DSC thermographs of nifedipine materials and stearic acid.  Two 
preparations of nanoparticles were analyzed, one processed with and the other without 
stearic acid.  The agglomerates were prepared with stearic acid, following aggregate 
formation the supernatant was not removed before lyophilization. 
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Figure 3.10.  TGA thermographs of stock nifedipine and stearic acid. 
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permit observation of a glass-transition event (Tg ~45 °C)32 so it is not possible to 
eliminate the presence of amorphous nifedipine in any of the materials.  Thus, 
DSC was not able to unambiguously identify the physical form of nifedipine that 
is present in the nanoparticles and agglomerates. 
 
3.3.3.3 SSNMR Spectroscopy 
 The stock nifedipine 13C CPMAS spectrum in Figure 3.11 agrees well with 
the previously reported SSNMR characterization of Form I.32  The spectra of the 
nanoparticles and agglomerates match the spectrum of stock material, indicating 
that the physical form was not changed during the processing steps.  
Additionally, the nifedipine peaks in the nanoparticle sample were slightly 
broader (~2 Hz) and the material had a shorter 1H T1 relaxation time when 
compared to the stock material (15 vs. 37 sec).  This is consistent with previous 
reports regarding the relationship of particle size to SSNMR line width and 
relaxation properties.35,36 
 The nanoparticle sample was prepared with stearic acid and peaks are can 
be clearly observed in the 13C CPMAS spectrum, indicating the presence of 
stearic acid in the sample (Figure 3.11).  However, the spectrum of the 
agglomerates only shows peaks from nifedipine, but the DSC clearly showed 
melting of stearic acid (Figure 3.9).  These differences were caused by the 
methods in which the two samples were isolated.  The DSC sample was 
lyophilized without any further processing after the agglomeration was 
performed.  Conversely the SSNMR sample was allowed to settle for 24 hrs, the 
supernatant was then poured off and the remaining material was lyophilized.  
This isolation method was used to remove most of the salt from the sample to
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Figure 3.11. 13C CPMAS spectra of nifedipine materials and stearic acid.  The 
nanoparticles and agglomerates were prepared with stearic acid, but following 
aggregate formation the supernatant was removed before lyophilization.  * = spinning 
sidebands 
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avoid any potential complications due to the large amounts of salt that would 
have been present in the SSNMR sample under the other isolation method.  
Thus, the SSNMR and DSC data demonstrate the dramatic differences that can 
occur in the sample composition when small, seemingly insignificant 
modifications are made to processing steps.  These differences also suggest that 
the stearic acid, or at least most of it, is not interacting directly with the 
nifedipine.  This conclusion is supported when the 1H T1 values of the nifedipine 
and stearic acid in the nanoparticle sample.  The two materials have different T1 
values (nifedipine 15 sec and stearic acid 8 sec) indicating that they are each in 
independent phases. 
 
3.3.4 Summary 
 As with budesonide, DSC was unable to clearly identify the physical form 
of nifedipine that was present in either the nanoparticles or agglomerates, 
However, SSNMR was able to unambiguously show that the nifedipine existed 
as Form I in all of the materials.  Thus, the processing steps did not result in any 
physical changes in the nifedipine, except for the altered particle sizes.  Thus it 
can be concluded that the changes in the observed dissolution of the materials 
was not due to any changes in the physical form of the API. 
 
3.4 Ciprofloxacin 
 
3.4.1 Background 
 Ciprofloxacin (Figure 3.1) is a fluoroquinolone antibiotic that is 
particularly effective against several types of lung infection.  It is typically 
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administered orally, but a pulmonary formulation that provides prolonged 
release might help ensure complete elimination of lung infections while limiting 
systemic drug concentrations.  In order to achieve the desired prolonged release, 
nanoparticles of ciprofloxacin were encased in microspheres of poly(D,L-lactic-
co-glycolic acid) (PLGA).  Following inhalation, the PLGA should slowly erode 
and release the ciprofloxacin while the relatively large size of the microspheres 
would prevent the alveolar macrophages from clearing the formulation from the 
lungs.  DSC of the ciprofloxacin nanoparticles displayed an endothermic 
transition that occurred at a temperature significantly below the melting point of 
ciprofloxacin, but there was no corresponding mass loss observed by TGA, 
suggesting that the nanoparticles and stock material may contain different 
physical forms.  This was confirmed with both 13C and 19F SSNMR; however, due 
to poor encapsulation efficiencies the microparticles could not be analyzed to see 
which form of ciprofloxacin they contained.21 
 
3.4.2 Experimental 
 
3.4.2.1 Materials 
Poly(D,L-lactide-co-glycolide) (50:50 lactic acid:glycolic acid; i.v. = 0.31 
dL/g; MW ~ 31,000) was obtained from Absorbable Polymers, Inc (Pelham, AL). 
Polyvinyl alcohol (MW = 22,000, 88% hydrolyzed) was purchased from 
Polysciences, Inc. (Warrington, PA).  Ciprofloxacin was obtained from Sigma 
Chemicals Co. USA (St. Louis, MO).  Commercial grade canola oil and silicone 
oil (viscocity = 57 cP and 100 cP, respectively) were used as porogens.  
Dichloromethane, dimethylsulfoxide, and heptane were purchased from Fisher 
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Scientific (Fair Lawn, NJ).  All materials were used without further purification, 
and solvents were of HPLC grade. 
 
3.4.2.2 Nanoparticle Preparation 
 A solution of 0.5 – 5% (w/v) poly(D,L-lactide-co-glycolide) (PLGA) in 
dichloromethane was prepared.  A nanosuspension was prepared by adding 
ciprofloxacin to the PLGA/dichloromethane solution and sonicating (Fisher 
Scientific Sonic Dismembrator, Model 500) the mixture for 90 sec.  If pore 
formation was desired, either canola or silicone oil were added to the 
nanosuspension (0.87 – 3.58 w/w oil:PLGA) and the mixture was sonicated for 
an additional 90 sec.  Microparticles were then produced from the 
nanosuspension by Precision Particle Fabrication technology,4-6,37-40 stirred in a 
solution of 1% PVA for ~3 hr, filtered, washed with heptane to remove the canola 
or silicone oil, and finally washed with deionized water.  The resulting 
microspheres were lyophilized for at least 48 hr and stored at -20 °C under 
desiccating conditions. 
 
3.4.2.3 DSC 
 A Q100 DSC (see Section 3.2.2.3 of this chapter) was used to evaluate the 
physical form of the ciprofloxacin nanoparticles.  Samples were placed in 
crimped aluminum pans and consisted of 1.5 – 4 mg of material.  Unless 
indicated otherwise, samples were heated from -80 to 400 °C at a heating rate of 
20 °C/min.  In order to differentiate thermal and kinetic events, some materials 
were heated at three different rates (3, 10, and 20 °C/min). 
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3.4.2.4 TGA 
 The TGA reported in Section 3.2.2.4 of this chapter, was used to determine 
if any residual solvent was present in the nanoparticles and to determine the 
degradation temperature of the ciprofloxacin.  Approximately 3 mg of material 
was placed in a platinum pan and was heated from room temperature to 400 °C 
at a rate of 20 °C/min. 
 
3.4.2.5 SSNMR Spectroscopy 
 All 13C SSNMR data was collected on the CMX-300 spectrometer (see 
section 3.2.2.5 of this chapter) but the packed samples were spun at 7.5 kHz.  
FIDs were collected using a variable amplitude CP41 sequence with ~68 kHz of 
proton decoupling using the two pulse phase modulation (TPPM) method.42  
Between 2,048 and 23,000 transients were collected for each FID with a pulse 
delay of 2 – 8 sec, a contact time of 1.5 – 2 msec, and a 1H 90° pulse width of 3.7 
µsec.  The FIDs contain 1,024 points with a dwell time of 33.3 µsec.  Spectra were 
externally referenced to TMS using the methyl peak of MGA at 18.84 ppm.27 
 All 19F SSNMR data was collected on a Tecmag Apollo spectrometer 
(Houston, TX) operating at a 1H resonance frequency of 300 MHz.  Samples were 
packed into 3.2 mm zirconia rotors and held in place with Torlon® end caps 
(Varian, Palo Alto, CA).  The packed rotors were spun with MAS24 at a rate of 21 
kHz in a 3.2 mm spin module (Varian, Palo Alto, CA).  The FIDs were collected 
using a ramped amplitude CP25 sequence with ~83 kHz of proton decoupling 
using the TPPM method.42  Between 256 and 1,024 transients were collected for 
each FID with a pulse delay of 2 – 15 sec, a contact time of 3 msec, and a 1H 90° 
pulse width of 3 µsec.  The FIDs contain 1,024 points with a dwell time of 10 µsec.  
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Spectra were externally referenced to Teflon® at -121.0 ppm. 
 
3.4.3 Results & Discussion 
 
3.4.3.1 Particle Characterization 
 The particle size of the nanoparticles was not directly measured but was 
estimated to be approximately 400 nm from scanning electron microscopy (SEM) 
images of the microspheres.  The PLGA microspheres had geometric and 
aerodynamic diameters ranging from approximately 4 to 30 µm.  The 
ciprofloxacin nanoparticles dissolved completely within about 5 days, but when 
they were encapsulated their release rate decreased as the size of the 
microspheres increased, with some of the materials releasing ciprofloxacin over 
the course of 25 days.  The target drug loading for the microspheres was 4 – 5% 
(w/w) but the encapsulation efficiency was very poor and only resulting in 
loadings of < 0.2% (w/w) with the exception of one sample that had a loading of 
0.4% (w/w).  Therefore, only the nanoparticles were examined for physical form 
changes, because it was not clear if the microspheres contained sufficient 
amounts of ciprofloxacin to be detected by any of the characterization 
techniques. 
 
3.4.3.2 Thermal Analysis (DSC/TGA) 
  The DSC of stock ciprofloxacin (Figure 3.12) displayed an endothermic 
transition with an onset of 271 °C that could be consistent with melting or 
degradation of ciprofloxacin.  Therefore, DSC thermographs were collected at
107 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.12.  DSC of two lots of stock ciprofloxacin that were received from Sigma.  Lot 
#1 was analyzed at three different heating rates and Lot #2 was analyzed at the fastest of 
those three heating rates.  All of the thermographs showed melting of ciprofloxacin at 
271 °C with the exception of Lot #1 heated at 3 °C/min which melted at 267 °C.  The 
insert is an expansion of the data to show the lower temperature endotherm that was 
observed. 
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several heating rates and the results showed that the onset temperature of the 
endotherm did not change significantly, indicating that the endotherm was due 
to melting of ciprofloxacin.  The peak of the transition was relatively noisy and 
was followed by additional events, which suggest that ciprofloxacin degrades at 
approximately the same temperature.  When the heating rate was dropped to 3 
°C/min there was a slight drop in the temperature of the transition (267 °C), this 
change was probably due to the kinetics of the ciprofloxacin degradation. 
 The stock ciprofloxacin also showed an endotherm at 130 °C when it was 
heated at the fastest heating rate (Figure 3.12).  The origin of this endotherm was 
unknown as there are no reported polymorphs of ciprofloxacin and it was 
smaller in size and at a higher temperature than would typically be expected for 
desolvation.  Another lot of ciprofloxacin was purchased from Sigma and it 
showed the same behavior when analyzed by DSC. 
 A batch of nanoparticles was also analyzed by DSC and showed the same 
melting behavior at 271 °C when the heating rate was changed (Figure 3.13).  
However, at all three heating rates there was a very large endotherm that was 
similar to the observed event in the two lots of stock material except that it was 
significantly larger in the nanoparticle sample.  In order to confirm the 
observations and identify how reproducible they were, another batch of 
nanoparticles were prepared and analyzed by DSC (Figure 3.14).  Again they 
showed the same transitions but the size of the 130 °C transition was much 
smaller and matched more closely with the stock ciprofloxacin.  In addition, the 
transition did not correlate to any observed mass loss by TGA (Figure 3.15).  The 
nanoparticles did show a mass loss of 2.1% below 70 °C and then no further
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Figure 3.13.  DSC of ciprofloxacin nanoparticles from Batch #1, analyzed at three heating 
rates.  The material melted at 271 °C for the two fastest heating rates, but melting was 
observed at 265 °C when the heating rate was reduced to 3 °C/min.  The peak 
temperature of the other endotherm in each thermograph shifted from 126 to 142 °C 
when the heating rate was increased from 3 to 20 °C/min. 
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Figure 3.14.  DSC of stock ciprofloxacin Lot #1 and two batches of nanoparticles.  The 
inset is an expansion of the thermographs to show the lower temperature endotherms 
for the samples, particularly the stock ciprofloxacin and Batch #2 of the nanoparticles. 
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Figure 3.15.  TGA of ciprofloxacin nanoparticles Batch #2. 
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changes were observed until approximately 275 °C (Figure 3.15).  It is thought 
that the 2.1% mass loss is either due to residual dichloromethane or water that is 
adsorbed to the surface of the particles, while the mass loss at 275 °C agrees with 
the previous observations regarding the similarity of the melting and 
degradation temperatures of the stock ciprofloxacin (Figure 3.12). 
 Consequently, the DSC appears to suggest that the samples contained 
different forms of ciprofloxacin.  It also implies that production of the 
nanoparticles can alter the relative amounts of the forms.  However, the extent of 
the form changes does not appear to be completely reproducible.  Additionally, 
closer inspection of the endotherms in Figure 3.13 suggests that there may 
actually be at least two overlapping endotherms at approximately 130 °C, which 
may indicate that several forms are present or several form conversions may 
occur around that temperature.  SSNMR was used to obtain a more complete 
picture of the differences between these materials. 
 
3.4.3.3 SSNMR Spectroscopy 
 The 13C CPMAS spectrum of stock ciprofloxacin (Figure 3.16) displays 
relatively narrow peaks, particularly the peaks in the aromatic and carbonyl 
regions.  This indicates that it is crystalline and it seems to be of a relatively pure 
form and not a mixture of forms.  Comparison of the spectra of the stock material 
and the first batch of nanoparticles reveals numerous, differences between them.  
However, the peaks in the spectrum of the nanoparticle sample are also narrow, 
indicating that it is crystalline, and the large number of peaks suggests that it is 
either a mixture of crystalline forms or that the crystal structure has a Z’ > 1. 
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Figure 3.16. 13C CPMAS spectra of stock ciprofloxacin Lot #1 and both batches of 
ciprofloxacin nanoparticles.  * = spinning sidebands 
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 The spectrum of the second batch of nanoparticles (Figure 3.16) appears to 
match very closely with the stock material, but it does appear to contain some 
small peaks that may be consistent with the other batch of nanoparticles.  In 
order to make the differences more apparent, the carbonyl region of the spectra 
in Figure 3.16 have been expanded and are shown in Figure 3.17.  The spectrum 
of the stock material has two peaks in this portion of the spectrum, one each for 
C-7 and C-11 (Figure 3.1).  However, the first batch of nanoparticles has five 
peaks in this region of the spectrum and none of the peaks correspond with the 
peaks in the stock material.  None of the peaks appear to be similar in intensity 
which suggests that the sample is simply a mixture of forms and does not seem 
to display any signs of peak splitting due to a Z’ > 1.  That would imply that the 
first nanoparticle batch is a mixture of at least three crystalline forms that are all 
different from the form in the stock ciprofloxacin. 
 The carbonyl region of the second batch of nanoparticles (Figure 3.17) 
shows two prominent peaks that correlate with the peaks of the form in the stock 
material.  Yet, there is also a small peak at ~175 ppm that corresponds with a 
peak in the first batch.  Additionally, there appear to be several other small 
signals and shoulders that correlate with the peaks from the first batch of 
nanoparticles, but the signal-to-noise ratio (S/N) of the spectrum is not sufficient 
to state with certainty that they are peaks.  Thus, the 13C spectra of the materials 
are consistent with the DSC observations that the first batch of nanoparticles 
appears to be primarily a mixture of several crystalline forms and the second 
batch may contain small amounts of the forms but primarily consists of the form 
that was present in the stock material. 
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Figure 3.17.  13C CPMAS spectra from Figure 3.16, expanded to show only the carbonyl 
peaks for each of the materials.  The red lines are intended to aid visualization of the 
relative positions of the peaks in the spectra. 
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 The ciprofloxacin molecule also contains a fluorine atom, which can also 
be observed with SSNMR and is considerably more sensitive than 13C.  The 19F 
CPMAS spectra (Figure 3.18) show the same results as the previous 13C 
experiments.  The stock material displays a single peak while the first batch of 
nanoparticles shows at least four peaks.  Additionally, the other batch of 
nanoparticles is almost an exact match of the stock material but may display 
some very small peaks due to the presence of a small amount of other forms. 
 Unfortunately, due to poor encapsulation efficiency during the production 
of the microspheres it was not possible to examine how the additional processing 
steps may have further altered which ciprofloxacin physical forms that were 
present.  Also, it was not possible to determine what, if any, affect the 
ciprofloxacin forms had on the release profiles of the microspheres.  However, 
when all of the stock ciprofloxacin and nanoparticles were stored at ambient 
conditions for approximately one month and then reanalyzed, they all matched 
the DSC and SSNMR results for the stock material, and the endotherm at 130 °C 
was no longer observed.  This indicates that the physical forms in the first 
nanoparticle batch are metastable at ambient conditions.  Therefore, if the forms 
were present in the microspheres they would likely have converted to the stable 
form over the course of the dissolution studies (up to 25 days) and probably 
would have impacted the dissolution rates. 
 
3.4.4 Summary 
 DSC was able to detect the change in the physical form of the 
ciprofloxacin when the nanoparticles were generated.  But SSNMR was able to 
show that the processing actually generated a mixture of crystalline forms.
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Figure 3.18. 19F CPMAS spectra of ciprofloxacin stock material and both nanoparticle 
batches. 
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Unfortunately, the ciprofloxacin in the PLGA microspheres had a low 
encapsulation efficiency and so the physical form of the ciprofloxacin in those 
materials were not determined.  The generation of the metastable ciprofloxacin 
forms appears to be inconsistent and they could have converted to the stable 
form over the course of the dissolution studies if they were present in the 
microspheres. 
 
3.5 Overall Summary 
 
 It has been shown previously that the physical form of the API in a 
formulation, even a formulation utilizing nanoparticles, will influence the 
dissolution behavior of the formulation.8  Thus it is critical to characterize 
formulations to identify the physical form of the API in the final formulation.  
The above sections have presented three cases demonstrating some of the pitfalls 
that can be encountered when developing a new formulation. 
 The budesonide and nifedipine examples showed that one processing 
method can sometimes result in API physical form changes and at other times 
have no impact.  In the case of budesonide the stock material was crystalline but 
in the final formulation it was amorphous.  Nifedipine showed no change in its 
physical form even though the processing steps were almost identical, although 
the actual compounds used in the formulations were different.   Additionally, the 
nifedipine example demonstrated how significantly the composition of the final 
formulation can be altered by small changes in the processing of the materials. 
 The third example, ciprofloxacin, is a case in which new physical forms 
are discovered unexpectedly.  The generation of the physical forms was not well 
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controlled or understood and likely influenced the dissolution profile of the 
formulations.  Furthermore, the new forms were metastable and so not only was 
the level of each of the forms likely different in each of the formulations, but they 
were probably changing over the course of the dissolution studies. 
 These examples also help to illustrate the limitations of techniques such as 
DSC.  In both the budesonide and nifedipine cases DSC was not able to offer any 
significant insight into the physical form of the API in any of the samples, apart 
from the stock materials.  DSC did offer some limited information in the 
ciprofloxacin example; however, it was not information that could not also be 
obtained from the SSNMR spectra.  Instead, a technique such as SSNMR is 
clearly more applicable to these types of studies.  It limits the likelihood of form 
changes during the experiment and offers a wealth of information about the 
sample (relaxation properties, etc.), which is not available from other techniques. 
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Chapter 4 
 
Quantitation of Physical Forms in Formulations 
by SSNMR Spectroscopy 
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4.1 Introduction 
 The specific aim of this chapter is to understand how SSNMR can be used 
to measure the relative amounts of API physical forms within a formulation.  
Ideally this understanding will show why SSNMR does not require the use of 
pure reference materials or the preparation of a calibration curve.  In addition, 
the efficiency of these measurements will be addressed and improved relative to 
traditional SSNMR quantitation approaches. 
 NMR spectroscopy has found widespread use within the pharmaceutical 
industry for both qualitative1-3 and quantitative4-6 applications, typically in the 
solution state.  However, SSNMR spectroscopy has gradually expanded in 
prominence for the analysis of pharmaceuticals7 but has primarily been used for 
the qualitative characterization of these materials.8-16  This is especially true for 
the analysis of pharmaceutical formulations.17-19 
 NMR spectroscopy is inherently quantitative because the equilibrium 
magnetization (M0), and hence the observed signal (S), of a sample is given by 
Equation 4.1 and is directly proportional to the number of nuclei (N) that
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contribute to the signal.  In this equation the signal is related to the gyromagnetic 
ratio (!) of the nucleus, Planck’s constant (  
! 
!), the static magnetic field (B0), 
Boltzmann’s constant (k), and the temperature (T).  For the same nucleus, such as 
13C, it is possible to determine the relative amounts of two components within a 
sample by taking the ratios of the signals because all of the terms in Equation 4.1, 
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with the exception of N, are identical (Equation 4.2).  Therefore, relative
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quantitation can be achieved by NMR spectroscopy without the use of 
calibration standards and the development of calibration curves.  This is not the 
case with other spectroscopic techniques such as UV-Vis, infrared, and Raman 
spectroscopy, where the extinction coefficient (i.e., response factor) may vary for 
each peak. 
Although NMR is inherently a quantitative technique, there are several 
caveats that must be considered before a quantitative spectrum can be aquired.  
For example, an important stipulation regarding quantitation with all NMR 
methods is related to the rate at which a sample approaches its equilibrium state, 
M0.  In most modern NMR spectrometers the sample is allowed to come to 
equilibrium with the magnetic field.  A series of radio frequency (RF) pulses is 
then applied to the sample and a free induction decay (FID) is collected.  
However, since NMR is a relatively insensitive technique, the experiment is 
repeated several times and each time the data is added to the FID in a process 
called signal averaging.  These repetitions are generally identified as transients, 
and an FID can be the result of averaging thousands of transients.  After the 
sample is perturbed, it will begin to relax back to its equilibrium state, and 
different components within the sample may relax at different rates.  Therefore, 
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when performing quantitative measurements, it is generally accepted that the 
sample must be allowed to completely relax back to its equilibrium state between 
transients or the signals will not be directly proportional to the composition of 
the sample. 
 Quantitation studies in the solution state typically utilize 1H spectra 
because of its relatively high sensitivity and fast relaxation rates, which leads to 
reasonably short experiment durations.  However, in 1H SSNMR spectroscopy it 
is typically not possible to resolve the signals due to the strong homonuclear 
dipolar coupling that exists between the 1H nuclei (see the 1H MAS spectra of 
levofloxacin in Chapter 2, Figure 2.14).  In addition, other NMR active nuclei that 
have high natural abundance (such as 19F) are not commonly present in 
pharmaceutical compounds.  Therefore, the 13C is typically employed for the 
quantitative analysis of pharmaceutical systems with SSNMR spectroscopy.  
Additionally, this analysis has generally been focused on relatively simple 
mixtures of API physical forms, as opposed to formulated materials, due to the 
relative insensitivity of the 13C nucleus.20-23 
 In SSNMR spectroscopy, 13C data is either collected with a direct 
polarization (DP) or cross polarization (CP) experiment, and each method offers 
benefits and disadvantages.  In a DP experiment the observed signals are directly 
proportional to the sample composition, provided that the sample is allowed to 
fully relax to its equilibrium magnetization between transients.24  However, the 
relaxation rate of the 13C nuclei can be slow and often requires delays of minutes 
to hours between the collection of transients.  This leads to very long analysis 
times, since one spectrum is typically the result of hundreds or thousands of 
transients.  On the other hand, CP experiments allows dilute spins, such as 13C, to 
131 
be investigated while utilizing the relatively fast relaxation rates of abundant 
spins, such as 1H.  Additionally, 13C spectra that are collected with CP from 1H 
nuclei result in spectra that have a four-fold enhancement in their sensitivity or 
signal-to-noise ratio (S/N), which reduces the number of transients that are 
required.  One major complication of CP experiments is that the signals are not 
directly proportional to the sample composition because the transfer of the 
magnetization from the abundant spin to the dilute spin does not occur at a 
uniform rate.  Some studies involving the relative quantitation of API physical 
forms within formulations have relied upon calibration curves25 or reference 
spectra of pure forms for spectral addition26 in order to correct for the CP 
dynamics.  But, by understanding the CP dynamics of each of the materials it is 
possible to obtain quantitative results without pure standards or calibration 
curves.21,27  
 Another method for increasing the sensitivity of 13C is by utilizing isotopic 
labels.  The 13C isotope makes up only 1.1% of all carbon atoms in nature, and 
NMR does not detect the other naturally occurring isotopes of carbon (12C and 
14C).  Therefore, if the relative abundance of 13C is increased via isotopic labeling 
the sensitivity of the NMR experiment can be increased.  This can be particularly 
beneficial for the analysis of formulated APIs.17  However, if two adjacent carbon 
atoms in a molecule are both 13C then they will undergo dipolar coupling and 
result in broadening of the peaks in the 13C spectrum, in addition to experiencing 
J-coupling interactions.28  This 13C coupling is not observed in natural abundance 
materials because the probability of having two adjacent 13C nuclei is 
exceptionally low.  Additionally, the generation of even small amounts of 
isotopically labeled material is relatively expensive and large amounts of labeled 
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material may be needed to study the effect of various processing steps of the 
physical form of an API in a formulation.  Therefore, most processing steps 
would need to be scaled down in order to utilize labeled API, but changing the 
scale of processing could alter the product that is obtained.  Hence, isotopic 
labeling is not perceived as a feasible method for increasing the sensitivity of 
quantitative SSNMR spectroscopic studies, especially when trying to characterize 
the formulated API. 
 In a previous SSNMR study, Apperley et al.29 reported that they were able 
to detect fomoterol fumerate dihydrate when it was diluted to a level of 0.45% 
(w/w) in !-lactose monohydrate.  Additionally, they were able to quantify the 
relative amounts of fomoterol fumerate dihydrate and anhydrate (45% 
anhydrate) when the mixture was diluted to 2% (w/w) in !-lactose 
monohydrate.  They were able to achieve these results while using a method that 
did not wait the traditionally accepted period for complete relaxation to 
equilibrium.  In addition, the method benefited from several fortuitous 
properties of the materials, which simplified the quantitative analysis. 
 The goal of the work reported in this chapter is to develop a systematic 
approach to quantitation by SSNMR spectroscopy that is based on the method of 
Apperley et al.29  Specifically, the reproducibility of peak intensity and area 
measurements will be addressed.  The phenomenon of spinning sidebands and 
their potential impact on quantitation will be addressed.  In addition, the 
measurement of relaxation rates as they pertain to quantitation will be 
considered.  Efforts will also be made to improve the sensitivity of quantitative 
SSNMR measurements without increasing the total experiment time.  Finally, 
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two model formulations will be investigated to assess the accuracy of this 
approach to API physical form quantitation by SSNMR spectroscopy. 
 
4.2 Experimental 
 
4.2.1 Materials 
 3-methylglutaric acid (MGA), hexamethylbenzene (HMB, purified by 
sublimation), and cortisone 21-acetate (CortA) were purchased from Sigma-
Aldrich (St. Louis, MO) and were used without further purification or 
processing, unless indicated.  !-Lactose monohydrate was obtained as Foremost 
#310 Regular Lactose NF from Foremost Farms USA (Baraboo, WI) and was used 
without further purification or processing.  Starch 1500, a partially pregelatinized 
maize starch, from Colorcon (Harleysville, PA) was kindly provided by Dr. John 
Haslam. 
 A mixture of MGA and HMB was prepared by mixing 350.7 mg of MGA 
and 87.2 mg of HMB and is referred to in the text as “4:1 MGA:HMB.”  Stock 
CortA was heated to 200 °C for one hour to generate Form I.30,31  CortA Form II 
was produced by dissolving ~3 g of the material in 200 mL of chloroform, which 
was allowed to evaporate at ambient conditions for 24 hr.  A 1:1 Form I:II 
mixture of CortA was produced by mixing 220.73 mg of Form I and 223.95 mg of 
stock material.  Additionally, two CortA formulations in Starch 1500 were 
prepared by mixing either 13.30 mg of Form I and 14.59 mg of stock CortA with 
371.81 mg Starch 1500 to produce a 7% (w/w) formulation, or 17.51 mg of stock 
CortA was mixed directly with 874.41 mg Starch 1500 to produce a 2% (w/w) 
formulation. 
134 
4.2.2 SSNMR Instrumentation 
 Unless otherwise indicated all 13C data was collected using the 
Chemagnetics CMX-300 spectrometer that was reported in Chapter 2 (Section 
2.2.6).  Some data sets were collected on a similar Chemagnetics CMX-400 
spectrometer, operating at a 1H resonance frequency of 400 MHz.  19F SSNMR 
spectra were collected with the Bruker Avance DSX 500 MHz spectrometer 
(Chapter 2, Section 2.2.6).  The data collection parameters for 19F were also the 
same as the previous reported values with the exception of the MAS rate and the 
number of transients that were collected (see caption of Figure 4.10). 
 
4.2.3 Signal Reproducibility 
 All of the data that was collected for this portion of the study using the 4:1 
MGA:HMB mixture utilized the following instrument parameters: 3.2 µsec 1H 90° 
pulse width, 15 msec contact time, 5 sec pulse delay, 4 kHz MAS, and ~81 kHz of 
proton decoupling.  In addition, two dummy pulses were always applied to the 
sample prior to beginning each experiment and all FIDs contain 2,048 points with 
a dwell of 33.3 µsec. 
 Three separate data sets (4x96 [4], 12x32 [12], and 384x1 [384]) were 
collected for the 4:1 MGA:HMB mixture and are named according to the number 
of transients that were used to collect the FIDs and how many times the 
experiment was repeated (“transients”x”repetitions” [original transients]).  Thus, 
in the 4x96 [4] data set 4 transients were collected for each FID and 96 separate 
FIDs were collected with the same conditions.  A systematic approach of FID 
addition was developed in order to simulate an experiment in which more 
135 
transients were collected for each FID.  To simulate an experiment in which 8 
transients were collected, the 1st and 49th FID of the 4x96 [4] data set were 
summed to produce a new FID.  This process was repeated until all of the 
original FIDs had been utilized (2nd and 50th, 3rd and 51st, …, 48th and 96th FIDs).  
The resulting FIDs simulated a data set in which 8 transients were collected 48 
times.  The 1st, 33rd, and 65th FIDs of the 4x96 [4] data set were summed to 
produce a new FID to simulate an experiment of 12 transients per FID, and this 
process was again repeated to yield a data set which simulates 12 transients per 
FID repeated 32 times.  This process was continued and ultimately resulted in 11 
simulated data sets: 8x48 [4], 12x32 [4], 16x24 [4], 24x16 [4], 32x12 [4], 48x8 [4], 
64x6 [4], 96x4 [4], 128x3 [4], 192x2 [4], and 384x1 [4]. 
 The 4x96 [4] data set and its associated 11 simulated data sets were 
processed and various S/N, intensity, integration, and deconvolution 
measurements were performed.  The relationship between the absolute values 
and errors of these measurements to the number of transients was then 
examined.  The 12x32 [12] data set was collected to determine if the simulation 
approach introduced bias.  Additional simulated data sets were generated from 
the 12x32 [12] data set using the same systematic approach.  This resulted in 5 
simulated data sets: 24x16 [12], 48x8 [12], 96x4 [12], 192x2 [12], and 384x1 [12].  
As an additional check for bias a 384x1 [384] data set was also collected to for 
comparison to the simulations. 
 The S/N measurements were performed by searching for the smallest 
root-mean-square (RMS) noise in a 30 ppm window over the entire spectral 
width.  A noise window of 30 ppm corresponds to approximately 7.7% of the 
entire spectral width.  The MGA and HMB methyl peaks were integrated over 
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ranges of 21 – 18.3 and 18.3 – 15 ppm, respectively.  The deconvolution model 
was optimized on the MGA and HMB methyl peaks in the 384x1 data set.  The 
optimal MGA peak model was determined to be a peak centered at 18.8 ppm 
with a width of 17.6 Hz and an 18% Gaussian shape.  The HMB peak model was 
restricted to a single peak centered at 17.4 ppm with a width of 58.5 Hz and an 
86% Gaussian shape.  All of the data sets were fit with these models and only the 
intensity was allowed to vary during the fitting routine. 
 
4.2.4 T1 Measurements 
 The MGA 13C T1 measurements were performed on the CMX-400 
spectrometer, along with the 1H T1 comparisons of the saturation recovery, 
inversion recovery, and Torchia32 methods of T1 measurement.  The data was 
collected at an MAS rate of 7 kHz, contact time of 1.5 msec, and a pulse delay of 7 
sec except for the saturation recovery measurements, which used a pulse delay of 
2 sec.  The FIDs contained 4,096 points and were the result of either 16 or 64 
transients for 13C and 1H T1 measurements, respectively. 
 The MGA and !-lactose monohydrate 1H T1 repeatability experiments 
were collected on the CMX-300 spectrometer, with an MAS rate of 4 kHz.  The 
MGA measurements used a contact time of 1.5 msec, a pulse delay of 3 sec, and 
the FIDs consisted of 3,072 points that were the result of either 64 or 256 
transients.  The experiments were repeated three times and were labeled A, B, 
and C.  The !-lactose monohydrate measurements used a contact time of 1.5 
msec, a pulse delay of 1 sec, and the FIDs consisted of 2,048 points that were the 
result of 4 transients.  The experiments were repeated three times and were 
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labeled A, B, and C.  In order to simulate a 1H T1 data set of 12 transients per FID 
the corresponding FIDs from each of the A, B, and C data sets were summed to 
yield the simulated ABC data set. 
 Relaxation profiles from each of the T1 measurement experiments were fit 
to the appropriate mathematical models with KaleidaGraph version 4.0 from 
Synergy Software in a nonlinear regression method utilizing the Levenberg–
Marquardt algorithm to minimize the !2 of the model.  The reported error values 
are the standard errors for each respective parameter that were obtained from 
the nonlinear regression. 
 
4.2.5 CP Dynamics (TCH and T1!) 
 The CP dynamics of MGA were determined by collecting spectra with 
ramped-amplitude CP, where the duration of the CP pulse was varied from 0.01 
to 18 msec.  This data was collected on the Chemagnetics CMX-400 spectrometer 
with a pulse delay of 7 sec and MAS rate of 7 kHz.  The FIDs were the result of 
128 transients and consisted of 4,096 points.  The data was fit to the appropriate 
model by nonlinear regression with the KalediaGraph software (Section 4.2.4). 
 
4.2.6 Quantitation Measurements 
 All of the CortA data was collected with a variable amplitude CP 
experiment utilizing two-pulse phase modulated (TPPM) proton decoupling.  
The FIDs consisted of 4,096 points and were the result of between 1,024 and 
58,176 transients.  Unless otherwise indicated the contact time was between 1.5 
and 5 msec, the pulse delay was 8 sec, and MAS was performed at a rate of 4kHz. 
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4.3 Results & Discussion 
 
4.3.1 Signal Reproducibility 
 When performing quantitative measurements it is necessary to consider 
both the accuracy and the precision of the method that is being used.  Ultimately, 
both are dependent upon several factors including errors in preparing the 
samples and the reproducibility of the instrument’s response.  Thus, an 
experiment was devised in which a single sample was repeatedly investigated to 
assess the reproducibility of the SSNMR spectrometer’s response. 
  A mixture of MGA and HMB was selected for this study because they are 
routinely used as standards in SSNMR, have very favorable relaxation properties 
that allow for rapid data collection.  They were mixed in a ratio of 4:1 MGA:HMB 
so that all of the peaks of MGA would have a greater intensity, but the HMB 
peaks would have a greater integrated area due to the differences in the width of 
the peaks from each material (Figure 4.1).  While the HMB peaks are smaller in 
intensity, they are approximately 3 times broader, thus the peak areas of the 
HMB are larger than those of MGA. 
 In order to test the stability of the spectrometer response, 96 FIDs 
consisting of 4 transients each were collected of the 4:1 MGA:HMB mixture, and 
the data are referred to as the 4x96 [4] data set.  The FIDs were then subjected to 
Fourier transformation (FT) to produce 96 corresponding spectra.  The peak 
intensity of the MGA and HMB peaks in each spectrum were determined and 
then the average and standard deviations (SD) of the peak intensities were 
calculated.  The results were 1,810 ± 10 and 920 ± 10 for MGA and HMB, 
respectively.  It is generally accepted that the intensity of the NMR signal 
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Figure 4.1.  13C CPMAS spectrum (from 384x1 [384] data set) of 4:1 MGA:HMB mixture.  
Chemical structures of both MGA and HMB are provided with carbon numbering.  * = 
spinning sidebands 
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increases linearly with the number of transients and that the noise increases with 
the square root of the number of transients.  Therefore, if more transients are 
collected per FID, the relative SD (RSD) of the peak intensity should decrease.  In 
order to test this hypothesis, 11 data sets were simulated from the 4x96 [4] data 
set (see Section 4.2.3) and the resulting average MGA and HMB peak intensity 
from each data set is plotted against the number of transients of that data set in 
Figure 4.2 (MGA 4x96 and HMB 4x96). 
 It can be seen from the linear fits of both MGA and HMB that the signal 
does increase linearly with the number of transients (R2 = 1.0000) as would be 
expected.  In order to determine if this relationship was due to the simulation of 
the data sets, another data set consisting of 32 FIDs, each consisting of 12 
transients, was collected, and the same simulation method was applied to 
generate an additional 5 data sets (see Section 4.2.3).  The average peak 
intensities from these data sets are also shown in Figure 4.2 (MGA 12x32 and 
HMB 12x32) and agree very well with the previous results.  As a final check, the 
intensities of the methyl peaks from the spectrum in Figure 4.1 were measured 
and are also shown in Figure 4.2 (MGA 384x1 and HMB 384x1) and also agree 
very well.  Therefore, two FIDs of a sample can be summed and the signals will 
scale linearly with the number of transients that were used to collect the data.  
One caveat is that the FIDs must be collected with the same instrument 
parameters. 
 As an additional check of these data sets, the S/N of both peaks were 
measured for all of the spectra, and the average values for each data set are 
shown in Figure 4.3.  This figure is analogous to Figure 4.2 but the relationship is 
no longer linear.  Since the signal increases linearly and the noise increases with
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Figure 4.2.  Average methyl peak intensities of MGA and HMB plotted against the 
number of transients used to collect the data for the 4:1 MGA:HMB mixture.  The plot 
shows the results from the 4x96 [4], 12x32 [12], and 384x1 [384] data sets and their 
associated simulations (see section 4.2.3 for details).  The linear fit was only applied to 
the results from the 4x96 [4] data set.  The relative intensities of MGA and HMB are not 
directly proportional to the sample composition due to differences in the widths of the 
two peaks (see Figure 4.4).  SDs are not shown because they are significantly smaller 
than the size of the symbols that are shown, and the RSDs were not more than 0.6% and 
1% for MGA and HMB, respectively. 
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the square root of the number of transients, the S/N increases with the square 
root of the number of transients (Equation 4.3).  This relationship is well
 
 
  
! 
S
N "
Transients
Transients
= Transients  Equation 4.3 
 
established and accepted within the NMR community.33,34  Thus, the approach of 
FID summation to achieve higher S/N and simulate the acquisition of additional 
transients is a valid approach because the results in Figure 4.3 abide by the 
square root relationship between S/N and thee number of transients. 
 While the measurement of signal intensity is relatively easy and 
straightforward, it cannot be used for relative quantitation in NMR if calibration 
curves are not used.  In NMR, the signal is distributed over some chemical shift 
range, which results in the observed peak, and different materials will display 
different distributions of their signals.  The most obvious example of this in 
SSNMR is the peaks of crystalline and amorphous materials, where the 
amorphous peaks are approximately an order of magnitude broader than their 
crystalline counterparts.  Thus, for the same mass of material, amorphous form 
peaks will be about an order of magnitude less intense than the crystalline form 
peaks.  For this reason it is generally necessary to measure the actual area of the 
peaks rather than the intensity of the peaks. 
 There are two main approaches to measuring peak areas in NMR 
spectroscopy: integration and deconvolution.  Integration is generally preferred 
due to its relative simplicity, but it has certain disadvantages.  One major issue 
with integration is that the peak often extends well beyond the observed width of
143 
 
 
 
 
 
 
Figure 4.3.  Average methyl peak S/N of MGA and HMB plotted against the number of 
transients used to collect the data for the 4:1 MGA:HMB mixture.  The plot shows the 
results from the 4x96 [4], 12x32 [12], and 384x1 [384] data sets and their associated 
simulations (see section 4.2.3 for details).  The power fit was only applied to the results 
from the 4x96 [4] data set.  The relative S/N of MGA and HMB peaks are not directly 
proportional to the sample composition due to differences in the widths of the two 
peaks (see Figure 4.4).  SDs are not shown because they are smaller than, or on the order 
of, the size of the symbols that are shown.  The RSDs were not more than 3% for both 
MGA and HMB. 
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the base of the peak.  Therefore, in order to integrate the entire peak the 
integration range must be relatively broad.  However, the edges of the peak only 
contain a very small fraction of the entire signal and increasing the integration 
range incorporates more noise in the measurement.  Thus a tradeoff exists 
between accuracy (wider integration range to measure the total peak area) and 
precision (narrow integration range to limit the contribution of noise).  
Additionally, if peaks of two components are not fully resolved it can be difficult 
to accurately integrate the peaks.  
 Deconvolution can be used to minimize the issues that are encountered 
with integration.  Because deconvolution uses a mathematical model to represent 
the peaks, it is able to, in theory, exclude the noise that is present in the data.  
Since it is modeling the peak it should be able to more accurately estimate the 
entire peak area without being influenced by the noise as heavily as a wide 
integration range would be.  Additionally, it can be used to model two 
overlapping peaks, although ideally the shape and width of the peaks are known 
to help develop an accurate model.  Unfortunately, peaks are not always 
symmetrical and do not fit a model perfectly, therefore deconvolution is not 
perfect and it is more difficult to perform routinely and accurately on large sets 
of data. 
 In order to determine the reproducibility of peak intensity, integration, 
and deconvolution measurements, each was used to analyze the methyl peaks of 
the entire 4x96 [4] data set of the 4:1 MGA:HMB mixture.  The intensity and 
integration methods are depicted in Figure 4.4.  The peaks appear to be 
sufficiently resolved so that the intensity at the peak maxima should not be 
significantly influenced by the tail of the adjacent peak.  The integration ranges
145 
 
 
 
 
 
 
 
 
Figure 4.4.  13C CPMAS spectrum of 4:1 MGA:HMB mixture from Figure 4.1, expanded 
to show methyl peaks.  The top spectrum demonstrates the integration method with the 
MGA peak integrated from 21 to 18.3 ppm and the HMB from 18.3 to 15 ppm.  The 
bottom spectrum demonstrates the intensity method, where the maximum intensity is 
measured for each peak is determined at the positions indicated by red lines. 
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are shown by the red traces in Figure 4.4 and demonstrate the difficulties of 
integrating overlapped peaks because one tail of the HMB peak is included in the 
MGA integral and one tail of the MGA peak is included in the integration of the 
HMB peak.  The deconvolution models were developed with the 384x1 [384] data 
set because it had the best S/N and thus offered the best opportunity to 
accurately model the peaks (Figure 4.5).  When the data was modeled with two 
peaks the raw data was represented fairly well; however, the difference between 
the model and raw data in the region of the HMB signal did show noticeable 
systematic “noise”.  A third peak was added to help model the HMB signal and 
the !2 of the fit improved from 0.03 to 0.01.  But the fit of the MGA signal was not 
noticeably improved by the addition of a fourth peak (data not shown), and it 
was not clear why the HMB signal might be represented by two poorly resolved 
peaks.  Therefore, the two peak model was fit to one of the spectra from the 4x96 
[4] data set with all parameters held constant, except for the peak intensity.  The 
result was an acceptable fit, and the difference of the raw data and the model 
showed no large residual signals.  The same issues with the fit of the HMB signal 
were observed; the errors in the fit however, appeared to average out over the 
width of the signal.  Therefore, the two peak model was used for all of the 
subsequent deconvolutions of the 4:1 MGA:HMB mixture. 
 The 4x96 [4] data set and ten of its simulated data sets were analyzed by 
measuring the size of the MGA and HMB signals by intensity, integration, and 
deconvolutions.  The 384x1 [4] was not used for this portion of the study because 
it contained only one spectrum and thus provided no statistical information.  The 
integrated and deconvoluted peak areas were seen to exhibit the same linear 
relationship to the number of transients (data not shown) as was observed for the  
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Figure 4.5. 13C CPMAS spectrum of 4:1 MGA:HMB mixture from Figure 4.1 (top and 
middle) and the first increment of the 4x96 [4] data set (bottom), expanded to show 
methyl peaks.  In all cases the raw data is shown in black, the individual peaks of the 
model are shown in green, the sum of the model peaks is shown in red, and the 
difference between the raw data and the model is shown in blue.  The top spectrum was 
deconvoluted with a model containing three peaks.  The middle spectrum shows the 
deconvolution of the same spectrum but with a model consisting of only two peaks.  The 
bottom spectrum shows the two peak model from the middle spectrum but will all 
variables (peak width, position, and shape) held constant and only the intensity was 
allowed to change. 
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intensities (Figure 4.2).  The RSD of the MGA intensity, integration, and 
deconvolution measurements are plotted against the corresponding average S/N 
of each data set (Figure 4.6).  It can be seen from the data that as the S/N of the 
spectra increases, the RSD of all three measurement techniques decreases, 
indicating that the reproducibility of the measurements is related to relative size 
of the noise.  Additionally, the deconvolution tended to give the lowest RSDs 
while integration tended to result in the highest RSDs. 
 The RSD values for the HMB peak measurements are provided in Figure 
4.7, and show the same general relationship of RSD and S/N.  As with MGA, the 
deconvolutions typically give smaller RSDs than the intensities and integrations.  
However, for HMB the intensity measurements tended to have higher RSDs than 
the integrations.  This change in the relative behavior of the two measurement 
methods between MGA and HMB is probably due to the difference in the width 
of the peaks.  The MGA peak is relatively narrow so that most of the signal is 
concentrated near the peak maximum, but the HMB signal is more dispersed.  
Therefore, in a given spectrum the absolute intensity of the HMB peak is small 
relative to the MGA peak but the size of the noise is constant and thus the noise 
has greater influence on the HMB intensity measurement. 
 The data in Figures 4.6 and 4.7 indicate that there is a trade off when 
choosing between collecting multiple FIDs or increasing the number of transients 
for each FID.  When the S/N of the data is relatively low, the data suggests that 
the experiment should be biased towards fewer FIDs and more transients.  Most 
NMR measurements are typically collected only once with the highest number of 
transients, and thus S/N, that can be obtained in a reasonable amount of time.  It 
is then assumed that the error involved in preparing the sample (masses and
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Figure 4.6.  RSDs of the analysis of the MGA methyl peak from the entire 4x96 data set 
for the 4:1 MGA:HMB data set.  The RSD values are plotted against the average S/N 
value for the MGA methyl peaks for each of the subsets of 4x96 data set (S/N values 
shown in Figure 4.5).  The colored lines are intended only to help show the relative 
trends for each of the measurement methods (intensity, integration, and deconvolution).  
Note that the number of measurements that were used to determine the RSDs is not 
constant, as the S/N ratio increases n drops changes in the following order 96, 48, 32, 24, 
16, 12, 8, 6, 4, 3, and 2. 
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Figure 4.7.  RSDs of the analysis of the HMB methyl peak from the entire 4x96 data set 
for the 4:1 MGA:HMB data set.  The RSD values are plotted against the average S/N 
value for the HMB methyl peaks for each of the subsets of 4x96 data set (S/N values 
shown in Figure 4.5).  The colored lines are intended only to help show the relative 
trends for each of the measurement methods (intensity, integration, and deconvolution).  
Note that the number of measurements that were used to determine the RSDs is not 
constant, as the S/N ratio increases n drops changes in the following order 96, 48, 32, 24, 
16, 12, 8, 6, 4, 3, and 2. 
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volumes) will contribute more to the uncertainty in the NMR results than the 
response of the NMR spectrometer.  Thus, error of NMR measurements are 
typically assessed by comparing independently prepared samples rather than 
replicate measurements of a single sample. 
 In Figures 4.6 and 4.7 the number of measurements that contribute to the 
RSD values shown decreases as the S/N increases, for example the RSD at the 
lowest S/N was calculated from 96 measurements while the RSD at the highest 
S/N was calculated from only two measurements.  The confidence interval (CI) 
(Equation 4.4) was calculated for each of the data sets to correct for these
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differences, where t95% is the Student’s t value for the 95% confidence level, s is 
the SD, and n is number of observations.  The 95% CIs for the intensities, 
integrations, and deconvolutions increase as the S/N of the data sets increases.  
The absolute value for the measurements also increase so the relative CIs (RCIs) 
were calculated by dividing the CI by the average of the corresponding 
measurement and were found to be approximately constant for each 
measurement method.  The RCIs for the intensities, integrations, and 
deconvolutions were approximately 0.001, 0.002, and 0.0007 for MGA and 0.002, 
0.002, and 0.001 for HMB.  Thus, it appears that even when a single spectrum is 
collected the 95% CI can be estimated by multiplying the measured value by the 
appropriate RCI.  For example, the intensities of the MGA peak in the 384x1 [4], 
384x1 [12], and 384x1 [384] data sets were 174,373, 174,018, and 174,408, 
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respectively.  If the RCI is used to predict the CIs the following results are 
obtained for the three data sets: 174,400 ± 200, 174,000 ± 200, and 174,400 ± 200.  
This suggests that the RCIs can be used to estimate the confidence intervals of 
peak measurements that are performed on a single spectrum. 
 For SSNMR quantitative studies, particularly for formulated materials, the 
S/N of the spectra will be significantly lower than the values that were observed 
with the 4:1 MGA:HMB data sets.  Therefore, another series of experiments were 
devised to test these observations with spectra that had lower S/N values.  
 Lactose, specifically !-lactose monohydrate, was selected because its spectrum 
(Figure 4.8) contains several well resolved peaks at 107.3, 92.9, and 87.4 ppm.  
Additionally, the peaks had S/N values of ~30 to 40.  Three FIDs (A, B, and C) of 
the lactose were collected and each consisted of 4 transients, and the three FIDs 
were summed to yield one FID (ABC) consisting of 12 transients.  Each of the 
FIDs were Fourier transformed to produce spectra, and the three resolved peaks 
were analyzed by measuring the S/N, intensity, integral, and deconvoluted area 
of each peak (Table 4.1). 
 The raw measurements of the A, B, and C data sets for the lactose data are 
shown in Table 4.1, along with the averages and the 95% CI for the 
measurements.  The measurements of the ABC data, which was simulated by 
summing the other three FIDs, are also shown; however, these measurements 
cannot be directly compared to the averages of the other measurements because 
the signals increase with increasing transients.  The relationship of all four 
measurements with the number of scans were shown previously and were used 
to scale the results from ABC to be of the same relative scale as the other 
measurements.  The scaled S/N measurements from all three peaks in the ABC
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Figure 4.8.  Chemical structure and 13C CPMAS spectrum of  !-lactose monohydrate.  
The spectrum was extracted from longest relaxation period of a 1H T1 experiment.  No 
peaks were observed outside the spectral region that is shown. 
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data match very well with the averages from the other measurements.  However, 
none of the scaled intensities from the ABC data set were within the 95% CIs of 
the average value of the other experiments.  This is likely because of the 
significantly higher noise levels that are present in this data relative to the 
previous 4:1 MGA:HMB study.  In contrast, the scaled integration and 
deconvolution areas for the peaks at 92.9 and 87.4 ppm in the ABC data are in 
very good agreement with the averages of A, B, and C.  This is likely due to the 
relative insensitivity of deconvolution to the noise that is present in the data. 
 The integration and deconvolution areas for the peak at 107.3 ppm are 
also in good agreement with, but fall outside of, the 95% CI for the A, B, and 
data.  It can be seen that the CI95% values for the integration and deconvolution 
measurements are approximately an order of magnitude lower for the peak at 
107.3 ppm than for the other two peaks.  This is probably not an accurate 
representation of the true confidence intervals for these two measurements of the 
peak at 107.3 ppm because these CI95% values are considerably different than the 
values from the analysis of the other peaks.  The results in Table 4.1 for the 
lactose data supports the earlier observations from the 4:1 MGA:HMB mixture. 
 Thus, several general conclusions can be drawn from these experiments.  
When performing relative quantitation studies with NMR the signal sizes should 
be determined by measuring the peak areas, rather than the intensities because 
differences in the width of the peaks will result in dissimilar distributions of the 
total signal intensity.  In addition, when feasible, the areas should be determined 
by deconvolution rather than integration to help reduce the influence of the noise 
that is present in the data.  When the S/N of the data is limited by long 
experiment times it is also possible to reduce the uncertainty in the measured 
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peak areas by maximizing the number of transients per FID, rather than trying to 
limit the uncertainties by collecting multiple FIDs. 
 
4.3.2 Spinning Sidebands 
 In NMR spectroscopy the observed chemical shifts are the result of 
differences in the chemical environment of the nuclei.  However, the rigid nature 
of solid materials results in a phenomenon called chemical shift anisotropy, 
which results in broad SSNMR signals when analyzing powders due to the 
various orientations of the molecules to the external magnetic field.  When 
magic-angle spinning (MAS) is used the broad signal is split into a series of 
peaks that are separated by the rate at which the sample is rotated. 
This phenomenon is demonstrated in Figure 4.9 with levofloxacin 
hemihydrate 19F spectra collected at three MAS rates.  The spectra show that as 
the MAS rate is increased there is a proportional increase in the separation 
between the isotropic peaks and the spinning sidebands.  If the MAS rate was 
increased sufficiently all of the spinning sidebands would disappear; however, in 
the demonstrated case of levofloxacin hemihydrate an MAS rate of > 45 kHz 
would be required to eliminate all of the spinning sidebands in the 19F spectrum.  
Most commonly used MAS rotors are limited to rates < 35 kHz so eliminating 
spinning sidebands through MAS spinning is typically not feasible. 
 The spectra in Figure 4.9 also show that as the MAS rate is increased the 
fraction of the total signal (isotropic peaks and spinning sidebands) that appears 
in the isotropic peaks also increases.  Therefore, using a relatively fast MAS rate 
will simplify the spectrum (fewer spinning sidebands) and will increase the 
sensitivity of the isotropic signals.  However, there is a tradeoff because sample
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Figure 4.9.  Chemical structure and 19F MAS spectra of levofloxacin hemihydrate.  See 
Chapter 2, Section 2.2.6, for instrument details and parameters.  The 5 and 15 kHz MAS 
data was collected 64 transients, while the 12 kHz data was collected with 16 transients.  
The separation distances of one isotropic peak and some of the corresponding spinning 
sidebands are shown for the bottom two spectra.  The separation distance in Hz can be 
divided by the operating frequency of the spectrometer (469 MHz for 19F) to determine 
the separation in ppm, for example 15,000 Hz / 470 MHz = 32 ppm. 
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heating is observed at MAS rates above approximately 7 kHz,35 which could 
result in physical form changes.  Therefore, pulse sequences are often used to 
suppress the appearance of the spinning sidebands in the data and are generally 
referred to as total suppression of spinning sideband (TOSS) methods. 
 The fraction of the SSNMR signal that is contained in the isotropic peaks 
and spinning sidebands is influenced by the packing of the molecules within the 
material.  Thus, different physical forms can result in different distributions of 
the signal.  Therefore, it is necessary to integrate the isotropic peak and its 
associated spinning sidebands for each physical form that is being analyzed in 
order to obtain quantitative information.  An alternative is to select an 
appropriate MAS rate for the experiments and then characterize the fraction of 
the total signal (fMAS) that is contained within the isotropic signal (A0).  Then, 
when a quantitative analysis of that form is done, the isotropic signal can be 
measured and then divided by the fraction of the total signal that it represents at 
that MAS rate to estimate the total signal area (S), Equation 4.5. 
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 As mentioned previously, a faster MAS rate will result in larger isotropic 
signals and minimize the size of the spinning sidebands.  However, in addition 
to sample heating, it is important to consider the potential overlap of signals.  
Therefore, the MAS rate should be carefully selected so that the isotropic peaks 
of interest do not overlap with the spinning sidebands of other signals within the 
spectrum.  This can be especially difficult when performing quantitation with 13C 
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spectra for formulated APIs because not only must the spinning sidebands of the 
API peaks be considered, but the excipients may also interfere with the signals of 
interest.  The use of TOSS methods does not negate these considerations because 
the suppression is not always complete, so sideband artifacts could impact the 
analysis even when TOSS methods are used.  The issues of MAS rate selection 
and the analysis of signal distribution in spinning sidebands will be addressed 
again in Section 4.3.6 as they apply to a specific example of relative quantitation 
of CortA physical forms diluted in an excipient. 
 
4.3.3 Longitudinal Relaxation Time (T1) 
 The introduction to this chapter pointed out that the rate at which the 
magnetization of the sample approaches equilibrium is an important variable in 
quantitative NMR measurements.  This is an exponential process (Equation 4.6)
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and is referred to as spin-lattice or longitudinal relaxation and is often reported 
as a time constant (T1).  In Equation 4.6 the observed signal (S) is directly 
proportional to the magnetization along the z-axis (Mz,tau) when the sample is 
allowed to relax for a given time (!), and is a function of equilibrium 
magnetization (Mz,∞).  According to Equation 4.6, a quantitative NMR experiment 
should use a ! that is approximately 5-times the T1 so that the exponential term is 
negligible (e-5 = 0.00674) and the sample is able to relax completely to its 
equilibrium state before the collection of each transient.  This is especially 
160 
important when the sample components relax at different rates and thus have 
different T1s; in these cases the delay between transients is 5-times the longest T1 
value of the components that are being analyzed. 
 This is demonstrated in Figure 4.10, which shows the profiles of the MGA 
peaks from a 13C T1 experiment.  While the magnetization of the sample grows 
along the z-axis (parallel with the B0) with increased relaxation time, the Torchia 
method32 results in a peak profile that displays an exponential decay.  The profile 
can then be fit to obtain the T1 of the relaxation (Table 4.2).  The results 
demonstrate the primary issue with collecting quantitative spectra via DP of 13C 
nuclei.  The methyl carbon (C-4) relaxes very quickly (T1 = 0.4 sec), but the acid 
carbons (C-5,8) relax much more slowly (T1 > 100 sec).  Therefore, in order to 
obtain a quantitative 13C spectrum by DP, a delay of >500 sec must be used 
between transients to avoid incomplete relaxation, also referred to as saturation, 
of C-5,8. 
 As a comparison, the CP spectra that were collected for the signal 
reproducibility study (Section 4.3.1) with 4 transients had a S/N of ~80 for the 
MGA C-4 peak and each FID was collected in 20 sec.  If a DP spectrum of similar 
S/N were to be collected it would require the collection of approximately 16 
transients (CP results in approximately a 4-fold sensitivity enhancement for 13C) 
and with a 500 sec delay between transients would take over 2 hours to collect.  
Additionally, in order to obtain a DP spectrum similar to the one in Figure 4.1, 
the experiment would take approximately 9 days, as compared to the 32-min 
acquisition that was required to collect the CP spectrum. 
 In CP experiments, magnetization is transferred from an abundant spin, 
such as 1H, to a dilute spin, such as 13C.  As mentioned previously, in the case of
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Figure 4.10.  Relaxation profiles of MGA peaks in 13C T1 measurement experiment 
performed via the Torchia method.32  In the Torchia method the integrated peak area 
decays as the relaxation delay (!) is increased.  The symbols represent the integrated 
peak areas while the lines show the results from the nonlinear regression of the data 
(results shown in Table 4.2).  See Figure 4.1 for the carbon numbering scheme of MGA. 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 4.2  Results of nonlinear regression analysis† of the MGA 13C relaxation data that is 
shown in Figure 4.10.  See Figure 4.1 for the carbon numbering scheme for MGA. 
 
Parameter‡ C-5,8 C-1,3 C-2 C-4 
S0 ± Error 1.57 ± 0.03 1.74 ± 0.03 0.945 ± 0.007 1.081 ± 0.006 
T1 ± Error (sec) 125 ± 5 102 ± 4 29.1 ± 0.7 0.395 ± 0.006 
Offset 0.2 0.2 0.05 -0.006 
 !2 0.00219 0.00324 0.00190 0.00101 
R2 0.99933 0.99932 0.99925 0.99958 
 
† = The profiles in Figure 4.10 were fit to the equation below with the KaleidaGraph 
software package.  S0 represents the signal area at " = 0. 
 
  
! 
S" = S0e
# "T1
$ 
% 
& 
' 
( 
) + Offset  
 
‡ = The Error of the S0 and T1 parameters reflect the standard error of the corresponding 
parameter from the nonlinear regression.  The  !2 and R2 represent the quality of the 
regressions. 
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1H and 13C, this results in approximately a 4-fold increase in the 13C signal that is 
observed.  In addition, the 13C nuclei do not have to relax significantly between 
transients.  Instead, the delay between transients in CP experiments is dictated 
by the T1 of the abundant spins, and 1H T1s are typically on the order of a few 
seconds (Table 4.3). 
 In SSNMR, 1H T1 values are typically measured by one of three methods: 
saturation recovery, inversion recovery, or the Torchia32 method.  All three 
methods were used with CP to indirectly detect the 1H T1 of MGA, and the 
results are shown in Table 4.3.  The results from the inversion recovery and 
Torchia methods agree with one another very well both within and between the 
methods.  This data also demonstrates that 1H T1s are typically uniform for a 
material (all of the 13C peaks give the same value) because of the dipolar coupling 
that exists between the 1Hs in the material.  The saturation recovery method gave 
similar results but tended to give values that were slightly higher than those 
obtained with the other two methods.  Additionally, the standard errors from the 
nonlinear regressions also agreed well with the CI95% values that were calculated. 
 It was unclear if the differences that were observed in the 1H T1 values in 
Table 4.3 were due to the methods used to measure the values or uncertainties in 
the measurements.  Therefore, the 1H T1 of MGA was measured with the 
saturation recovery method three times to assess the reproducibility of the 
measurement.  Additionally, two separate data sets were collected with either 64 
or 256 transients per FID in order to determine the influence of S/N of the data.  
The results are shown in Table 4.4, and it should be noted that the T1 value was 
significantly different from the value that was observed in Table 4.3 because the 
measurements were done at different field strengths (Table 4.3 and Table 4.4 at
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Table 4.3  1H T1 values for MGA from three different experimental methods: Saturation 
Recovery, Inversion Recovery, and the Torchia32 Method.  See Figure 4.1 for the carbon 
numbering scheme for MGA. 
 
 Saturation Recovery‡ Inversion Recovery‡ Torchia‡ 
C-5,8 1.40 ± 0.01 1.34 ± 0.01 1.326 ± 0.007 
C-1,3 1.39 ± 0.01 1.330 ± 0.005 1.33 ± 0.01 
C-2 1.376 ± 0.009 1.323 ± 0.006 1.33 ± 0.01 
C-4 1.343 ± 0.008 1.333 ± 0.005 1.334 ± 0.009 
Average ± CI95% 1.38 ± 0.04 1.32 ± 0.01 1.33 ± 0.01 
 
‡ = The errors of the T1 values for C-5,8, C-1,3, C-2, and C4 are the standard errors from 
the nonlinear regressions.  The averages and CI95% values are calculated from the T1 
values for each experimental methods, respectively. 
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Table 4.4  1H T1 values for MGA from the saturation recovery method repeated three 
times (#1, #2, and #3) with either 64 or 256 transients collected for each FID.  See Figure 
4.1 for the carbon numbering scheme for MGA. 
 
64 transients 
 #1 ± Error‡ #2 ± Error ‡ #3 ± Error‡ Average ± CI95%‡ 
C-5,8 1.086 ± 0.009 1.080 ± 0.005 1.08 ± 0.01 1.083 ± 0.008 
C-1,3 1.089 ± 0.009 1.090 ± 0.008 1.08 ± 0.01 1.09 ± 0.01 
C-2 1.079 ± 0.009 1.088 ± 0.008 1.07 ± 0.01 1.08 ± 0.02 
C-4 1.075 ± 0.007 1.079 ± 0.007 1.068 ± 0.008 1.07 ± 0.01 
Average ± CI95%‡ 1.08 ± 0.01 1.084 ± 0.009 1.08 ± 0.1  
 
256 transients 
 #1 ± Error‡ #2 ± Error ‡ #3 ± Error‡ Average ± CI95%‡ 
C-5,8 1.085 ± 0.006 1.094 ± 0.008 1.090 ± 0.006 1.09 ± 0.01 
C-1,3 1.092 ± 0.007 1.102 ± 0.008 1.106 ± 0.008 1.10 ± 0.02 
C-2 1.087 ± 0.008 1.096 ± 0.008 1.097 ± 0.007 1.09 ± 0.01 
C-4 1.073 ± 0.005 1.076 ± 0.004 1.075 ± 0.005 1.075 ± 0.005 
Average ± CI95%‡ 1.08 ± 0.01 1.09 ± 0.02 1.09 ± 0.02  
 
‡ = The errors of the T1 values for C-5,8, C-1,3, C-2, and C4 are the standard errors from 
the nonlinear regressions.  The averages and CI95% values are calculated for each 
peak (C-5,8, C-1,3, C-2, and C4) and data set (#1, #2, and #3). 
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400 MHz and 300 MHz 1H frequencies, respectively) and the T1 is dependant 
upon the magnetic strength of the spectrometer.  It is clear from the data in Table 
4.4 that the standard error of the nonlinear regression is a relatively accurate 
predictor of the CI95% for replicate measurements and performing a 1H T1 
measurement multiple times does not give significantly different values.  
Additionally, doubling the S/N of the spectra by quadrupling the number of 
transients that are collected does not significantly impact the values. 
 The 1H T1 of !-lactose monohydrate was previously shown to be 
approximately 250 sec,36 and so it was investigated to determine if the general 
conclusions from the data in Table 4.4 could be extended to materials with long 
T1s and data sets that contain spectra with low S/N values.  The T1 was 
measured by the saturation recovery method using 4 transients per FID and the 
experiment was repeated three times (A, B, and C).  The corresponding FIDs 
from the A, B, and C data sets were summed to simulate an experiment in which 
12 transients were collected for each FID and this simulated data set was 
designated ABC.  The results of the analysis are shown in Table 4.5. 
 The relative error of the T1 values in Table 4.5 are significantly larger than 
the previous observations with MGA.  This is most likely due to the significantly 
lower S/Ns of the spectra within the data sets for !-lactose monohydrate.  In 
fact, when the peaks between 78 and 68 ppm were integrated the error of the T1 
value was significantly lower than that of the other integration regions that only 
contained one peak.  It is also observed that when the CI95% is calculated for each 
data set, it is in good agreement with the largest error within the data set.  When 
the T1 values from the ABC data set are compared to the other data sets, they do
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Table 4.5  1H T1 values for  !-lactose monohydrate from the saturation recovery method 
repeated three times (A, B, and C) with 4 transients collected for each FID and the 
simulated ABC data set. 
 
Integration 
Range (ppm) A ± Error
‡ B ± Error ‡ C ± Error‡ ABC ± Error‡ 
110 – 104 300 ± 20 290 ± 20 290 ± 10 291 ± 8 
96 – 90 270 ± 20 260 ± 10 320 ± 20 281 ± 9 
90 – 84 270 ± 20 240 ± 20 280 ± 20 261 ± 9 
78 – 68 267 ± 5 268 ± 4 274 ± 4 270 ± 3 
65 – 59 269 ± 9 270 ± 10 273 ± 9 271 ± 5 
Average ± CI95%‡ 270 ± 20 260 ± 20 290 ± 20 270 ± 10 
 
‡ = The errors of the T1 values for each integration range are the standard errors from the 
nonlinear regressions.  The averages and CI95% values are calculated from all of the 
integration ranges within each data set (A, B, C, and ABC). 
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not vary as significantly across the spectrum as with the A, B, and C data sets.  
This is also likely due to the relatively higher S/N of the spectra in the ABC data 
set.  Thus, all of the data in Tables 4.4 and 4.5 suggests that when performing 1H 
T1 measurements each of the peaks in the spectrum can be integrated 
independently and then compared to determine the CI95% of the measurement.  
Additionally, if only one peak is available for analysis then the standard error of 
the T1 from the nonlinear regression can be used as an estimate of the CI95%.  
Finally, when choosing between performing multiple 1H T1 measurements and 
increasing the number of transients collected for low S/N data sets, increasing 
the number of transients and performing the measurement once should yield 
values with more confidence than performing replicate measurements. 
 The accurate measurement of 1H T1 values is important for quantitation 
measurements because different physical forms will have different T1 values.  
Therefore, if the delay between transients is not at least 5 times the 1H T1 of the 
slowest relaxing species that is being analyzed, then its peaks will be artificially 
small compared to the other component and will yield inaccurate quantitative 
measurements. 
 
4.3.4 Optimization of Pulse Delay 
 The delay between transients is referred to as the pulse delay because 
during this time no RF pulses are applied to the sample.  With fast relaxing 
materials, such as MGA, this delay is relatively short.  MGA has a 1H T1 of 1.1 sec 
(in a spectrometer operating at 1H resonance frequency of 300 MHz) and thus the 
pulse delay should be at least 5.5 sec to allow the magnetization to relax fully 
when collecting quantitative spectra of MGA.  A delay of approximately 6 
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seconds is not prohibitive, especially considering the relatively high S/N of 
MGA spectra when only a few transients are collected.  However, !-lactose 
monohydrate has a 1H T1 of approximately 270 sec, so a quantitative spectrum of 
a mixture of MGA and !-lactose monohydrate would need to be collected with a 
pulse delay of more than 23 min.  That permits only one transient every half 
hour, or just 48 transients in a day. 
 With most organic molecules, when spectra are collected with these long 
pulse delays, only a tiny fraction of the time is actually spent manipulating the 
magnetization and acquiring the FID.  The majority of the time the spectrometer 
is idle.  For the case of MGA only about 2% of the time is spent applying the RF 
pulses and acquiring the data.  The other 98% of the time is spent waiting for the 
magnetization to return to equilibrium.  In the case of !-lactose monohydrate 
>99.99% of the time is spent waiting for the material to relax.  Therefore, these 
experiments are exceptionally inefficient. 
 Recall that Equation 4.6 shows the exponential relationship between the 
fraction of the magnetization that is present when the sample is allowed to relax 
for some time (").  When " is at least 5 times the T1 value of the material, the 
magnetization will be at >99% of its equilibrium value.  But if " is twice the T1 
then the magnetization will only be at approximately 86% of its equilibrium 
value.  If two sets of data are collected with the same number of transients but 
with pulse delays of 5 and 2 times the T1 of the sample, then the relative intensity 
of the second spectrum will only be about 86% that of the first spectrum.  
However, if the duration of the experiment is held constant it is possible to 
collect more transients with the shorter pulse delay and the spectrum of the data 
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collected with the shorter pulse delay will be approximately 38% more intense 
than the spectrum from the data where full relaxation was achieved.  In fact, it 
can be shown that for the time that is invested in collecting data, a pulse delay 
that is 1.26 times the T1 will yield the highest S/N.37 
 When attempting to detect the physical form or forms of an API within a 
formulation, the S/N of the spectra is typically the primary issue.  By using a 
pulse delay that is approximately 1.25 to 2 times the average T1s of the known 
forms the resulting S/N of the data will be as high as is feasibly possible for the 
amount of time that is spent collecting the data, which can be anywhere from 
hours to days.  However, since the components were not allowed to relax fully 
the relative sizes of the signals are not directly proportional to the sample 
composition.  If the T1s of the forms are known, then Equation 4.6 may be 
rearranged to predict the size of the signals, had they been allowed to fully relax 
(Equation 4.7).  In Equation 4.7, Stau is the observed signal size, ! is the pulse
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delay, T1 is the longitudinal relaxation time constant of the material, and S∞ is the 
signal size when complete relaxation to the equilibrium state is allowed.  It is 
important to note that when collecting quantitative data with a pulse delay that 
is significantly shorter than 5 times the T1, several “dummy” transients should be 
performed at the beginning of the experiment.  These dummy transients should 
be identical to the conditions under which the actual transients are collected and 
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are used to ensure that “steady state” conditions are established before data 
acquisition begins.  This approach to performing efficient quantitation studies in 
SSNMR will be tested with the CortA examples in Section 4.3.5. 
 
4.3.5 CP Dynamics (TCH and T1!) 
 The major advantages of using CP to collect 13C spectra of solid materials 
have been discussed previously.  The two main advantages are a 4-fold 
sensitivity enhancement relative to DP 13C spectra and a reduction in experiment 
times due to the faster relaxation of 1H nuclei.  Unfortunately, the magnetization 
transfer between the nuclei does not happen instantaneously and simultaneously 
the material is undergoing additional relaxation processes. 
 Generally, the CP process can be represented by Equation 4.8, where S is
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the observed 13C signal, M0 is the equilibrium magnetization of the 13C nuclei, !H 
and !C are the gyromagnetic ratios of the 1H and 13C nuclei, respectively, t is the 
duration of the CP pulse, TCH is the time constant of magnetization transfer from 
the 1H nuclei to the 13C nuclei, and T1!,H is the time constant for spin-lattice, or 
longitudinal, relaxation in the rotating frame of the 1H nuclei.20,38  Equation 4.8 
shows that as the duration of the CP pulse is increased the observed signal will 
also increase according to TCH.  However, at long CP pulse duration the signal 
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will be diminished according to T1!,H.  This behavior is demonstrated in Figure 
4.11 with MGA. 
 The CP dynamics depend upon several variables and thus peaks in a 13C 
CP spectrum will exhibit different CP dynamics and their relative sizes will 
depend upon the duration of the CP pulse.  Therefore, in order to obtain 
quantitative information it is necessary to correct for these differences in the CP 
dynamics of the peaks that are used in the analysis.  The duration of the CP pulse 
is typically selected to correspond to the maximum signal for the CP dynamics 
profiles in order to maximize the S/N of the spectra.  However, it is necessary to 
apply a correction factor to obtain quantitative information since the dynamics 
are dissimilar for different peaks, compounds, and physical forms.  Determining 
the appropriate correction factor from Equation 4.8 is rather cumbersome; 
however, the relationship can be simplified to make the analysis simpler.  At 
short CP pulse durations the observed signal intensity is determined by both the 
TCH and T1!,H; but, when t is more than 5 times the TCH Equation 4.8 can be 
simplified (Equation 4.9) and yields a simple monoexponential decay where the
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M0, !, and denominator of Equation 4.9 are collapsed into a single constant (C).  
Therefore, when the spectra are collected in this manner the observed signals can
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Figure 4.11.  CP dynamics profiles of MGA peaks from spectra collected by varying the 
duration of the CP pulse (t).  The symbols represent the integrated peak areas while the 
lines show the results from the nonlinear regression of the data using Equation 3.8 with 
M0 and the gyromagnetic ratios treated as a single parameter.  See Figure 4.1 for the 
carbon numbering scheme of MGA. 
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be scaled with the CP time (t) and the appropriate T1!,H. 
 The CP dynamics profiles can be fit to Equation 4.8 in order to determine 
the TCH and T1!,H values and ultimately determine the appropriate CP pulse 
duration for quantitation experiments and for use in scaling the observed signals 
for the differences in the CP dynamics.  Figure 4.11 shows the results from the 
nonlinear regression of the MGA CP dynamics profile.  Protonated carbons 
typically display relatively short TCH values relative to non-protonated carbons, 
and this is demonstrated in the MGA data because the C-5,8 signal requires a 
longer CP pulse to achieve its maximum value as compared to the other signals.  
The C-5,8 profile also is modeled very well by Equation 4.8.  Unfortunately, some 
of the assumptions that lead to Equation 4.8 do not hold up in the case of the 
other MGA signals, evidenced by the relatively poor fits to the observed profiles.  
If accurate TCH values were required, a more sophisticated model could be used 
to model the data; however, the TCH of these signals is clearly much shorter than 
the C-5,8 signal and thus will have no significant impact on determining the t 
that would be used to quantitative studies.  Therefore, in order to more 
accurately determine all of the T1!,H values all of the data points with t < 1 msec 
were excluded and the profiles were modeled again (Figure 4.12).  The TCH and 
T1!,H of the C-5,8 signal and the standard error of each did not change 
significantly between the regressions shown in Figures 4.11 and 4.12; however, 
the standard errors of the T1!,H values for the other signals dropped significantly 
when the short t points were excluded.  The results of the regressions in Figure 
4.12 are shown in Table 4.6. 
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Figure 4.12.  CP dynamics profiles of MGA peaks from Figure 4.11, with t values shorter 
than 1 msec excluded.  The symbols represent the integrated peak areas while the lines 
show the results from the nonlinear regression of the data using Equation 3.8 with M0 
and the gyromagnetic ratios treated as a single parameter.  See Figure 4.1 for the carbon 
numbering scheme of MGA. 
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Table 4.6  CP dynamics for MGA from the data shown in Figure 4.12. 
 
Parameter‡ C-5,8 C-1,3 C-2 C-4 
S0 ± Error 12.91 ± 0.06 15.04 ± 0.04 7.67 ± 0.04 8.25 ± 0.04 
TCH ± Error 
(msec) 0.87 ± 0.01 0.33 ± 0.01 0.42 ± 0.02 0.46 ± 0.02 
T1!,H ± Error 
(msec) 
15.5 ± 0.2 7.89 ± 0.05 11.5 ± 0.2 15.1 ± 0.3 
 !2 0.0298 0.0241 0.0244 0.0383 
R2 0.99942 0.99988 0.99936 0.99881 
 
† = The profiles in Figure 4.12 were fit to the equation below with the KaleidaGraph 
software package, which was adapted from Equation 4.8. 
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‡ = The Error of the S0, TCH, and T1!,H parameters reflect the standard error of the 
corresponding parameter from the nonlinear regression.  The  !2 and R2 represent the 
quality of the regressions. 
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 According to the results in Table 4.6, quantitative MGA spectra should be 
collected with a CP pulse duration of at least 4.4 msec (5 times the longest TCH) 
and then each of the peaks should be scaled with the exponential relationship in 
Equation 4.9 to correct for the T1!,H relaxation that occurred as part of the CP 
process.  Thus, CP can be used to obtain 13C with a higher S/N and in less time 
than an analogous DP spectrum of the same sample.  In addition, by accounting 
for differential distributions of signal in spinning sidebands and relaxation rates 
of materials, it should be possible to achieve quantitative measurements from 13C 
spectra without producing a calibration curve and without waiting for the 
sample to completely relax to its equilibrium state between transients.  The last 
section of the chapter will combine all of these concepts and apply them to CortA 
to test the validity of this approach. 
 
4.3.6 Quantitation of Cortisone 21-Acetate (CortA) Polymorphs Diluted in Starch 
 CortA was chosen as a model compound to test this approach to 
quantitation via SSNMR because this commonly used anti-inflammatory agent 
has several relatively stable crystalline forms.  In addition, it falls within the 
“typical” range of most drug molecules with a molecular weight of 402.5, various 
types of functional groups, and displays moderate NMR relaxation rates.  In 
addition, Harris et al.31 have previously reported reference 13C CPMAS spectra 
and chemical shifts for the known crystalline forms. 
 The 13C CPMAS spectra of CortA Forms I and II are shown in Figure 4.13 
along with the spectrum of Starch 1500.  The CortA spectra display relatively 
narrow peaks, consistent with crystalline materials, and the observed chemical
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Figure 4.13.  13C CPMAS/TOSS spectra of Starch 1500 and CortA Forms I and II.  Form I 
was prepared by heating the CortA to 200 °C for an hour while Form II was produced 
by recrystallization from chloroform.  The chemical structure of CortA is provided with 
carbon numbering.  * = Form I and III impurities 
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shifts in each spectrum agree with the previously reported values for each of the 
forms.31  Additionally, the spectrum of Form II displays numerous small peaks 
that are consistent with both Forms I and III, indicating that when the CortA was 
crystallized from chloroform a mixture of physical forms was produced.  The 
spectrum of Starch 1500 displays very broad peaks, consistent with an 
amorphous material, that do not overlap significantly with most of the CortA 
peaks.  Therefore, Starch 1500 should not hinder the quantitative analysis of the 
CortA peaks. 
 Equations for quantitation by SSNMR can be derived based upon the 
previous discussions regarding the relationship of spinning sidebands, relaxation 
rates, and experimental parameters upon quantitative analysis by SSNMR 
spectroscopy.  For the relative quantitation of two physical forms (X and Y) by 
SSNMR, the fraction of the material in the X form (FX) is given by Equation 4.10
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In this equation f is the fraction of the relevant signal that is observed in the 
isotopic peak, t is the duration of the CP pulse, and d is the delay between 
transients.  All of these variables can either be measured for the relevant physical 
forms (f, T1!,H, and T1) or are parameters that are chosen by the spectrometer 
operator (t and d).  Additionally, Equation 4.10 assumes that CP is utilized to 
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collect the spectra, in which case the 1H T1 is used.  If however, DP is to be used, 
the appropriate 13C T1 values must be used and the e-t/T1
! terms are removed from 
the equation. 
 In the case of CortA, the chemical shifts for C-3, C-11, and C-20 were 
selected for quantitative analysis because they were all relatively well resolved.  
The observed chemical shifts of the three carbons are 202.6, 210. 6, and 204.6 ppm 
and 198.7, 209.5, and 206.0 for C-3, C11, and C-20 in Forms I and II, respectively.31  
Figure 4.14 shows the isotropic peaks (0) and spinning sidebands (+1, -1, and -2) 
for these three peaks in both Form I and II, and Table 4.7 shows that for all three 
carbons the isotropic peaks contain approximately half of the total signal 
intensity for both Forms I and II. 
 The relaxation properties of Form I and II were also measured and are 
shown in Table 4.8.  Based on the 1H T1 values, a delay of approximately 30 sec 
between transients should allow the sample to relax fully to its equilibrium 
magnetization, but a delay of about 8 sec would yield spectra with the best S/N 
for the total amount of time that is spent collecting the data.  Additionally, a CP 
duration of at least 4.5 msec must be used in order to utilize Equation 4.10 for 
quantitative measurements.  Thus, all of the material properties that are needed 
to perform relative quantitation studies of CortA Forms I and II with Equation 
4.10 are provided in Tables 4.7 and 4.8.  However, in order to test this approach 
samples of known composition must be prepared and only pure Form I is 
available. 
 Several attempts to produce pure Form II were made but always 
generated a mixture of forms similar to what is observed in Figure 4.13.
181 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.14.  13C CPMAS spectra of CortA Forms I and II, expanded to show the carbonyl 
peaks (198 to 211 ppm) and their spinning sidebands.  The numbers indicate the 
isotropic peaks (0) and the first (+1 and -1) and second (-2) order spinning sidebands of 
C-3, C-11, and C-20 (Figure 4.13).31 
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Table 4.7  Determination of fI and fII for C-3, C-11, and C-20 of CortA, from the spectra 
shown in Figure 4.14. 
 
Physical Form  C-3 C-11 C-20 
Form I +1 8.0190 7.9641 7.6646 
 0 13.8942 15.4586 17.4136 
 -1 4.7003 4.7060 4.8422 
 -2 2.6348 1.9443 2.0871 
 fI ± CI95%† 0.475 ± 0.004 0. 514± 0.004 0.544 ± 0.004 
     
Form II +1 1.6788 2.0854 1.5073 
 0 3.3834 3.8199 3.6650 
 -1 0.9019 1.0718 0.9462 
 -2 0.6127 0.782 0.2962 
 fI ± CI95%† 0.514 ± 0.009 0.492 ± 0.008 0.57 ± 0.01 
 
† = The f of each carbon is calculated based on the equation below where A is the 
integrated peak area.  The CI95% is estimated by the propagation of CI of each 
integration, assuming a RCI95% of 0.002 from the 4:1 MGA:HMB mixture (Section 
4.3.1). 
 
  
! 
f = A0A+1 + A0 + A"1 + A"2
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Table 4.8  1H T1 and CP dynamics for CortA Forms I and II. 
 
  Form I Form II 
1H T1 ± CI95% (sec)†  4.3 ± 0.1 5.4 ± 0.7 
TCH ± Error (msec) ‡ C-3 0.70 ± 0.04 0.42 ± 0.01 
 C-11 0.58 ± 0.02 0.34 ± 0.01 
 C-20 0.80 ± 0.04 0.50 ± 0.02 
1H T1! ± Error (msec) ‡ C-3 20 ± 1 120 ± 10 
 C-11 24 ± 1 130 ± 20 
 C-20 25 ± 2 130 ± 20 
 
† = Measured by saturation recovery method and reported as the Average ± CI95% based 
on integrations of five separate regions of the spectra. 
 
‡ = The Error of the TCH and T1! parameters reflect the standard error of the 
corresponding parameter from the nonlinear regression. 
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Additionally, even the stock CortA from Sigma was found to contain primarily 
Form II, with some unknown amounts of Forms I and III (Figure 4.15).  Without 
pure standards it was not possible to determine the relative amounts of the three 
forms in the stock material by other solid-state characterization techniques such 
as DSC, PXRD, or Raman spectroscopy.  Therefore, an SSNMR quantitation 
method that was previously reported by Offerdahl et al.21 was used to determine 
the relative amounts of Forms I and II in the stock CortA.  The relative amount of 
Form III was not determined because it was only observed at very low levels and 
thus it was difficult to estimate its relaxation properties and fIII.  Also, it is 
assumed that the amount of Form III will be below the limit of detection of the 
later quantitation studies. 
 According to the method of Offerdahl et al.,21 five FID’s were collected 
with a 30 sec delay between transients to allow full relaxation of the nuclei.  Each 
FID was collected with a different CP pulse duration, but in all cases it was 
longer than 5 times the TCH to yield a monoexponential decay in the observed 
signals, dictated by T1!.  The C-3, C-11, and C-20 peak areas of Form I and Form 
II in the stock material were then measured and plotted on a semi-log plot 
against the CP pulse duration.  The profiles were extrapolated to find the y-
intercepts, which represent the peak areas without the influence of the T1! 
relaxation, and are proportional to the relative amounts of Form I and II in the 
stock material.  Since this was done with three separate carbons it was possible to 
directly obtain the CI95% based on the difference in the values that were obtained 
from each of the carbons.  This experiment indicated that the fractions of stock 
CortA that are present as Forms I and II are 0.15 ± 0.02 and 0.85 ± 0.02,
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Figure 4.15.  13C CPMAS spectra of CortA Form I and stock material, expanded to show 
the peaks of C-3, C-11, and C-20 (Figure 4.13).31  The spectrum of stock material displays 
peaks that are consistent with Form I and some of the reported chemical shifts of Form 
III.31 
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respectively.  However, recall that this experiment neglected to include the Form 
III, but if it is assumed that the NMR properties (relaxation rate, etc.) of all three 
forms are similar it is possible to estimate that Form III constitutes approximately 
5% of the stock CortA. 
 The goal of this work is to apply this method to quantitation of physical 
forms when they are present in formulations.  Therefore, the API will only 
constitute a fraction of the entire sample and the S/N of the data will be one of 
the primary limiting factors in the analysis.  Thus, it is desirable to collect data in 
the most efficient manner possible so that the data will have the highest S/N that 
can be achieved in the time that is spent collecting the data, which could be a 
period of hours or even days.  For this reason CP is used to yield the 4-fold 
sensitivity enhancement and shorter relaxation delay between transients; 
however, according to Equation 4.10 it should be possible to correct the observed 
peak areas for saturation due to incomplete T1 relaxation when the relaxation 
delay is shorter than 5 times the longest T1. 
 A 1:1 Form I:II CortA mixture was prepared in order to test the validity of 
the T1 saturation correction of Equation 4.10.  The mixture was then analyzed by 
collecting 13C CPMAS spectra where the delay between transients was varied 
from <1H T1 to 5-times the longest 1H T1.  Each experiment was preceded by 16 
“dummy” transients to ensure that a steady state was achieved prior to 
acquisition of the corresponding FID.  The C-3, C-11, and C-20 of Form I and II 
were then analyzed for each of the resulting spectra and processed with Equation 
4.10.  The results of these measurements are shown in Table 4.9.  The FI 
measurement that was obtained from each of the carbons did not differ 
significantly when the delay was changed.  Therefore, it appears that the delay
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Table 4.9  Comparison of FI measured from data collected with delays between 
transients of <1H T1 to 5-times the longest T1 of the sample, on the 1:1 Form I:II CortA 
mixture. 
 
Delay Delay/1H T1,II† C-3‡ C-11‡ C-20‡ 
3 sec 0.56 0.64 ± 0.02 0.55 ± 0.03 0.62 ± 0.02 
5 sec 0.93 0.63 ± 0.02 0.54 ± 0.02 0.62 ± 0.02 
7 sec 1.3 0.63 ± 0.02 0.54 ± 0.02 0.62 ± 0.02 
10 sec 1.9 0.62 ± 0.01 0.54 ± 0.01 0.61 ± 0.01 
15 sec 2.8 0.629 ± 0.007 0.543 ± 0.008 0.608 ± 0.008 
30 sec 5.6 0.618 ± 0.005 0.549 ± 0.005 0.603 ± 0.005 
 
† = The ratio of the relaxation delay between transients and the T1 of CortA Form II.  The 
30 sec. delay provides full relaxation of the nuclei and the 7 sec. delay provides data 
with the highest S/N for the time that is spent on the experiment. 
 
‡ = The FI ± CI95% are obtained from Equation 4.10, the CI95% is an estimate of the 
uncertainty based on the propagation of the uncertainties from the parameters (f, T1!, 
T1). 
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between transients can be relatively short in order to maximize S/N and not 
significantly impact the results obtained from Equation 4.10, provided that 
sufficient “dummy” transients are performed before the data is acquired.  The FI 
that was obtained from each of the carbons differed, particularly C-11, this was 
most likely due to the relatively short CP pulse duration (2.5 msec) so that 
magnetization transfer may not have been complete (5-times TCH). 
 The C-3, C-11, and C-20 peaks from the spectrum of a model CortA 
formulation are shown in Figure 4.16, with the deconvolution model that was 
used to fit the peaks.  The sample was prepared by mixing stock CortA and Form 
I with Starch 1500 so that CortA composed 7% (w/w) of the mixture.  The 
fraction of the CortA in the formulation that was present as Form I (FI) was 0.56 ± 
0.03.  The areas of the Form I and II peaks were treated with Equation 4.10 and 
gave FI values of 0.66 ± 0.02, 0.61 ± 0.02, and 0.62 ± 0.02 for C-3, C-11, and C-20, 
respectively.  Thus, the results agree very well with the known composition from 
the mass.  However, all of the NMR results where slightly higher than the FI from 
the prepared mass, and this may be due to the impact of the Form III that was 
ignored in the purity calculations or reflect an error in the preparation of the 
sample, but most likely it is the result of both factors. 
 In order to limit the errors from mixing the physical forms, another 
sample was prepared in which the stock CortA was simply diluted in the Starch 
1500.  The sample was prepared with a CortA content of 2% (w/w) to test the 
method in situations of very low drug loading.  The stock CortA was previously 
determined to have a FI of 0.15 ± 0.02 based on a different SSNMR method.  
When the peaks of the 2% CortA formulation spectrum were analyzed (Figure 
4.17) the C-3, C-11, and C-20 peaks gave FI values of 0.143 ± 0.007, 0.130 ± 0.007,
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Figure 4.16.  13C CPMAS spectra of the 7% CortA formulation, expanded to show the 
peaks of C-3, C-11, and C-20 (Figure 4.13).31  The spectrum is shown in black, the 
deconvolution model is shown in red, and the difference between the spectrum and 
model is shown in green.  No peaks of Form III were observed in the spectrum.31  The 
S/N of all of the peaks are between 25 and 38. 
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Figure 4.17.  13C CPMAS spectra of the 2% CortA formulation, expanded to show the 
peaks of C-3, C-11, and C-20 (Figure 4.13).31  The spectrum is shown in black, the 
deconvolution model is shown in red, and the difference between the spectrum and 
model is shown in green.  The deconvolution model was improved by the inclusion of 
peaks at 203.6 and 198.0 ppm, which correspond to the peaks of Form III in Figure 4.15.  
The FID was treated with 10 Hz of exponential apodization prior to Fourier 
transformation.  The S/N of the peaks at 198.7 and 202.7 ppm are 32.5 and 5.5, 
respectively. 
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and 0.134 ± 0.007 for C-3, C-11, and C-20, respectively.  Additionally, the 
spectrum of the 2% formulation in Figure 4.17 does not show any clearly 
resolved peaks for Form III; however, when the deconvolution model was fit to 
the data it was clearly improved by the addition of the peaks at 203.5 and 198.0 
ppm, which are consistent with peaks that have been observed for Form III 
(Figure 4.15).31 
 Thus, this approach of performing relative quantitation of physical forms 
of APIs within formulations appears to quite accurate.  In addition, traditional 
quantitative SSNMR methods required the measurement of 1H T1 values to 
ensure that the materials are allowed to relax fully between transients; however, 
this work shows that the data can actually be collected in situations where full 
relaxation does not occur and the T1 can simply be included as part of the 
correction for the CP dynamics and TOSS. 
 
4.4 Summary 
 
 This chapter has addressed the reproducibility and uncertainty of 
variousNMR measurements and properties including the reproducibility of 
signal intensities and relaxation measurements.  This work demonstrates that, in 
SSNMR, signal averaging supplements replicates as a method for reducing the 
uncertainty in measurements.  The collection of many transients to obtain the 
FID acts to increase the absolute signal and results in a relative reduction in the 
size of the noise. 
 It was shown that performing a measurement (spectrum, relaxation rate, 
etc.) very well once is comparable or better than repeating the measurement 
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multiple times with data that is of lower quality.  This may prevent the direct 
observation of the uncertainty of the measurement.  But, in these cases, indirect 
measures such as the error of a nonlinear regression to determine a relaxation 
rate, may offer a good relative measure of the uncertainty. 
 Additionally, the quantitation method of Apperley et al.29 was extended to 
a more general case (Equation 4.10), which may be simplified when the 
properties of physical forms are very similar.  This method also allows the 
duration between transient to be shortened relative to “traditional” quantitative 
methods and can lead to a sensitivity enhancement of ~44% without increasing 
the total experiment duration.  It was possible to apply this method to a 
formulation of CortA and obtain quantitative information on a component that 
made up <0.3% of the entire sample, and it suggested the presence of Form III 
would be present at levels of ~0.1%.  These results are much better than can be 
achieved with traditional SSNMR quantitative methods and other solid-state 
characterization techniques, particularly for formulated APIs. 
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Chapter 5 
 
Comparison of Physical Form Quantitation  
by Solid-State Characterization Techniques 
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5.1 Introduction 
 
 The specific aim of this chapter is to utilize the quantitative SSNMR 
method that was developed in the previous chapter and compare its 
performance against other common techniques.  This analysis will involve 
mixtures of physical forms of an API in both pure API and a 10% (w/w) 
formulation.  The application of all of these common techniques to the same set 
of samples should allow a more direct comparison of the techniques than has 
typically been available for such characterization. 
 Various solid-state characterization techniques have been used to quantify 
polymorphs for both pure API and formulated products.  Often times, these 
studies focus on the application of one or two methods to the system that is being 
investigated.  In other cases, a model compound may be chosen to demonstrate a 
particular technique.  Additionally, some studies have been able to demonstrate 
extremely low levels of detection and quantification by utilizing non-standard 
equipment, such as synchrotron sources for PXRD.1 
 There is also no universal method for reporting the quality of the models 
that are used to quantify physical forms of pharmaceuticals.  In some cases, a 
limit-of-detection (LOD) and limit-of-quantification (LOQ) are reported.  In other 
cases the statistics that are obtained from the generation of a multivariate model 
are reported.  Also, unlike quantitative analysis in solution, where the samples 
are homogeneous, solids are inherently inhomogeneous and the quality of the 
samples will also impact the results.2,3  Therefore, a broad comparison of the 
techniques across all of the studies is difficult.  However, it has been possible to 
generally conclude that most techniques can be applied to the analysis of pure 
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API and generally yield LODs and LOQs of approximately 1–2% and 3–5%, 
respectively.  Formulated materials are significantly more challenging due to the 
presence of the excipients which often overlap with signals from the API 
physical forms.  Therefore, quantitative analysis of formulated materials is 
typically accomplished with PXRD or Raman spectroscopy and generally have 
LODs and LOQs of approximately 5 and 10%, respectively, and vary by physical 
form. 
 The approach here is to develop basic quantitative methods for the most 
common solid-state characterization techniques: DSC, TGA, PXRD, and Raman 
spectroscopy.  In addition, the SSNMR quantitation method will be used in order 
to compare its performance against the other techniques.  The methods will then 
be applied to two systems, one consisting of binary mixtures of a pure API and 
the other containing the same binary blends of API diluted in excipients to 
simulate a formulation. 
 Norfloxacin (Figure 5.1) was chosen as the model API because it could be 
readily obtained in sufficient quantities for the study.  It was also possible to 
generate two relatively stable physical forms.  The molecule also contains 
fluorine, which will allow the comparison of both 13C and 19F SSNMR, and a 
methyl group that should result in relatively short NMR relaxation times.  Drug 
loadings in a formulation can range from a few percent for potent compounds, to 
>20% when large doses are required.  Therefore a 10% (w/w) drug loading was 
selected and lactose, microcrystalline cellulose, sodium alginate, and magnesium 
stearate were chosen to compose the remainder of the formulation because they 
are routinely used as excipients.  The relative amounts of each of the excipients 
were selected to simulate their typical levels within a formulation. 
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Figure 5.1.  Chemical structure of norfloxacin with carbon numbering scheme from 
Barbas et al.4,5 
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5.2 Experimental 
 
5.2.1 Materials 
 Norfloxacin, magnesium stearate, microcrystalline cellulose (Avicel ® PH-
101, Fluka), and sodium alginate (alginic acid sodium salt, from brown algae, 
viscosity of 2% solution at 25 °C: 250 cps) were purchased from Sigma-Aldrich 
(St. Louis, MO). Foremost® #310 Regular NF Lactose monohydrate was obtained 
from Foremost Farms (Baraboo, WI). 
 Norfloxacin Form A was produced by drying stock material at 80 °C, 
under vacuum, for 4 hours after which the oven was turned off and left 
overnight to return to room temperature.  Approximately 150 mL of N,N-
dimethyl formamide (DMF) was added to 15.5 g of the norfloxacin Form A.  Seed 
crystals of norfloxacin Form B, which were generated by suspending 
approximately 200 mg of norfloxacin in 10 mL of DMF for 6 months, were added 
to the DMF suspension and the mixture was stirred at room temperature for a 
week to convert all of the norfloxacin to Form B.  The norfloxacin Form B was 
recovered by vacuum filtration and then was dried according to the same drying 
procedure outlined above (80 °C for 4 hours under vacuum), lightly ground in a 
mortar and pestle and then dried overnight at 40 °C, under vacuum. 
 Norfloxacin mixtures were produced in order to generate calibration 
curves and to test the calibrations.  Each mixture had a total mass of 
approximately 1 g and consisted of either only norfloxacin or 10% (w/w) 
norfloxacin in placebo.  The placebo consisted of !-lactose monohydrate, 
microcrystalline cellulose, sodium alginate, and magnesium stearate in sufficient 
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quantities such that when mixed with norfloxacin they would make up 75, 10, 4, 
and 1% (w/w), respectively.  The samples consisting of only norfloxacin were 
generated by mixing norfloxacin Forms A and B such that the samples contained 
either 0, 1, 2.5, 5, 10, 20, 40, 60, 80, 90, 95, 97.5, 99, or 100% (w/w) Form A.  The 
10% norfloxacin formulations all contained the same relative concentration of 
norfloxacin, but it was present as different physical forms.  In these formulations 
the relative Form A composition was the same as the previously described 
binary blends of Form A and B.  In addition, five binary blends and five 10% 
(w/w) norfloxacin formulations were generated to act as “unknown” samples, in 
order to test the calibration curves. 
 
5.2.2 DSC 
 A Q100 DSC from TA Instruments (New Castle, DE) with a refrigerated 
cooling system was utilized to characterize all of the materials and the 
quantitation mixtures.  In all cases approximately 4 to 10 mg of material was 
placed in DSC pan for the analysis.  The placebo blend and norfloxacin were 
analyzed by heating from -80 to 235 °C at a rate of 10 °C/min.  All of the 
calibration mixtures and “unknowns” were analyzed in triplicate and were held 
at 150 °C for 2 min. and then were heated to 235 °C at 10 °C/min.  All samples 
were analyzed in a dry nitrogen atmosphere (N2 flow rate = 50 mL/min).  Two 
processing methods, signal change and peak integration, were applied to the 
DSC thermographs.  The signal change was the difference in the heat flow signal 
190 and 200 °C.  The peak integration method was performed by applying a 
sigmoidal horizontal integration from 190 to 227 °C.  Divisions were then placed 
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at 214 and 216 °C to subdivide the integration into three peaks. 
 
5.2.3 TGA 
 All of the materials and quantitation mixtures were analyzed by TGA 
(Q50 TGA from TA Instruments, New Castle, DE).  Approximately 4 to 10 mg of 
each sample was placed in platinum pans under a dry nitrogen atmosphere (total 
N2 flow rate = 100 mL/min).  The placebo blend and norfloxacin were heated 
from room temperature to 300 °C at a rate of 10 °C/min.  All of the calibration 
mixtures and “unknowns” were analyzed in triplicate and were held at 150 °C 
for 2 min. and then were heated to 250 °C at 10 °C/min.  The TGA thermographs 
were analyzed by measuring the percent weight loss between 170 and 220 °C. 
 
5.2.4 PXRD 
 PXRD patterns were collected on a Bruker D8a series XRD instrument 
where the sample was rotated at 30 times per min during data acquisition.  
Reference diffraction patterns of placebo and norfloxacin Forms A and B were 
collected from 3 to 40 °2" with a step size of 0.020 °2"/step and 4 sec/step. The 
calibration mixtures and the “unknowns” were analyzed in triplicate and the 
diffraction patterns were collected from 9 to 26 °2" with a step size of 0.010 
°2"/step and 4 sec/step.  The divergence, anti-scatter, absorbance, detector, and 
monochrometer slits were set to 1.0, 0.6, 6.0, 0.6, and 0.6 mm, respectively.  Data 
processing and analysis was performed with The Unscrambler (see section 5.2.9). 
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5.2.5 FT-Raman Spectroscopy 
 FT-Raman spectra were collected on an NXR 9650 FT-Raman spectrometer 
(Nicolete 6700 FT-IR outfitted with an FT-Raman module) with a liquid nitrogen 
cooled germanium detector and a Nd:YVO4 laser (1064 nm).  All spectra were the 
result of 100 scans collected with 4 cm-1 resolution.  The calibration mixtures and 
“unknowns” were collected in triplicate with a laser power at the sample of 0.5 
and 1.0 W, respectively.  Samples were loaded into NMR tubes and rotated 
during data acquisition.  The NMR tubes were inverted multiple times between 
acquisitions to generate the replicates.  Only one binary norfloxacin calibration 
mixture (20% Form A) was analyzed by preparing three independent NMR 
tubes.  Data processing and analysis was performed with The Unscrambler (see 
section 5.2.9). 
 
5.2.6 PhAT Probe Raman Spectroscopy 
 Dispersive Raman spectra were collected with a Raman Rxn System from 
Kaiser Optical Systems, Inc.  The instrument consisted of a PhAT probe with a 6 
mm spot size and a 785 nm laser set to 400 mW.  The system was calibrated for 
both wavelength and intensity with the provided calibration accessory and 
cyclohexane.  All spectra were collected with dark subtraction and intensity 
calibration, but no cosmic ray filtering was used.  A total of 24 exposures, each 
with an exposure time of 5 sec, were collected and all 10 channels of the detector 
were summed together to yield each spectrum.  The calibration mixtures and 
“unknowns” were each subjected to six replicates each and the sample was 
agitated between each replicate.  Data processing and analysis was performed 
with The Unscrambler (see section 5.2.9). 
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5.2.7 13C SSNMR Spectroscopy 
 13C SSNMR data was collected on a Tecmag (Houston, TX) 300 MHz (1H 
resonance frequency) spectrometer with a custom built probe.  The probe 
consisted of two spin modules and was designed to allow two samples to be 
analyzed simultaneously.  Samples were packed into 7 mm zirconia rotors and 
held in place with Teflon® end caps (Revolution NMR, Fort Collins, CO).  
Packed rotors were spun with MAS at a rate of 4.9 kHz in 7 mm spin modules 
(Revolution NMR, Fort Collins, CO). 
 The FIDs were collected with ramped amplitude CP sequence with 
SPINAL-64 decoupling.  Placebo and norfloxacin Form A and B FIDs consisted of 
2,048, 7,168, and 7,168 transients, respectively, collected with a 6 sec pulse delay 
and 3 ms contact time.  All of the calibration mixtures and unknown samples 
were analyzed with a pulse delay of 6 sec, a contact time of 6 msec, and utilized 
16 “dummy” pulses to ensure steady state conditions.  All of the FIDs consist of 
1024 points and are the result of between 128 and 1,024 or 6,144 and 43,008 
transients for pure norfloxacin and 10% formulations, respectively. 
 
5.2.8 19F SSNMR Spectroscopy 
 19F SSNMR studies were performed on the same Tecmag 300 MHz 
spectrometer, but utilized a traditional probe with only one spin module. 
Samples were packed into 4 mm zirconia rotors and held in place with Torlon® 
end caps (Revolution NMR, Fort Collins, CO).  Packed rotors were spun with 
MAS at a rate of 11 kHz in a 4 mm spin module (Revolution NMR, Fort Collins, 
CO). 
 The FIDs were collected with ramped amplitude CP sequence with 
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SPINAL-64 decoupling.  Placebo and norfloxacin Form A and B FIDs consisted of 
512, 16, and 16 transients, respectively, collected with a pulse delay of 6 to 8 sec 
and a contact time of 0.5 to 4 ms.  All of the calibration mixtures and unknown 
samples were analyzed with a pulse delay of 6 sec and utilized 16 “dummy” 
pulses to ensure steady state conditions.  Each sample was analyzed with contact 
times of 4, 6, and 8 msec.  All of the FIDs consist of 128 points with a dwell time 
of 20 µsec and are the result of between 512 and 2,048 or 512 and 4,096 transients 
for pure norfloxacin and 10% formulations, respectively. 
 
5.2.9 Data Analysis (Multivariate Regression) 
 Multivariate methods were utilized to perform the quantitative analysis of 
the data from all of the analytical methods, with the exception of both 13C and 19F 
SSNMR results.  The Unscrambler X version 10.1 from CAMO Software (Oslo, 
Norway) was utilized to perform both multiple linear regression (MLR) and 
partial least squares (PLS) analysis.  MLR models were subjected to validation by 
leverage correction.  PLS analysis was performed with cross validation in 20 
random segments with the number of samples per segment being determined by 
the total number of samples in the calibration set.  The PLS analysis utilized the 
non-linear iterative partial least squares (NIPALS) algorithm.  The Savitzky-
Golay (SG) algorithm was used for both smoothing and calculation of 2nd 
derivatives with 3rd order polynomials and a symmetrical kernel of ±5 points. 
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5.3 Results & Discussion 
 
5.3.1 Characterization of Materials 
 Two anhydrous polymorphs of norfloxacin (Form A and Form B) and a 
placebo, or blend of excipients, were prepared.  The DSC thermographs of the 
materials are shown in Figure 5.2.  Form A of norfloxacin showed a single 
melting endotherm at 220 °C, which was consistent with previous observations.4,5  
However, Form B displays two endotherms at 211 and 221 °C, which correspond 
to melting of Forms B and A, respectively.4,5  Additionally, an exothermic event is 
observed between the melting endotherms and is attributed to crystallization of 
Form A from the melted material.  The thermograph of the placebo displays two 
prominent endotherms at 145 and 200 °C that are primarily from the !-lactose 
monohydrate component.  The placebo’s endotherm at 200 °C could significantly 
impact the ability to analyze the formulations due to signal overlap of the 
norfloxacin melting endotherms and placebo signal. 
 When TGA of the materials was performed (Figure 5.3) an interesting 
phenomenon was observed.  Both Form A and B began to undergo significant 
mass loss above 220 °C, likely due to degradation.  However, Form B exhibited a 
small but reproducible mass loss between 190 and 210 °C that was not associated 
with residual DMF.  This mass loss was not observed with Form A, thus the 
measurement of the mass loss over this temperature range might provide 
quantitative information.  The placebo showed mass loss in the same 
temperature range (mostly attributed to !-lactose monohydrate and sodium 
alginate), which would likely limit any quantitative information that could be
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Figure 5.2.  DSC thermographs of placebo and norfloxacin Forms A and B.  The two 
endotherms of the placebo are primarily from the !-lactose monohydrate.  Form A 
displays a single endotherm at 220.3 °C.  Form B shows an endotherm at 211.0 °C, which 
was immediately followed by an exotherm and another endotherm at 220.7 °C. 
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Figure 5.3.  TGA thermographs of placebo and norfloxacin Forms A and B.  The mass 
loss at 140–150 °C is from the !-lactose monohydrate, while the loss above 200 °C is due 
to the lactose and sodium alginate.  Both forms of norfloxacin begin to degrade at about 
250 °C, but Form B also showed a small mass loss from approximately 190 to 210 °C (see 
insert). 
213 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.4.  Illustration of DSC analysis for quantitation of norfloxacin Forms A and B.  
The insert shows the signal change method where the difference in the DSC heat flow is 
measured between 190 and 200 °C.  Integration of the Form A melting endotherm 
resulted in a melting point of 220.3 °C and a heat of fusion of 124.6 J/g.  For Form B the 
entire region from 190 to 227 °C was integrated, the integrated area (158.4 J/g) was then 
subdivided into three individual peaks. The peaks at 211.0 °C (60.74 J/g), 213.3 °C (8.738 
J/g), and 220.7 (106.4 J/g) represented melting of Form B, crystallization of Form A, and 
melting of Form A, respectively. 
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obtained from TGA of formulated norfloxacin. 
 Closer inspection of the DSC thermographs of Forms A and B (Figure 5.4) 
revealed a small endothermic event just prior to the melting of Form B.  This 
event has previously been attributed to solid-solid conversion of some of the 
Form B to Form A prior to melting of the remaining Form B.4  This transition 
occurs over the same temperature range as the observed Form B mass loss in 
Figure 5.3.  In addition to this event, the crystallization of Form A from the melt 
during the collection of the DSC thermographs significantly complicates the 
analysis of the data for quantitative measurements. 
 Two general approaches to quantitative analysis of the DSC data were 
adopted (Figure 5.4).  The first is demonstrated in the insert of the figure and 
involves the measurement of the change in the heat flow over the temperature 
range from 190 to 200 °C.  The second involved integration of the entire peak 
range (190 to 227 °C) which was then divided into three peaks (#1, #2, and #3) 
representing melting of Form B, crystallization of Form A, and melting of Form 
A, respectively.  The results are demonstrated in Figure 5.4 and yielded 
integrated areas of 60.7, 8.7, and 106.4 J/g for Peaks #1, #2, and #3, respectively, 
and a total integrated area of 158.4 J/g.  The melting of Form A in both samples 
occurs at the same temperature, but the heat of fusion is approximately 18 J/g 
lower for the material that crystallized from the melt of Form B.  It is not clear 
why the two values differ by almost 15% but might indicate that the material did 
not completely crystallize to Form A. 
 The PXRD diffraction patterns of norfloxacin Forms A and B (Figure 5.5) 
are consistent with previous reports with some differences in the relative 
intensity of the peaks.4,5  This may indicate that Form B is subject to preferred
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Figure 5.5.  PXRD patterns of placebo and norfloxacin Forms A and B.  The diffraction 
peaks of the placebo are primarily from the !-lactose monohydrate.  Quantitative 
analysis was performed on the diffraction pattern from 9 to 26 °2" or over one of the 
other regions shown above (#1 9–11 °2", #2 15.5–16.3 °2", #3 15.5–19 °2", and #4 22–26 
°2"). 
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orientation, but the samples were rotated during the acquisition of the powder 
patterns to minimize this effect.  As with the DSC and TGA, the PXRD patterns 
are subject to significant overlap of the API and placebo peaks, particularly !-
lactose monohydrate.  This will likely frustrate the quantitative analysis of the 
formulations.  To minimize the interference of the excipients on the analysis, four 
regions were selected for quantitative analysis (#1 9–11 °2", #2 15.5–16.3 °2", #3 
15.5–19 °2", and #4 22–26 °2"). 
 The Raman spectra of the materials are shown in Figure 5.6.  The intensity 
of the Form A and B spectra relative to the placebo indicate that norfloxacin is a 
strong Raman scatterer compared to the placebo components, which should aid 
in detection of norfloxacin in the formulations.  There is significant overlap of 
most of the norfloxacin and placebo peaks; however, three regions with no or 
limited signal overlap were identified.  Region #1 is shown in Figure 5.7 (600 to 
820 cm-1), and does contain some relatively weak signals from the placebo.  The 
other two regions are shown in Figure 5.8, where Region #2 (1500 to 1760 cm-1) 
contains no placebo peaks and Region #3 extends over a wider range (1220 to 
1760 cm-1) and does contain some weak placebo signals. 
 The Raman spectra that were collected with the PhAT probe (Figure 5.9) 
showed very few differences from the FT-Raman spectra (Figure 5.6).  The most 
significant difference is the elevated baseline at lower wavenumbers.  This is due 
to differences in the wavelength of the lasers that are used with each instrument, 
the lower wavelength of the PhAT probe system (785 vs. 1064 nm) will tend to 
result in more background due to fluorescence. 
 The 13C CPMAS spectra of the norfloxacin polymorphs and placebo are
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Figure 5.6.  FT-Raman spectra of placebo and norfloxacin Forms A and B. 
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Figure 5.7.  FT-Raman spectra of placebo and norfloxacin Forms A and B from Figure 5.6 
expanded to show quantitation region #1 (600 to 820 cm-1, region displayed). 
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Figure 5.8.  FT-Raman spectra of placebo and norfloxacin Forms A and B from Figure 5.6 
expanded to show quantitation regions #2 (1500 to 1760 cm-1, indicated on the figure) 
and #3 (1220 to 1760 cm-1, region displayed). 
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Figure 5.9. Raman spectra of placebo and norfloxacin Forms A and B, collected with a 
dispersive Raman spectrometer via a PhAT probe. 
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Figure 5.10.  13C CPMAS spectra placebo and norfloxacin Forms A and B.  Peaks that 
were selected for quantitation are marked with arrows (Form B at 124.1 ppm and Form 
A at 120.3 ppm).  The narrow peaks between 60 and 110 ppm in the spectrum of the 
placebo are from the lactose, but are relatively small due to its long 1H T1 (~270 sec, 
Table 4.5) and the short delay between transients (6 sec).  * = spinning sidebands 
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shown in Figure 5.10.  The spectra of Forms A and B are consistent with the 
previously reported chemical shifts of both forms.4,5  The spectrum of the placebo 
shows peaks from the different components.  The peak at ~43 ppm is due to 
magnesium stearate while the broad peaks between 60 and 110 ppm are from 
microcrystalline cellulose and sodium alginate, which also results in the peak at 
175 ppm.  The relatively narrow peaks between 60 and 110 ppm are due to the !-
lactose monohydrate, but while the lactose makes up the majority of the material 
the signals are relatively small.  This demonstrates one of the benefits of SSNMR, 
depending upon the conditions used to collect the data signals can be suppressed 
or enhanced relative to one another.  The !-lactose monohydrate takes a very 
long time to fully relax to its equilibrium magnetization (1H T1 ~270 sec) but the 
sample was only allowed to relax for approximately 6 sec between transients.  In 
that relatively short amount of time only about 2% of the equilibrium 
magnetization has been recovered, which results in very weak signals from the 
lactose in the material.  Upon inspection, the peaks for C-4a (Figrue 5.1 and 5.10 
indicated by arrows) were selected for quantitation to avoid overlap of 
norfloxacin and placebo peaks.4,5  Additionally, an MAS rate of 4.9 kHz was 
selected to avoid the overlap of spinning side bands with the C-4a peaks. 
 Since the chemical structure of norfloxacin (Figrue 5.1) contains fluorine, 
19F SSNMR can be used to study the norfloxacin forms (Figure 5.11).  The spectra 
demonstrate the distinct advantages of 19F, chiefly the lack of fluorine in most 
excipients and the dramatically higher sensitivity of 19F as compared to 13C 
SSNMR.  Norfloxacin Form A and B each show one isotropic signal in their 19F 
CPMAS spectra, due to the presence of only one fluorine atom in the molecule
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Figure 5.11.  19F CPMAS spectra placebo and norfloxacin Forms A and B.  The insert is 
an expansion of the spectra around the isotropic peaks to show the Form B impurity in 
the Form A sample, the impurity was estimated to be ~0.5% (w/w).  * = spinning 
sidebands 
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and one molecule per asymmetric unit cell of the crystal structure (Z’ = 1).  
Additionally, 19F is 100% naturally abundant, which leads to significantly higher 
sensitivity when compared to 13C.  In fact the spectra in Figure 5.10 were the 
result of 7,168 transients collected over the period of 12 hrs while the spectra in 
Figure 5.11 only required 16 transients and a total collection time of less than 2 
min.  Additionally, the insert of Figure 5.11 shows that 19F SSNMR was able to 
detect a small amount of Form B in the Form A sample, this impurity was 
estimated at ~0.5% (w/w) 
 
5.3.2 Multivariate Regression 
 Quantitative measurements are typically performed with a univariate 
regression where it is assumed that the response (i.e., UV absorbance) is only 
influenced by a single factor (i.e., concentration of the analyte).  This assumption 
is not always valid, especially for the quantitative analysis of solids.  For 
example, the peaks in the Raman spectrum of an amorphous material are 
generally broad and poorly resolved from the peaks of the crystalline forms of 
the material.  Thus, intensity of a Raman peak for a crystalline form may depend 
upon the amount of the corresponding crystalline form and the amorphous 
material that are present. 
 Multivariate regression takes several variables into account when 
performing the regression, and has the ability to differentiate independent 
factors, such as the concentrations of sample components.  Therefore, 
multivariate regression has become popular within the field of solid form 
quantitation, particularly for spectroscopic techniques because it allows the use 
of the entire spectrum or spectral regions rather than the intensity at a single 
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point in the spectrum.  Ideally, if the samples are a mixture of two physical forms 
then the multivariate regression will only depend upon a single factor, the 
relative concentrations of the two forms. 
 When performing multivariate regressions, cross validation is typically 
employed to test the robustness of the model.  The entire calibration data set is 
initially used to build the model and the predicted sample compositions are 
determined from the model.  In order to predict how the model will predict 
future results the calibration data set is validated by removing a small portion of 
the samples (test set), recreating the calibration model using the remaining 
training set, and then predicting the composition of the samples in the test set.  
This process is repeated until all of the samples have been used in a test set.  The 
predicted compositions from the initial calibration and subsequent validation 
steps should be similar to one another.  Additionally, the correlation of 
determination (R2) will provide a measure of the correlation between the 
predicted and reference sample compositions in the model.  The quality of a 
model is interpreted from the root mean square error (RMSE) and is given by 
Equation 5.1, where p is the predicted value, o is the observed value, and n is the
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 Equation 5.1 
 
number of samples.  The RMSE is determined for both the calibration (RMSEC) 
and the validation (RMSEV) of the model.  These values can be used to compare 
the error of two models, where the model with the lower RMSE values should 
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offer a more accurate and precise measurement. 
 
5.3.3 Quantitation by DSC 
 In Section 5.3.1 it was shown that several DSC signals could be analyzed 
for Form A and B of norfloxacin, these included the change in the heat flow 
between 190 and 200 °C and the integration of various peaks (Figure 5.4).  
Melting of Form A was observed as Peak #3 and showed no correlation to the 
relative amount of Form A in the binary mixtures because Form A crystallized 
from the melted Form B during the experiment.  Additionally, crystallization of 
Form A (Peak #2) showed only a very weak correlation due to variability in the 
crystallization behavior.  A multiple linear regression (MLR) of the total 
integrated area resulted in a calibration model with an RMSEC and RMSEV of 
9.4 and 9.9, respectively.  When the MLR was performed with either Peak #1 
(melting of Form B) or the change in heat flow measurement, the RMSEC and 
RMSEV values fell to 7.5 and 8.0 or 6.4 and 6.7 for each of the models, 
respectively. 
 A partial least squares (PLS) model was generated to utilize both the Peak 
#1 area and heat flow change, with each measurement weighted by 1/(standard 
deviation).  The PLS model had the lowest RMSEC and RMSEV values (5.6 and 
5.9, respectively) and the predicted versus reference plot from the model is 
shown in Figure 5.12.  The calibration and validation sets are in good agreement, 
indicating that the model is a relatively good model.  However, the DSC 
thermographs of the 10% formulations showed no signals from norfloxacin.  
Thus, the peaks could not be integrated, but the signal change was determined 
for some of the samples to see if there was any discernable correlation.  The
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Figure 5.12.  Predicted vs. reference plot for the PLS model of the DSC results from Peak 
#1 (Form B melting) and the heat flow change of the binary mixtures of Form A and B.  
The model was generated by weighting each of the DSC results by (1/Standard 
Deviation).  The model has an RMSEC of 5.6 and an RMSEV of 5.9. 
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predicted versus reference plot from the resulting MLR model is shown in Figure 
5.13, and the model had RMSEC and RMSEV values of 33 and 37, respectively.  
These results indicate that the MLR model for the signal change in the 
formulation was very poor and there was no correlation in the data to the 
percent Form A in the samples.  This is not surprising considering the significant 
overlap of the placebo endotherm with the norfloxacin signals.  Thus, DSC 
should allow quantification of the relative amounts of Form A and B in binary 
mixtures but not in the formulated materials. 
 
5.3.4 Quantitation by TGA 
 When the calibration materials were analyzed by TGA the trends were 
similar to those observed with DSC.  The MLR of the mass loss in the binary 
blends showed a good correlation with the percent Form A in the mixtures 
(Figure 5.14) and suggested that it was a better method than DSC (RMSEC = 2.5 
and RMSEV = 2.6).  However, the MLR of the 10% formulations is significantly 
worse (Figure 5.15) than the binary blends.  A correlation was observed but there 
was a large amount of uncertainty with an RMSEC of 10 and an RMSEV of 11.  It 
can be seen in Figure 5.3 that the noise in the data is relatively large, compared to 
the transition that is observed.  Therefore, smoothing was applied over a 5 °C 
window prior to measuring the mass loss, but had no significant impact on the 
quality of the MLR of the binary mixtures or 10% formulations.  Thus TGA 
model appears to be superior to DSC for the analysis of both the binary mixtures 
and 10% formulations, but the model for the formulations is still relatively weak. 
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Figure 5.13.  Predicted vs. reference plot for the MLR model of the DSC results from the 
heat flow change of the 10% (w/w) norfloxacin formulation.  The model has an RMSEC 
of 33 and an RMSEV of 37. 
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Figure 5.14.  Predicted vs. reference plot for the MLR model of the TGA mass loss of the 
binary mixtures of Form A and Form B.  The model has an RMSEC of 2.5 and an RMSEV 
of 2.6. 
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Figure 5.15.  Predicted vs. reference plot for the MLR model of the TGA mass loss of the 
10% (w/w) norfloxacin formulation.  The model has an RMSEC of 10 and an RMSEV of 
11. 
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5.3.5 Quantitation by PXRD 
 The PXRD patterns were subjected to various processing steps prior to 
generation of the calibration models.  The diffraction patterns were used in their 
raw form, smoothed with Savitzky-Golay (SG) filtering, or smoothed with SG 
filtering and then normalized with either the standard normal variate (SNV) 
function or multiplicative scattering correction (MC).  PLS models of raw data 
from the full diffraction patterns, Region #3, and Region 4 were significantly 
better than Regions #1 and #2 (Figure 5.5).  Smoothing of the diffraction patterns 
had no significant impact on the quality of the models, but normalization did 
improve the results.  The best results were obtained by smoothing the diffraction 
patterns and then normalizing them by the SNV function.  The best model was 
obtained from the analysis of Region #4 (Figure 5.16) and had an RMSEC of 4.1 
and an RMSEV of 4.2. 
 The results were similar for the effects of processing on the diffraction 
patterns of the 10% formulations, and the best model was again found to be of 
Region #4 with SG smoothing and SNV normalization.  The predicted versus 
reference plot of the model is shown in 5.17, and clearly shows the same trend as 
the TGA results with a large amount of uncertainty (RMSEC = 14 and RMSEV = 
16).  Additionally, all of the data is clustered around the calibration and 
validation trend lines, with the exception of the 10% formulations where 60% of 
the norfloxacin is present as Form A.  These data points are significantly skewing 
the quality of the model but it is not clear if this is due to the sample itself or the 
instrument.  If the sample does not actually contain the reported amount of 
Forms A and B then it should be excluded from the model.  However, if the 
sample composition is correct then the issue must be with the PXRD instrument
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Figure 5.16.  Predicted vs. reference plot for the PLS model of the PXRD signals from 
Region #4 of the diffraction patterns binary mixtures of Form A and Form B.  The entire 
diffraction pattern was smoothed with the SG algorithm and normalized by SNV 
transformation prior to generating the model. of the.  The model has an RMSEC of 4.1 
and an RMSEV of 4.2. 
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Figure 5.17.  Predicted vs. reference plot for the PLS model of the PXRD signals from 
Region #4 of the 10% (w/w) norfloxacin formulation diffraction patterns.  The entire 
diffraction pattern was smoothed with the SG algorithm and normalized by SNV 
transformation prior to generating the model.  The model has an RMSEC of 14 and an 
RMSEV of 16. 
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or the method.  Unfortunately, it is not possible from this data to clearly identify 
the source of the error.  But, if the same sample shows similar results by other 
instrumental methods it should be possible to attribute the error to an inaccurate 
sample composition. 
 
5.3.6 Quantitation by FT-Raman Spectroscopy 
 Several processing methods were applied to the FT-Raman spectra prior 
to generating the PLS models for the binary mixtures and 10% formulations.  The 
spectra were used in their raw form, normalized by the SNV function, or 
normalized with SNV and then converted to 2nd derivatives with the SG filter.  
The various processing methods had little impact on the PLS models of the full 
spectra and subregions of the spectra.  However, Region #2 (Figure 5.8) did show 
moderate improvement with processing and resulted in the best model when 
both SNV normalization was performed and the spectra were converted to 2nd 
derivatives.  Figure 5.18 shows the predicted versus reference plot for the model, 
RMSEC = 2.0 and RMSEV = 2.0.  The same behavior was seen with the 10% 
formulation, but as with the previous methods the model was significantly worse 
for the formulations (Figure 5.19) with an RMSEC of 9.9 and an RMSEV of 10. 
 These results suggest that FT-Raman spectroscopy is slightly better than 
TGA at quantifying Form A in the binary mixtures and both methods are 
approximately equivalent for the analysis of the formulations.  However, Figure 
5.19 shows that the 10% formulation with 60% of the norfloxacin as Form A is 
predicted to have more Form A than it actually contains, according to the sample 
preparation.  This suggests that there is a problem with the sample that is 
skewing the error of the formulation models.  There does not seem to be a
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Figure 5.18.  Predicted vs. reference plot for the PLS model of the FT-Raman signals 
from Region #2 of the spectra of binary mixtures of Form A and Form B.  The entire 
spectra were normalized by SNV transformation and then converted to 2nd derivatives 
with the SG algorithm prior to generating the model.  The model has an RMSEC of 2.0 
and an RMSEV of 2.0. 
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Figure 5.19.  Predicted vs. reference plot for the PLS model of the FT-Raman signals 
from Region #2 of the 10% (w/w) norfloxacin formulation spectra.  The entire spectra 
were normalized by SNV transformation and then converted to 2nd derivatives with the 
SG algorithm prior to generating the model.  The model has an RMSEC of 9.9 and an 
RMSEV of 10. 
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noticeable trend in the other formulation samples, which indicates that the issue 
is with the sample preparation and not that the norfloxacin is undergoing a 
polymorphic form conversion.  It is not entirely surprising that a sample could 
have been improperly prepared considering the relatively small masses of 
norfloxacin that were involved in preparing the sample (900 mg of placebo, 40 
mg of Form B and 60 mg of Form A).  The incorrect transfer of just 5 mg of one 
norfloxacin polymorph would result in about a 5% error in the Form A content.  
This is a common issue with the generation of calibration standards for solid-
state quantitation studies, this issue will be addressed further in Section 5.3.9. 
 
5.3.7 Quantitation by PhAT Probe 
 PhAT probe technology is very popular within the pharmaceutical 
industry because it samples a much larger area than FT-Raman, and it can easily 
be utilized to actively monitor many industrial-processing steps.  This makes it a 
valuable tool for the monitoring of production lines.  Not surprisingly the Raman 
spectra that were collected with the PhAT probe showed almost identical 
calibration model properties as the FT-Raman spectra.  The same processing 
methods from the FT-Raman data were used, and again resulted in the best 
model when SNV normalization is used and the spectra are converted to 2nd 
derivatives with the SG filter.  However, in this case the best model was obtained 
for Region #1 (Figure 5.7), RMSEC = 2.1 and RMSEV = 2.1 (Figure 5.20).  And the 
quality of the 10% formulation model (Figure 5.21, RMSEC and RMSEV of 11) 
was slightly worse than the FT-Raman results.  Also, the 10% formulation with 
60% of the norfloxacin as Form A showed the same behavior, offering further 
proof that the reference composition of the sample is incorrect.  The sample was
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Figure 5.20.  Predicted vs. reference plot for the PLS model of the PhAT probe Raman 
signals from Region #1 of the spectra of binary mixtures of Form A and Form B.  The 
entire spectra were normalized by SNV transformation and then converted to 2nd 
derivatives with the SG algorithm prior to generating the model.  The model has an 
RMSEC of 2.1 and an RMSEV of 2.1. 
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Figure 5.21.  Predicted vs. reference plot for the PLS model of the PhAT probe Raman 
signals from Region #1 of the 10% (w/w) norfloxacin formulation spectra.  The entire 
spectra were normalized by SNV transformation and then converted to 2nd derivatives 
with the SG algorithm prior to generating the model.  The model has an RMSEC of 11 
and an RMSEV of 11. 
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only included in the model to allow comparison of the RMSE values of the PhAT 
probe model to the other models. 
 
5.3.8 Quantitation by 13C SSNMR Spectroscopy 
 It was shown in the previous chapter of this dissertation, that the relative 
amounts of two physical forms could be determined by SSNMR without 
generating a calibration curve.  Therefore, only two of the calibration samples 
were analyzed by 13C SSNMR in order to provide a comparison with the analysis 
methods, apart from the analysis of the “unknowns”.  The same general 
approach as was developed in the previous chapter with one noticeable 
exception.  An additional term, Z, needs to be added to account for differences 
that were observed due to the use of a custom built two-module probe. 
 The probe is able to simultaneously collect FIDs of two samples, by 
interleaving the periods of pulsing and delays of the two samples.  This 
approach allows two samples to be analyzed without utilizing any more 
resources (another spectrometer) or time.  However, it was discovered that when 
analyzed with the two-module probe, a particular amount of the signal was lost.  
If the effect was the same for all physical forms it could be ignored; however it 
was found that this value was not consistent for all physical forms.  The amount 
of signal that was retained is referred to as Z and can be incorporated into 
Equation 4.10 of Chapter 4 to account for these effects.  The Z of norfloxacin 
Form A and B were determined on the reference materials and are provided, 
along with the other relevant NMR properties in Table 5.1. 
 Two binary mixtures of norfloxacin Forms A and B were analyzed by 
SSNMR to determine the relative amount of Form A.  The first sample consisted
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Table 5.1  NMR properties for 13C and 19F SSNMR Quantitation Measurements 
 
Parameter ± Error‡ Detected by Form A Form B 
1H T1 (sec) 13C 1.98 ± 0.03 4.29 ± 0.09 
1H T1 (sec) 19F 2.25 ± 0.02 4.37 ± 0.02 
19F T1 (sec) 19F 42.5 ± 0.4 8.3 ± 0.2 
TCH (msec) 13C 0.94 ± 0.05 1.5 ± 0.1 
1H T1! (msec) 
13C 12 ± 1 ---‡ 
TFH (msec) 19F 0.12 ± 0.01 0.3 ± 0.3 
1H T1! (msec) 
19F 12 ± 1 ---‡ 
 f4.9 kHz (13C) 13C 0.673 0.679 
 f11 kHz (19F) 19F 0.481 0.573 
Z 13C 0.825 0.665 
 
† = Relevant NMR properties for Equation 4.10, with the multiple sample correction 
factor (Z) for each form incorporated in the equation below.  The parameters are 
reported with their associated errors from nonlinear regression. 
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‡ = The 1H T1! of Form B was too long to be determined from the data sets.  For the 
purposes of quantitation it is assumed to be ~50 msec or longer. 
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of 40.0% Form A, according to the masses used to prepare the mixture.  Two 7 
mm zirconia rotors were packed with the material and both rotors were placed in 
the two-module probe for analysis.  The relevant peaks of the spectra from both 
rotors were integrated and analyzed with the corrected equation.  The samples 
gave Form A compositions of 35.8 and 37.0%, with an average and standard 
deviation of 36.4 and 0.9%, respectively.  The results from the two samples agree 
very well with one another but are approximately 3.6% lower than the reference 
value.  The other mixture had a reference Form A composition of 90.0% but the 
resulting 13C CPMAS spectra resulted in values of 87.6 and 88.3 %.  Again, the 
SSNMR results agree very well with each other (standard deviation ~0.5%) but 
are approximately 2.1% lower than the known value.  This raises an important 
issue regarding the “known” composition of reference standards in quantitative 
solid-state analysis.  These issues will be considered further in Section 5.3.9. 
 
5.3.9 Quantitation by 19F SSNMR Spectroscopy 
 The sensitivity of 19F is significantly higher than that of 13C, which results 
in much shorter experiments and allows the detection of components of a 
mixture at relatively low levels.  This was demonstrated in Figure 5.11 where a 
very small amount of Form B was detected in the Form A with a spectrum that 
was collected in less than 2 min while no other technique detected its presence.  
When performing quantitation by 19F SSNMR the considerations are largely the 
same as when using 13C.  Cross-polarization (CP) does not offer the same increase 
in sensitivity as is observed for 13C but it can shorten the relaxation delay 
between transients.  This is the primary reason that the 19F data here was 
collected with the CP method, since the 19F T1 of Form A is 43 sec, a delay 
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between transients of at least 54 sec should be used to maximize the S/N of the 
data.  But by using CP the delay can be shortened by almost an order of 
magnitude, and the results can be corrected with Equation 4.10 of Chapter 4 to 
account for the CP dynamics. 
 Since 19F yield such high S/N data in very short time experiments the 
quantitation method was changed slightly.  Rather than collecting data with a 
single CP duration and using Equation 4.10 of Chapter 4 to correct for the CP 
dynamics, data was collected with three different CP durations.  The areas from 
the three spectra were then extrapolated back to the y-intercept and allowed an 
uncertainty in the intercept and ultimately the percent Form A that was 
measured. 
 When the binary blends of norfloxacin Forms A and B were analyzed by 
19F SSNMR the results were in good agreement with the percent Form A from the 
prepared masses.  In most cases the 19F SSNMR and Mass values were within 
1.5%.  These results were used to generate an MLR model (Figure 5.22) in order 
to see how the correlation of the values compared to the previous calibration 
models.  The 19F SSNMR MLR model was clearly the best model that was 
developed for the binary mixtures with an RMSEC of 1.3 and an RMSEV of 1.5.  
However, note that unlike the other models, the model in Figure 5.22 was only 
generated for comparison since the quantitation was actually performed by 
comparing the corrected peak areas. 
 As a measure of the uncertainty of the 19F results, the uncertainty of the 
linear regressions for the CP dynamics were used to estimate the uncertainty in 
the percent Form A that was obtained from the same extrapolation.  In every case 
the uncertainty was less than 0.5%, with the exception of one sample where the
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Figure 5.22.  Predicted vs. reference plot for the MLR model of the 19F SSNMR results of 
the binary mixtures of Form A and Form B.  The model has an RMSEC of 1.3 and an 
RMSEV of 1.5. 
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value was 0.6%.  In fact, most of the samples gave values of 0.2% or lower.  This 
suggests that the percent Form A that is determined from each of these 
measurements is an accurate representation of the sample that is being analyzed.  
In order to test this, two samples (40.0 and 90.0% Form A) were analyzed by 19F 
in triplicate.  The 40.0% Form A sample gave values of 35.2 ± 0.6%, 38.3 ± 0.5%, 
and 38.6 ± 0.2% with an average of 37.3% and standard deviation of 1.8%.  These 
results are interpreted as indicating that the sample is not completely 
homogeneous, thus when the material is placed in the 4 mm zirconia rotor the 
actual composition in the rotor may differ slightly.  While the NMR is able to 
measure the relative composition of the sample in the rotor the sample in the 
rotor may not accurately reflect the composition of the sample.  This is a well 
known issue with solid-state quantitation studies.  The variability of the data is 
not only dependent upon the variability of the instrument and the user but also 
the homogeneity of the materials that are being analyzed.  Analysis of the 90.0% 
Form A mixture resulted in values of 90.2 ± 0.1%, 88.8 ± 0.2%, and 88.3 ± 0.2% 
with an average of 89.1% and a standard deviation of 0.9%.  These results were in 
line with what was observed for the 40.0% mixture. 
 The 10% formulations were also analyzed with the same CP extrapolation 
technique and the results were used to generate another MLR model for 
comparison against the other techniques.  The predicted versus reference plot is 
shown in Figure 5.23 and shows a very good linear correlation with the exception 
of the 60% Form A sample, again, which was previously observed to be an 
outlier.  However, the other data points in the plot do not show as much scatter 
as was observed for previous techniques, thus the 60% Form A data was 
removed and the new MLR model is shown in Figure 5.24.  The model was
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Figure 5.23.  Predicted vs. reference plot for the MLR model of the 19F SSNMR results of 
the 10% (w/w) norfloxacin formulation.  The model has an RMSEC of 7.1 and an 
RMSEV of 7.9. 
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Figure 5.24.  Predicted vs. reference plot for the MLR model of the 19F SSNMR results of 
the 10% (w/w) norfloxacin formulation when the 60% Form A calibration formulation 
was excluded.  The model has an RMSEC of 1.7 and an RMSEV of 2.0. 
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noticeably better and the RMSEC decreased from 7.1 to 1.7 and the RMSEV went 
from 7.9 to 2.0, so that the quality of the new model was similar to the 19F model 
of the binary blends. 
 The previous observations regarding understanding sample homogeneity 
by 19F measurements were tested with two of the 10% formulations that were 
selected for analysis in triplicate.  The first was the 10.2% Form A and resulted in 
values of 11 ± 2%, 13 ± 2%, and 10.6 ± 0.6% with an average of 12% and a 
standard deviation of 2%.  These uncertainties are considerably larger than those 
that were observed from the results from the binary mixtures, but are likely due 
to the reduced S/N of the data that is being analyzed here because 
approximately the same number of transients were collected for the binary 
mixtures and 10% formulations but the formulations contained an order of 
magnitude less norfloxacin.  Thus the intensity of the signals that are being 
processed are approximately an order of magnitude lower and have a higher 
relative uncertainty.  The 10% formulation that consists of 59.9% norfloxacin as 
Form A gave results of 80.8 ± 0.6%, 74.7 ± 0.5%, and 81.8 ± 0.1% with an average 
of 79% and a standard deviation of 4%. 
 Thus the 19F SSNMR quantitation results appear to be relatively accurate 
for the material that was packed in the rotor and analyzed.  Additionally, it 
appears that while the composition obtained by a single measurement may not 
accurately reflect the composition of the sample, this is really due to 
inhomogeneity of the material and not inaccuracy of the SSNMR method.  These 
effects could be minimized by using a larger rotor for the analysis (4 mm rotors 
hold ~40 mg and 7 mm rotors hold ~350 mg) as with 13C analysis, but for a 
variety of practical reasons 19F data is typically not collected with rotors larger 
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than 4 mm.  Thus, when using small rotors multiple replicates should be 
performed to limit the inaccuracy of the measurements due to inhomogeneity. 
 
5.3.10 “Choice of Reference Composition Values” 
 When preparing standards for solid-state quantitation studies, the masses 
of all of the components are used to determine the known sample composition.  
One potential method to increase the accuracy of these known values is to use 
larger amounts of material.  The relative uncertainty of weighing 1 g is smaller 
than the relative uncertainty of weighing 1 mg on the same balance.  
Additionally, the transfer of a larger mass will likely be prone to less relative loss 
compared to the transfer of a smaller mass.  These concepts are routinely used to 
produce accurate calibration standards for solution studies.  However, in solids it 
can be difficult to ensure that mixtures are adequately blended to minimize 
inhomogeneity.  Also, it is often more difficult to ensure complete mixing of 
large samples of powders.  Thus the preparation of calibrations for solid-state 
quantitative methods typically involves the generation of the smallest amount of 
material that can be used for the analysis and yet large enough so that the 
components can be accurately weighed. 
 In general none of the calibration standards in the binary blends appeared 
to be outliers in the predicted versus reference plots (Figures 5.12, 5.14, 5.16, 5.18, 
and 5.20).  However, the 10% formulation the sample where 60% of the 
norfloxacin was present as Form A appeared to be an outlier in the PLS models 
of the PXRD, FT-Raman, and PhAT probe Raman methods (Figures 5.17, 5.19, 
and 5.21).  When this sample was removed from the MLR of the 19F model the 
quality of the model was improved significantly.  This sample was probably 
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subject to an error in preparation and typically would just have to be thrown out 
of the analysis.  Yet, the 19F SSNMR allowed the actual composition of the 
mixture to be determined since the method does not require a calibration curve.  
So the PXRD, FT-Raman, and PhAT probe models were regenerated, but the 
percent Form A from the 19F SSNMR measurements were used as the reference 
compositions, rather than the values from the prepared masses.  The predicted 
versus reference plot of the PhAT probe method is shown in Figure 5.25, and 
shows a significant improvement in the model.  Similar improvements were also 
observed for the PXRD and FT-Raman models.  The RMSEC and RMSEV of the 
models changed from 14 and 16, 9.9 and 10, and 11 and 11 to 11 and 13, 7.5 and 
7.9, and 7.1 and 7.2 for PXRD, FT-Raman, and the PhAT probe, respectively. 
 
5.3.12 LOD and LOQ of Methods 
 There are several methods for determining the LOD and LOQ for an 
instrumental method, and are typically based on either the S/N of the signal or 
some measure of the standard deviation of the repsonce.6 The LOD and LOQ are 
given by Equations 5.2 and 5.3, respectively, where # is the standard deviation of
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regression models were determined from the standard deviations of the
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Figure 5.25.  Predicted vs. reference plot for the PLS model of the PhAT probe Raman 
signals from Region #1 of the 10% (w/w) norfloxacin formulation spectra, with 19F 
results as reference compositions.  The entire diffraction pattern normalized by SNV 
transformation and then converted to 2nd derivatives with the SG algorithm prior to 
generating the model.  The model has an RMSEC of 7.1 and an RMSEV of 7.2. 
253 
either the blank, the regression line, or the y-intercept of the regression line and S 
is the slope of the calibration curve.6 The LOD and LOQ of the multivariate 
calibration regressions and are shown in Table 5.2.  The LOD and LOQ values 
follow the same trends as the RMSE values, where 19F SSNMR was the best 
model for both binary mixtures and the 10% formulations.  For the binary 
mixtures, DSC and PXRD provided the least sensitive measurements, while 
TGA, and both Raman methods were of intermediate sensitivity.  The 10% 
formulations have similar results but the TGA and PXRD had relatively similar 
sensitivity.  It is important to note that the LOD and LOQ values shown in Table 
5.2 for 19F SSNMR are based upon the MLR models of Figures 5.22 and 5.24, 
which were only used for comparison and not for the actual quantitation 
measurements. 
 The LOD and LOQ of the SSNMR measurements would be better 
represented by the S/N of the spectra since they do not actually rely upon a 
calibration curve.  It was possible to observe 0.5% of Form B within the Form A 
material when 2,048 transients were acquired (Figure 5.11) and the S/N of the 
peak was 6.2, which is well above the S/N limit of 2 to 3 for detection.  
Additionally, the 1% Form A binary mixture had a S/N of the Form A peak of 
8.5.  These two measurements indicate that for 19F SSNMR of norfloxacin binary 
mixtures the LOD of Form A is ~0.5% and Form B is ~0.25% when 2,048 
transients are collected with the appropriate spectrometer settings.  These results 
also indicate that the LOQs should be ~1.5% and ~0.75% for Forms A and B, 
respectively.  The analysis of the 19F SSNMR of the 10% formulations indicates 
that with 4,096 transients the LODs of Forms A and B are ~1.5% and ~0.5%, 
respectively, with LOQs of ~4.5% and ~1.5%. 
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Table 5.2  LOD and LOQ of Quantitation Methods for Binary Mixtures and 10% 
Formulation from standard error of regression.  The values represent the detection of 
Form A in the norfloxacin component of the mixtures. 
 
 Binary 10% Formulationa 
Instrumentation LOD† LOQ‡ LOD† LOQ‡ 
DSC 19% 58% --- --- 
TGA 8.5% 26% 37% 110% 
PXRD 14% 42% 40% 120% 
FT-Raman 6.7% 20% 26% 78% 
PhAT Probe 7.0% 21% 24% 73% 
19F SSNMR 4.8% 14% 6.2% 19% 
 
† = LOD is 3.3 times the standard error of the regression divided by the slope of the 
regression. 
‡ = LOQ is 10 times the standard error of the regression divided by the slope of the 
regression. 
a = Based on regressions with 19F SSNMR results as reference composition.  In the case of 
the 19F SSNMR, the values are based on the compositions by mass, but the results of 
the 10% formulation with 60% Form A were excluded from the regression. 
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 When LOD and LOQ are determined from the S/N they reflect the 
uncertainty in the intensity of the signals.  However, as discussed in the previous 
chapter of this dissertation (Chapter 4) the intensity of peaks in the SSNMR 
spectra are not typically used for quantitative analysis, rather the peak areas are 
analyzed for these measurements.  Therefore, the S/N of 2–3 and 10 for LOD 
LOQ may not be appropriate measures for SSNMR.  This is also supported by 
the work in Chapter 4 where 13C SSNMR was used to accurately quantitate a 
mixture of two cortisone 21-acetate polymorphs and one of the peaks had a S/N 
of only 5.5. 
 
5.3.12 “Unknowns” 
 In order to test the calibration models five “unknown” binary blends of 
norfloxacin Forms A and B were analyzed.  The results for each of the methods 
are given in Table 5.2, and appear to follow the same general trends that were 
observed with each of the calibration models.  The DSC method tended to give 
highly variable results while the TGA method tended to be more reproducible.  
The PhAT probe and 19F SSNMR results tended to be the most reproducible.  In 
addition, as with the calibration samples the extrapolation of the peaks to 
account for the CP dynamics resulted in uncertainties of less than 0.5% for all but 
two of the samples which were 0.9 and 0.7% and were from the same 
mixture(72.2% Form A).  Thus the data seems to suggest that as with the 
calibration samples, the CI95% of the 19F results is primarily due to inhomogeneity 
in the samples.  This will also influence the outcome of the other methods.  The 
13C results were shown as the raw results and show that for all of the mixtures 
where Form A was detected the two values agree very well with one another,
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except for the 72.2% Form A sample, which seems to be more inhomogeneous 
based on the 19F SSNMR. 
 The “unknown” 10% formulations (Table 5.3) are also consistent with 
these observations.  The TGA and PXRD models perform poorly when trying to 
predict the Form A component of the “unknowns.”  This is likely due to the 
significant overlap of the norfloxacin and excipient peaks.  Unlike the binary 
mixtures, the FT-Raman seems to be slightly better than the PhAT probe, but 
both are very similar to each other and the 19F SSNMR results.  Again, the 
uncertainties from the extrapolations in the 19F results were all at or below 1% but 
the CI95% is significantly higher for all of the samples.  Indicating that 
homogeneity may be an issue with all of the “unknown” 10% formulations, 
which would impact the uncertainty of the other methods as well.  This is also 
reflected in the 13C results where the values from the 92.6% Form A sample are in 
relatively good agreement (19F CI95% = 3%) but the others are centered around the 
percent Form A from the masses but are significantly different from one another, 
suggesting that material was split unevenly between the rotors, such that one 
appears to have a Form A content that is higher than the reference value and the 
other is lower than the reference value. 
 
5.4 Summary 
 
 These results demonstrate the complications that are typically 
encountered with performing quantitation studies in the solid state.  These 
observations are consistent with previous observations.  Specifically, DSC 
suffered from conversion of the materials during analysis, which complicated the
258 
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analysis.  TGA was able to quantify the binary mixtures, but apart from the 
detection of solvates, has limited applicability to quantitative measurements of 
mixtures of physical forms.  PXRD also had limited success in the quantification 
of the mixtures.  However, all three methods provided very poor quantitative 
data in the formulated materials.  This is attributed to the overlap of API and 
excipient signals, and in the case of PXRD the relatively weak diffraction peaks 
that had to be used in order to avoid the relatively intense peaks from !-lactose 
monohydrate. 
 Conversely, Raman spectroscopy performed relatively well but suffered 
from inhomogeneity of the samples and a 10% formulation calibration standard 
did appear to contain a different amount of Form A than was determined from 
the masses of the materials that were used to generate the sample.  However, 
SSNMR was able to give relatively accurate measurements of the Form A content 
of the sample that was currently being analyzed in the spectrometer, and could 
reflect the homogeneity of the samples by collection of several replicates.  
Typically, SSNMR is not utilized for quantitative studies either due to the long 
analysis times (especially for 13C) or unfamiliarity with the technique.  However, 
these results indicate that it could be a valuable tool to confirm the actual sample 
composition and provide reference compositions for the generation of calibration 
curves with other techniques. 
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Chapter 6 
 
Conclusions and Future Work 
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6.1 General Conclusions 
 
 The primary objective of this dissertation has been to evaluate the ability 
of various solid-state characterization techniques, especially solid-state NMR 
(SSNMR), to detect and quantify physical forms of drugs within model 
formulations.  This is critical to drug development because changes in the 
physical form of the drug can impact the dissolution and bioavailability of the 
drug from the formulation.  Additionally, changes in the physical form of the 
drug can also lead to chemical instability of the drug. 
 The identification and characterization of a new physical form is not 
always straightforward.  This was demonstrated in the second chapter of this 
dissertation with the dehydration of levofloxacin hemihydrate.  Previous studies 
had concluded that dehydration of the material resulted in a collapse of the 
crystal structure and produced a mixture of physical forms.1  However, through 
the use of SSNMR it was possible demonstrated that dehydration of levofloxacin 
actually does not result in collapse of the crystal structure.  In fact, levofloxacin 
hemihydrate acts like a channel hydrate, which was supported by the crystal 
structure of the material that was determined by single-crystal X-ray diffraction.  
Additionally, with SSNMR and other solid-state characterization techniques it 
was possible to show that the anhydrous material undergoes a polymorphic 
change to a previously unreported ! form.  Finally, analysis of the SSNMR 
results and examination of the crystal structure of levofloxacin was able to 
suggest the structural changes that occur between the ! and " anhydrous forms 
of levofloxacin. 
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 Incorporation of a drug into a formulation presents two major issues.  
First of all, the excipients often interfere with the analysis of the physical form of 
the drug either due to overlap of the excipient signals with those of the physical 
forms of the drug or altering the behavior of the drug.  An example of the latter 
issue is the formation of a eutectic between the drug and an excipient during 
DSC analysis.  The third chapter of this dissertation exemplified these issues with 
two nanoparticle formulations of budesonide and nifedipine.  In both cases when 
DSC was used to analyze the materials there was no conclusive evidence to 
indicate the physical form of the drugs.  However, SSNMR was able to 
unambiguously identify the budesonide as being in an amorphous state and 
nifedipine was present as crystalline Form I in the respective formulations that 
were analyzed. 
 In addition to signal overlap, the generation of a formulation can also 
result in physical form changes.  This was also demonstrated in the third chapter 
of this dissertation with ciprofloxacin.  When the material was processed to 
produce the nanoparticles for use in the formulation, new peaks were observed 
in the DSC thermographs and SSNMR spectra (13C and 19F) indicating that a 
physical form change had occurred.  Additionally, it was noted that the physical 
form or forms were metastable and converted to the original physical form over 
the course of a month.  These changes can have a significant impact on the 
behavior of the formulation, and may change over time if the drug converts to a 
more stable form with time.  Therefore, it is critical to characterize materials 
throughout the manufacturing process and especially in the final drug product to 
ensure that no unanticipated physical form changes have occurred.  Also, it is 
important to monitor the formulation for potential changes in the physical form 
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of the drug during storage. 
 When characterizing physical forms in formulations it is also important to 
understand the quantitative aspects of the instrumental method.  If the technique 
is not sufficiently sensitive it may not detect small amounts of a physical form 
that may be present.  Additionally, a final formulation may contain a mixture of 
physical forms and it may be necessary to determine if these forms are stable or 
are undergoing form conversions.  Thus a quantitative SSNMR method was 
developed to allow the relative quantitation of physical forms of drugs within 
formulations.  A major advantage of this method is that it does not require pure 
reference materials or the generation of a calibration curve, which is a significant 
issue with other solid-state characterization techniques.  Additionally, in Chapter 
4 of this dissertation it was demonstrated that the SSNMR data that is collected 
in the most efficient manner by optimization of the delay between transients and 
the use of cross polarization methods, can still provide quantitative results if the 
relaxation properties of the materials are known.  
  
6.2 Future Work 
 
 Analysis of the ciprofloxacin materials in the third chapter of this 
dissertation suggests that during production of the nanoparticles several 
crystalline forms of ciprofloxacin were produced.  There have been no reports of 
polymorphism of ciprofloxacin and thus it would be interesting to further 
characterize these new forms.  Unfortunately, attempts to produce the forms 
have thus far been unsuccessful but it is believed that one of the sonication steps 
was the cause of the form conversion.  Additionally, it would be interesting to 
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understand the rate of the form conversion back to the stable form and to 
characterize the impact of the form conversion on the release properties from the 
formulation. 
 The SSNMR approach to quantitation of physical forms in formulations 
was applied to the analysis of norfloxacin materials and its performance was 
compared against other commonly used solid-state characterization techniques 
such as DSC, PXRD, and Raman spectroscopy.  The data followed the general 
trends that have been reported previously in that most of the techniques were 
able to quantitate the relative physical forms of norfloxacin within samples of 
pure drug but suffered significantly when the drug is present in a formulation, 
with the exception of SSNMR.  The results indicated that the homogeneity of the 
samples was a significant issue, but that SSNMR could be used to characterize 
the homogeneity of samples.  Therefore it would be interesting to study mixtures 
of various degrees of homogeneity with the above-mentioned techniques in an 
attempt to separate the influence of sample homogeneity and technique 
variations (fluctuations in signal and sample handling) on the quality of the 
quantitation methods.  This has not previously been possible because most 
techniques, with the exception of SSNMR, require the generation of a calibration 
curve, which would also be influenced by the homogeneity and technique 
variations.  Additionally, SSNMR could provide more accurate reference 
compositions for reference standards when preparing calibration curves, since 
inaccuracies in the preparation of the materials may not be readily detected by 
other techniques. 
 SSNMR has gradually gained a foothold in the analysis if pharmaceutical 
solids, and continues to prove that it can have a significant impact on the 
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development of pharmaceuticals.  Its two major impediments have been the 
expertise required to utilize the instrumentation properly and the relatively long 
analysis times.  The first issue has gradually decreased as SSNMR has gained 
prominence within the solid-state characterization community.  The second issue 
has actually become more significant as the community has realized the potential 
impacts of utilizing SSNMR and has started to demand more use of the 
technique.  Thus increased throughput is needed to help meet these increasing 
demands and efforts are currently underway to develop technology that would 
allow the simultaneous analysis of multiple samples with a single SSNMR 
spectrometer.2 
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